Immunomodulator antibody drug conjugates and uses thereof

Immunomodulatory antibody-drug conjugates address the limitations of current cancer treatments by targeting tumor-specific antigens with cytotoxic and immunostimulatory agents, enhancing dendritic cell activation and immune response, thereby improving treatment efficacy.

JP7590354B2Active Publication Date: 2024-11-26SUTRO BIOPHARMA INC
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
JP2021573394
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-03-03
Filing Date
2020-06-10
Publication Date
2024-11-26
Estimated Expiration
2040-06-10

AI Technical Summary

Technical Problem

Current cancer treatment regimens using drug combinations face challenges with non-specific cytotoxic drugs causing side effects and limited immune response activation, particularly in overcoming tumor evasion mechanisms that suppress dendritic cell maturation and antigen processing.

Method used

Development of immunomodulatory antibody-drug conjugates (iADCs) that combine cytotoxic agents with immunostimulatory payloads to target tumor-specific antigens, enhancing dendritic cell activation and immune response through targeted delivery and immunogenic cell death.

Benefits of technology

iADCs improve cancer treatment efficacy by specifically delivering cytotoxic agents to tumors while stimulating immune responses, increasing effector T-cell recruitment and infiltration, and overcoming immune suppression by tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007590354000402
    Figure 0007590354000402
  • Figure 0007590354000403
    Figure 0007590354000403
  • Figure 0007590354000404
    Figure 0007590354000404
Patent Text Reader

Abstract

Provided herein are compounds, trifunctional antibody products thereof, methods and pharmaceutical compositions for use in the treatment of inflammatory and / or proliferative diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 62 / 859,629, filed June 10, 2019, and U.S. Provisional Patent Application No. 62 / 984,758, filed March 3, 2020, the contents of which are incorporated herein by reference in their entireties.

[0002] FIELD OF THE DISCLOSURE

[0002] This disclosure relates to compounds, trifunctional antibody products thereof, methods and pharmaceutical compositions for use in the treatment of inflammatory and / or proliferative diseases. [Background technology]

[0003]

[0003] Some currently used cancer treatment regimens use drug combinations that can exhibit therapeutic activity in vivo by acting through complementary mechanisms of action. For example, cytotoxic drugs are used in combination with adjuvants and / or immune system modulators. However, cytotoxic drugs are not tumor-specific, and traditional cancer chemotherapy is associated with side effects.

[0004]

[0004] Tumor cells express specific antigens that can be targeted, for example, by the use of antibodies. When antibodies are conjugated to cytotoxic drugs, i.e., when antibody-drug conjugates are used, targeted delivery of the cytotoxic drug to the tumor site can reduce the side effects associated with nonspecific cytotoxic drugs. If an immune response can be simultaneously induced, the immune system can recruit immune cells that target tumors expressing specific antigens, thereby improving the therapeutic efficacy of antibody-drug conjugate cancer therapy. Furthermore, the immune response may not be limited to targeting only tumor cells that express those tumor antigens. Peripheral tumor cells may also be targeted via antigen diffusion and / or less specific tumor cell killing mechanisms (e.g., cytokine release).

[0005]

[0005] Therapeutic induction of tumor cell apoptosis in combination with dendritic cell (DC) activation and maturation by certain currently used standard-of-care chemotherapeutics represents an attractive combinatorial approach for immuno-oncology (IO) compounds (G. Kroemer et al., Annu. Rev. Immunol. 31(2013)51-72). DCs are central to the initiation and regulation of anti-cancer immunity due to their highly sophisticated antigen presentation mechanisms (RM Steinman, J. Banchereau, Nature 449(2007)419-426). However, tumors have evolved several mechanisms that interfere with the maturation and antigen-processing capacity of tumor-resident DCs (J. Idoyaga, et al., Cancer Immunol. Immunother. 56(2007)1237-1250; B. Almand, et al., J. Immunol. 166(2001)678-689; F. Ghiringhelli, et al., J. Exp. Med. 202(2005)919-929).

[0006] In contrast to mature DCs, which efficiently promote tumor immune responses, immature or dysfunctional DCs can induce immunosuppressive effects. Tumors exploit these properties by suppressing DC maturation or inducing a dysfunctional state, allowing tumors to evade immune recognition (W. Zou, Nat. Rev. Cancer 5 (2005) 263-274; R.L. Sabado, et al., Immunotherapy 2 (2010) 37-56). Therefore, therapeutic approaches that activate tumor-resident DCs and promote the priming of tumor antigen-specific T cells may address the limitations of current anticancer therapies and increase cancer immunity. However, few studies have investigated the ability of cytotoxic cancer therapies, such as those used by antibody-drug conjugates (ADCs), to improve DC function.

[0007] One of the earliest reports identifying cytotoxic compounds with immunostimulatory functions that induce immune surveillance involved the mitotic spindle inhibitor vinblastine, which targets the beta subunit of tubulin. Vinblastine was identified as a potent and direct inducer of DC maturation, distinct from its antimitotic activity against tumor cells (N. Mizumoto, et al., Blood 106(2005)3082-3089; H. Tanaka, et al., Cancer Res. 69(2009)6978-6986; H. Tanaka, et al., Cancer Res. 69(2009)6987-6994). In an extension of this work, various tubulin toxins were shown to induce DC activation and maturation when exposed to mouse or human dendritic cells, suggesting a class effect. When tested in vitro, colchicine, vinblastine, vindesine, vincristine, combretastatin A4, dolastatin 10, dolastatin 15, monomethyl auristatin E (MMAE), ansamitocin P3, and DM1 induced phenotypic and functional dendritic cell (DC) maturation and activation (P. Muller, et al., Oncoimmunology 3(2014)e954460). Experimental endpoints used to study DC activation and maturation included expression of costimulatory molecules and maturation markers CD80 and CD86, and production of the proinflammatory cytokines IL-1b, IL-6, and IL-12. Studies testing dolastatin 10 and the synthetic analog MMAE, as well as the maytansinoid, ansamitocin P3 (K. Martin, et al., Cancer Immunol. Immunother. 63(2014)925-938; P. Muller, et al., Cancer Immunol. Res. 2(2014)741-755), were conducted in preclinical tumor growth assays in mice. These three cytotoxic agents are commonly used as payloads for ADCs and have been shown to target CD8 receptors to experimental tumors grown in mice. +It stimulates effector cell migration. When tested in vitro, it was reported to increase cytolytic activity and display major histocompatibility complex I, as well as upregulate the differentiation markers CD80 and CD86 on dendritic cells. Importantly, when tubulin inhibitor-based ADCs were administered in combination with immune checkpoint inhibitors, such as anti-PD-L1 and anti-CTLA-4 antibodies, additive antitumor effects were observed in allogeneic tumor models in mice. In these experiments, dolastatins efficiently promoted antigen uptake and migration of tumor-resident DCs to tumor-draining lymph nodes and significantly increased their ability to prime T cells (SJ Gardai, et al., Cancer Res. 75(2015)Abstract No. 2469; P. Mueller, et al., Sci. Trans. Med. 7(2015)188-202; SI Rothschild, et al., Swiss Med. Wkly. 145(2015)w14066). These findings revealed a novel mechanism of action of tubulin inhibitors when tested in vivo and provided a rationale for combining tubulin inhibitor-based ADCs with immune-based therapies.

[0008] Immunohistochemical analysis of tumor samples from patients treated with SGN-35, an ADC consisting of an anti-CD30 antibody conjugated to vcMMAE (H.P. Gerber, Biochem. Pharmacol. 79(2010)1544-1552), revealed significant changes in the population of inflammatory cells (P. Muller, et al., Cancer Immunol. Res. 2(2014)741-755). In Hodgkin lymphomas treated with SGN-35, intratumoral CD8 +A two- to three-fold increase in the number of effector T cells was observed (P. Muller, et al., Cancer Immunol. Res. 2(2014)741-755; SJ Gardai, et al., Cancer Res. 75(2015)Abstract No. 2469; P. Mueller et al., Sci. Trans. Med. 7(2015)188-202). These studies provided evidence of tubulin-destabilizing toxins to stimulate the cancer-immune cycle. However, further research is needed to identify the molecular pathways involved in tubulin inhibitors that lead to the activation and maturation of tumor-resident DCs. The field lacks a deeper understanding of the molecular events triggered by tubulin inhibitors that lead to DC activation. CD8 T cell proliferation in preclinical and clinical tumors after treatment with cytotoxic compounds. + Increased numbers of effector T cells have been reported, but it is unclear how broadly these observations apply to the development of ADCs. + There is a need in the art for the identification of optimal combination regimens between ADCs and immuno-oncology compounds that can overcome the limitations of current immune checkpoint inhibitors by increasing the recruitment and infiltration of effector T cells into tumors. Summary of the Invention [Problem to be solved by the invention]

[0009]

[0009] There is a continuing need for effective treatments for inflammatory and / or proliferative diseases. [Means for solving the problem]

[0010]

[0010] Provided herein are compounds useful, for example, for the treatment of cancer. The compounds are immunomodulator-antibody-drug conjugates, particularly trifunctional antibody conjugates such as immunostimulatory-antibody-drug conjugates (iADCs), which provide targeted delivery of two therapeutic agents (e.g., a cytotoxic agent and an immunomodulatory agent). In certain embodiments, the iADCs exhibit remarkable efficacy or bioavailability, or both, for example, for the treatment of cancer in humans. In certain embodiments, the iADCs enable targeted delivery of cytotoxic drugs to tumor sites while also enhancing immune system responses. Provided herein are compounds of formula (I):

[0011] [ka] and compounds of subformula thereof, During the ceremony, Ab is an antibody, or antigen-binding fragment thereof; each L is independently an optional linker; Each PA is independently a drug payload, Each IM is independently an immunomodulatory payload, the subscript n is an integer selected from 1 to 8; the subscript m is an integer selected from 1 to 8; Each bracketed group is covalently linked to an Ab.

[0012]

[0011] iADCs of Formula (I) and subformulas thereof are useful in methods of treating and preventing, detecting, and diagnosing cell proliferation and cancer. The conjugates are useful in methods of treating and preventing inflammatory diseases and conditions.

[0013] In another aspect, provided are compositions comprising an iADC of Formula (I) and subformulas thereof. In some embodiments, the composition is a pharmaceutical composition. Any suitable pharmaceutical composition may be used. In a further aspect, provided herein are kits comprising an iADC or pharmaceutical composition.

[0014] In another aspect, provided herein are methods of using the iADCs described herein. In some embodiments, the method is a method of delivering one or more payload moieties to a target cell or tissue. In some embodiments, the method is a therapeutic method. In some embodiments, the method is a diagnostic method. In some embodiments, the method is an analytical method. In some embodiments, the iADC is used to treat a disease or condition. In some aspects, the disease or condition is selected from cancer and / or an inflammatory disease or condition.

[0015]

[0014] Also provided herein are uses of the iADCs and pharmaceutical compositions thereof described herein for the treatment of cancer, and / or inflammatory diseases or conditions.

[0016]

[0015] In a further aspect, provided herein are linker payloads comprising a cytotoxic compound and linker payloads comprising an immunomodulatory compound, useful for preparing the iADCs described herein. [Brief explanation of the drawings]

[0017] [Figure 1]

[0016] Figure 1B is a graph showing induced immunogenic cell death (ICD) in the presence of certain anti-FolR1-ADCs described herein, as measured by ATP release in the cell culture medium (Figure 1A) and calreticulin expression on the cell surface (Figure 1B) in FolRa (also known as FolR1 or FolRα)-positive KB cells, but not in FolRa-negative A549 cells, 48 ​​hours after ADC treatment. [Figure 2]

[0017] Figures 2A and 2B show graphs depicting monocyte activation induced by immunogenic cell death in FolRa-positive KB cells in the presence of certain free compounds and anti-FolR1-ADCs described herein. Data shown are for treated isolated monocytes (two donors, Figures 2A and 2B) and treated isolated PBMCs (two donors, Figures 2C and 2D). [Figure 3]

[0018] Graphs showing monocyte activation in isolated PBMCs (two donors, Figures 3A and 3B) treated with free compound and anti-FolR1-immunostimulatory antibody conjugates (ISACs). Figures 3C and 3D show monocyte activation in isolated PBMCs (two donors, Figures 3C and 3D) in the presence of anti-FolR1-immunostimulatory / cytotoxin-antibody drug conjugates (iADCs), anti-FolR1-cytotoxin-ADCs, and anti-FolR1-ISACs. [Figure 4]

[0019] 4A-4E are graphs showing monocyte activation in isolated PBMCs in the presence of anti-FolR1-iADCs containing conjugated TLR7 / 8 agonists and cytotoxic drugs. No monocyte activation was observed for anti-GFP-iADCs conjugated to the same TLR7 / 8 agonists and cytotoxic drugs (FIGS. 4A, 4B, 4C, 4D, and 4E). [Figure 5]

[0020] Figure 5A shows graphs depicting the mean percent body weight change and tumor response for animals bearing established MC38-hFolRα tumors treated with conjugate 1 (ADC), conjugate 2 (ISAC), or a combination of conjugate 1 and conjugate 2. Figure 5A shows the effect of treatment on body weight, and Figure 5B shows the effect on tumor growth. [Figure 6]

[0021] Figure 6A shows the mean percent body weight change and tumor response in animals bearing established MC38-hFolRα tumors treated with conjugate 3 (mixed DAR4 iADC) or the combination of conjugate 1 (ADC) plus conjugate 5 (ISAC). Figure 6A shows the effect of treatment on body weight, and Figure 6B shows the effect on tumor growth. [Figure 7]

[0022] 1 is a graph showing iADC-induced monocyte activation for certain iADCs described herein. [Figure 8A]

[0023] Graph showing individual percent body weight change in animals bearing established MC38-hFolRα tumors treated with a single 20 mg / kg dose of the indicated mixed DAR4 iADC conjugates with a 1:1 or 3:1 ratio of cytotoxin to TLR agonist (gray) or vehicle (black). [Figure 8B] Graph showing individual percent body weight change in animals bearing established MC38-hFolRα tumors treated with a single 20 mg / kg dose of the indicated mixed DAR4 iADC conjugates with a 1:1 or 3:1 ratio of cytotoxin to TLR agonist (gray) or vehicle (black). [Figure 8C] Graph showing individual percent body weight change in animals bearing established MC38-hFolRα tumors treated with a single 20 mg / kg dose of the indicated mixed DAR4 iADC conjugates with a 1:1 or 3:1 ratio of cytotoxin to TLR agonist (gray) or vehicle (black). [Figure 8D] Graph showing individual percent body weight change in animals bearing established MC38-hFolRα tumors treated with a single 20 mg / kg dose of the indicated mixed DAR4 iADC conjugates with a 1:1 or 3:1 ratio of cytotoxin to TLR agonist (gray) or vehicle (black). [Figure 8E]Graph showing individual percent body weight change in animals bearing established MC38-hFolRα tumors treated with a single 20 mg / kg dose of the indicated mixed DAR4 iADC conjugates with a 1:1 or 3:1 ratio of cytotoxin to TLR agonist (gray) or vehicle (black). [Figure 9A]

[0024] Graphs depict individual tumor growth curves for animals bearing established MC38-hFolRα tumors treated with a single 20 mg / kg dose of the indicated mixed DAR4 iADC conjugates (gray) or vehicle (black) with a 1:1 or 3:1 ratio of cytotoxin to TLR agonist. The number of animals achieving a complete response (CR) is indicated in each figure. [Figure 9B] Graphs depict individual tumor growth curves for animals bearing established MC38-hFolRα tumors treated with a single 20 mg / kg dose of the indicated mixed DAR4 iADC conjugates (gray) or vehicle (black) with a 1:1 or 3:1 ratio of cytotoxin to TLR agonist. The number of animals achieving a complete response (CR) is indicated in each figure. [Figure 9C] Graphs depict individual tumor growth curves for animals bearing established MC38-hFolRα tumors treated with a single 20 mg / kg dose of the indicated mixed DAR4 iADC conjugates (gray) or vehicle (black) with a 1:1 or 3:1 ratio of cytotoxin to TLR agonist. The number of animals achieving a complete response (CR) is indicated in each figure. [Figure 9D] Graphs depict individual tumor growth curves for animals bearing established MC38-hFolRα tumors treated with a single 20 mg / kg dose of the indicated mixed DAR4 iADC conjugates (gray) or vehicle (black) with a 1:1 or 3:1 ratio of cytotoxin to TLR agonist. The number of animals achieving a complete response (CR) is indicated in each figure. [Figure 9E]Graphs depict individual tumor growth curves for animals bearing established MC38-hFolRα tumors treated with a single 20 mg / kg dose of the indicated mixed DAR4 iADC conjugates (gray) or vehicle (black) with a 1:1 or 3:1 ratio of cytotoxin to TLR agonist. The number of animals achieving a complete response (CR) is indicated in each figure. [Figure 10]

[0025] Graphs depict individual measurements from a re-challenge study in which naive (black) or mixed DAR4 iADC-treated animals with CR (gray) from Figures 9B, 9D, and 9E were re-implanted with MC38-hFolRa cells. [Figure 11]

[0026] Graph showing the mean percent body weight change in animals bearing established MC38-hFolRα tumors treated with a single dose of vehicle, 20 mg / kg of conjugate 1 (DAR4 ADC), 20 mg / kg of conjugate 11 (DAR2 ISAC), or 20 mg / kg of conjugate 13 (homogeneous 4+2 iADC). Data are expressed as the mean ± standard error of the mean (SEM). [Figure 12A]

[0027] Graphs showing individual tumor growth curves for animals bearing established MC38-hFolRα tumors treated with a single dose of vehicle, 20 mg / kg of conjugate 1 (DAR4 ADC), 20 mg / kg of conjugate 11 (DAR2 ISAC), or 20 mg / kg of conjugate 13 (homogeneous 4+2 iADC). The number of animals achieving a complete response (CR) is indicated in each figure. [Figure 12B] Graphs showing individual tumor growth curves for animals bearing established MC38-hFolRα tumors treated with a single dose of vehicle, 20 mg / kg of conjugate 1 (DAR4 ADC), 20 mg / kg of conjugate 11 (DAR2 ISAC), or 20 mg / kg of conjugate 13 (homogeneous 4+2 iADC). The number of animals achieving a complete response (CR) is indicated in each figure. [Figure 12C]Graphs showing individual tumor growth curves for animals bearing established MC38-hFolRα tumors treated with a single dose of vehicle, 20 mg / kg of conjugate 1 (DAR4 ADC), 20 mg / kg of conjugate 11 (DAR2 ISAC), or 20 mg / kg of conjugate 13 (homogeneous 4+2 iADC). The number of animals achieving a complete response (CR) is indicated in each figure. [Figure 12D] Graphs showing individual tumor growth curves for animals bearing established MC38-hFolRα tumors treated with a single dose of vehicle, 20 mg / kg of conjugate 1 (DAR4 ADC), 20 mg / kg of conjugate 11 (DAR2 ISAC), or 20 mg / kg of conjugate 13 (homogeneous 4+2 iADC). The number of animals achieving a complete response (CR) is indicated in each figure. [Figure 13]

[0028] Graphs depict individual measurements from a re-challenge study in which naive (black) or ADC- or homogenous iADC-treated animals with CR from FIG. 5 (gray) were re-implanted with MC38-hFolRa cells. [Figure 14]

[0029] Graph showing the plasma concentration-time profile of unconjugated antibody or homogeneous iADC in non-tumor-bearing C57BL / 6 mice after IV bolus administration of a 10 mg / kg dose up to day 14. Data are presented as mean ± standard deviation (SD). [Figure 15]

[0030] 13 is a graph showing that homogeneous iADC is stable in non-tumor-bearing C57BL / 6 mice following IV bolus administration of a 10 mg / kg dose with no change in mean DAR by day 7. Data are presented as mean ± standard deviation (SD) and correspond to animals treated with homogeneous iADC from FIG. [Figure 16]

[0031] 16A-C are graphs showing activation of monocytes (FIG. 16A), B cells (FIG. 16B), and DCs (FIG. 16C) by a TLR7 agonist associated with hemiasterlin warhead (compound 1) versus compound 7. [Figure 17]

[0032] Graphs showing anti-FolR1-iADC (generated with 6×pAMF; conjugate 15)-associated activation in monocytes (FIG. 17A), B cells (FIG. 17B), and DCs (FIG. 17C) compared to ISAC alone, ADC alone, or the combination of ISAC and ADC. [Figure 18]

[0033] Graphs showing activation in monocytes (FIG. 18A), B cells (FIG. 18B), and DCs (FIG. 18C) associated with anti-FolR1-ISAC (conjugate 23) and anti-FolR1-ADC (conjugate 24) versus anti-FolR1-iADC (4×pAMF+2×pAcF; conjugate 17). [Figure 19]

[0034] 19A and 19B are graphs showing activation in monocytes (FIG. 19A), B cells (FIG. 19B), and DCs (FIG. 19C) associated with anti-FolR1-ISAC (conjugate 22) and anti-FolR1-ADC (conjugate 27) versus anti-FolR1-iADC (4×pAMF+2×Q-tag; conjugate 28). [Figure 20]

[0035] 20A-20C are graphs showing comparable immune cell activation activities of three homogenous iADCs (conjugate 15, conjugate 17, and conjugate 28) in monocytes (FIG. 20A), B cells (FIG. 20B), and DCs (FIG. 20C). DETAILED DESCRIPTION OF THE INVENTION

[0018]

[0036] Cytotoxic compounds can induce antitumor immunity through two mechanisms: by direct activation and maturation of dendritic cells (DCs) and by inducing immunogenic cell death (ICD). Both mechanisms contribute to improved cross-presentation of tumor-derived antigens and specific CD8 + It has been shown to participate in adaptive immune responses through the priming of effector T cells, thereby inducing an immune response against tumors. Described herein are therapeutics that utilize both mechanisms, thereby addressing some of the current limitations of single-agent immuno-oncology therapies, such as lack of specificity and side effects.

[0019]

[0037] Described herein are trifunctional-arm antibody conjugates, such as immunomodulator-antibody-drug conjugates (iADCs), that (i) provide targeted delivery of a therapeutic agent (e.g., by targeting a tumor-specific antigen), (ii) deliver a cytotoxic payload at the target site, and (iii) deliver an immunomodulator at the target site. Cytotoxin-mediated cell death can also contribute to the recruitment of the immune system. Advantageously, iADCs recruit the immune system for co-stimulation of several cell types, resulting in a mixture of activated immune cells, cytokines, and chemokines at the tumor site while also delivering a therapeutic agent, thereby improving and / or prolonging the anti-cancer effect of the treatment and / or reducing side effects.

[0020] 1. Definition

[0038] Unless otherwise defined, all technical, notational, and other scientific and technical terms used herein are intended to have the meaning commonly understood by those skilled in the art to which the present invention pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and / or ease of reference, and the inclusion of such definitions herein should not necessarily be interpreted as representing a difference from what is commonly understood in the art. The techniques and procedures described or referenced herein are generally well understood and are described, for example, in Green & Sambrook, Molecular Cloning: A Laboratory Manual 4 th ed. (2012), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, and Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., commonly used by those skilled in the art. Where appropriate, procedures involving the use of commercially available kits and reagents are generally carried out according to manufacturer-specified protocols and conditions unless otherwise noted.

[0021]

[0039] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0022]

[0040] The term "about" refers to and encompasses the stated value and a range above and below that value. In certain embodiments, the term "about" refers to the specified value ±10%, ±5%, or ±1%. In certain embodiments, the term "about" refers to the specified value ±1 standard deviation of that value. In certain embodiments, for example, for a logarithmic scale (e.g., pH), the term "about" refers to the specified value ±0.3, ±0.2, or ±0.1.

[0023]

[0041] The term "immunoglobulin" generally refers to a class of structurally related proteins that contain two pairs of polypeptide chains: one pair of light (L) chains and one pair of heavy (H) chains. In an "intact immunoglobulin," all four chains are interconnected by disulfide bonds. The structure of immunoglobulins is well characterized. See, e.g., Paul, Fundamental Immunology 7th ed., Ch. 5 (2013) Lippincott Williams & Wilkins, Philadelphia, PA. Briefly, each heavy chain typically contains a heavy chain variable region (V H or VH) and heavy chain constant region (C H The heavy chain constant region typically comprises C H1 (or CH1), C H2 (or CH2), and C H3 (or CH3). Each light chain typically contains three domains, abbreviated as a light chain variable region (V L or VL) and a light chain constant region. The light chain constant region typically comprises L or contains one domain abbreviated as CL.

[0024]

[0042] The term "antibody" is used herein in its broadest sense. Antibodies include intact antibodies (e.g., intact immunoglobulins) and antibody fragments (e.g., antigen-binding fragments of antibodies). Antibodies contain at least one antigen-binding domain. An example of an antigen-binding domain is V H -V L It is an antigen-binding domain formed by a dimer.

[0025]

[0043] V H Area and V L The regions can be further subdivided into regions of hypervariability ("hypervariable regions (HVRs)"; also called "complementarity determining regions" (CDRs)), which are interspersed with more conserved regions. The more conserved regions are called framework regions (FRs). Each V H and V L generally contain three CDRs and four FRs arranged in the following order (from N-terminus to C-terminus): FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. The CDRs are involved in antigen binding and influence the antigen specificity and binding affinity of the antibody. See Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed. (1991) Public Health Service, National Institutes of Health, Bethesda, MD, which is incorporated by reference in its entirety.

[0026]

[0044] Light chains from any vertebrate species can be assigned to one of two types, called kappa and lambda, based on the sequence of their constant domain.

[0027]

[0045] Heavy chains from any vertebrate species can be assigned to one of five different classes (or isotypes): IgA, IgD, IgE, IgG, and IgM. These classes are also designated α, δ, ε, γ, and μ, respectively. The IgG and IgA classes are further subdivided into subclasses based on sequence and functional differences. Humans express the following subclasses: IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2.

[0028]

[0046] The amino acid sequence boundaries of the CDRs can be determined by one of skill in the art using any of several known numbering schemes, including those described by Kabat et al., supra (the "Kabat" numbering scheme); Al-Lazikani et al., 1997, J. Mol. Biol., 273:927-948 (the "Chothia" numbering scheme); MacCallum et al., 1996, J. Mol. Biol. 262:732-745 (the "Contact" numbering scheme); Lefranc et al., Dev. Comp. Immunol., 2003, 27:55-77 (the "IMGT" numbering scheme); and Honegge and Pluckthun, J. Mol. Biol., 2001, 309:657-70 (the "AHo" numbering scheme). Each of these references is incorporated by reference in its entirety.

[0029]

[0047] CDRs can be assigned using antibody numbering software such as Abnum, available at www.bioinf.org.uk / abs / abnum / and described in Abhinandan and Martin, Immunology, 2008, 45:3832-3839, which is incorporated by reference in its entirety.

[0030]

[0048] The "EU numbering scheme" is generally used when referring to residues of antibody heavy chain constant regions (e.g., as reported in Kabat et al., supra). Unless otherwise specified, the EU numbering scheme is used to refer to residues of antibody heavy chain constant regions described herein.

[0031]

[0049] "Antibody fragments" include portions of an intact antibody, such as the antigen-binding or variable region of the intact antibody. Antibody fragments include, for example, Fv fragments, Fab fragments, F(ab')2 fragments, Fab' fragments, scFv (sFv) fragments, and scFv-Fc fragments.

[0032]

[0050] An "Fv" fragment comprises a non-covalently associated dimer of one heavy- and one light-chain variable domain.

[0033]

[0051] A "Fab" fragment contains the heavy and light chain variable domains as well as the constant domain of the light chain and the first constant domain of the heavy chain (C H1 Fab fragments can be produced, for example, by recombinant methods or by papain digestion of a full-length antibody.

[0034]

[0052] An "F(ab')2" fragment contains two Fab' fragments joined by a disulfide bond near the hinge region. F(ab')2 fragments can be produced, for example, by recombinant methods or by pepsin digestion of an intact antibody. F(ab')2 fragments can be dissociated, for example, by treatment with β-mercaptoethanol.

[0035]

[0053] "Single-chain Fv" or "sFv" or "scFv" antibody fragments contain the V H Domains and V L Includes domain. V H and V Lare generally linked by a peptide linker. See Pluckthun A. (1994). In some embodiments, the linker is GGGGSGGGSGGGGS (SEQ ID NO: 75). In some embodiments, the linker is AAGSDQEPKSS (SEQ ID NO: 76). Antibodies derived from Escherichia coli. Rosenberg M. & Moore GP (Eds.), The Pharmacology of Monoclonal Antibodies vol. 113 (pp. 269-315). Springer-Verlag, New York, is incorporated by reference in its entirety.

[0036]

[0054] An "scFv-Fc" fragment comprises an scFv attached to an Fc domain. For example, the Fc domain may be attached to the C-terminus of the scFv. The Fc domain may be attached to the C-terminus of the scFv, regardless of the orientation of the variable domains of the scFv (i.e., V H -V L or V L -V H ) depending on V H or V L Any suitable Fc domain known in the art or described herein can be used. In some cases, the Fc domain comprises an IgG1 Fc domain. In some embodiments, the IgG1 Fc domain comprises SEQ ID NO: 77 or a portion thereof. SEQ ID NO: 77 is the C of the human IgG1 constant region. H1 , C H2 , and C H3 provides an array of

[0037]

[0055] The term "monoclonal antibody" refers to an antibody derived from a substantially homogeneous population of antibodies. A substantially homogeneous population of antibodies contains antibodies that are substantially similar and bind to the same epitope, except for variants that may normally arise during the production of monoclonal antibodies. Such variants are generally present in small amounts. Monoclonal antibodies are typically obtained by a process that includes selecting a single antibody from a plurality of antibodies. For example, the selection process may be the selection of a unique clone from a plurality of clones, such as a pool of hybridoma clones, phage clones, yeast clones, bacterial clones, or other recombinant DNA clones. The selected antibody can be further modified, for example, to improve its affinity for the target ("affinity maturation"), to humanize the antibody, to improve its production in cell culture, and / or to reduce its immunogenicity in a subject.

[0038]

[0056] The term "chimeric antibody" refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, while the remainder of the heavy and / or light chain is derived from a different source or species.

[0039]

[0057] "Humanized" forms of non-human antibodies are chimeric antibodies that contain minimal sequence derived from the non-human antibody. Humanized antibodies are generally human immunoglobulins (recipient antibodies) in which residues from one or more CDRs have been replaced by residues from one or more CDRs of a non-human antibody (donor antibody). The donor antibody may be any suitable non-human antibody, such as a mouse, rat, rabbit, chicken, or non-human primate antibody, that has the desired specificity, affinity, or biological effect. In some cases, selected framework region residues of the recipient antibody are replaced by corresponding framework region residues of the donor antibody. Humanized antibodies may also contain residues that are not found in either the recipient antibody or the donor antibody. Such modifications can be made to further refine antibody function. For further details, see Jones et al., Nature, 1986, 321:522-525; Riechmann et al., Nature, 1988, 332:323-329; and Presta, Curr. Op. Struct. Biol., 1992, 2:593-596, each of which is incorporated by reference in its entirety.

[0040]

[0058] A "human antibody" is one having an amino acid sequence that corresponds to the amino acid sequence of an antibody produced by a human or human cell, or that is derived from a non-human source in which a human antibody repertoire or human antibody coding sequences (e.g., obtained from a human source or designed de novo) are used. Human antibodies specifically exclude humanized antibodies.

[0041]

[0059] An "isolated antibody" is one that has been separated and / or recovered from a component of its natural environment. Components of natural environment may include enzymes, hormones, and other proteinaceous or non-proteinaceous substances. In some embodiments, an isolated antibody has been purified to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence, for example, by use of a spinning cup sequencer. In some embodiments, an isolated antibody has been purified to homogeneity by gel electrophoresis (e.g., SDS-PAGE) under reducing or non-reducing conditions and detected by Coomassie blue or silver staining. An isolated antibody includes an antibody in situ within recombinant cells, since at least one component of the antibody's natural environment will not be present. In some aspects, an isolated antibody is prepared by at least one purification step.

[0042]

[0060] In some embodiments, the isolated antibody is purified to at least 80%, 85%, 90%, 95%, or 99% by weight. In some embodiments, the isolated antibody is purified to at least 80%, 85%, 90%, 95%, or 99% by volume. In some embodiments, the isolated antibody is provided as a solution comprising at least 85%, 90%, 95%, 98%, 99%, or 100% by volume. In some embodiments, the isolated antibody is provided as a solution comprising at least 85%, 90%, 95%, 98%, 99%, or 100% by volume.

[0043]

[0061] "Affinity" refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise indicated, as used herein, "binding affinity" refers to the inherent binding affinity that reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of a molecule X for its partner Y is determined by the dissociation constant (K D) Affinity can be measured by common methods known in the art, including those described herein. Affinity can be determined, for example, using surface plasmon resonance (SPR) technology, such as a Biacore® instrument. In some embodiments, affinity is determined at 25°C.

[0044]

[0062] With respect to antibody binding to a target molecule, the terms "specific binding," "specifically binds to," "specific for," "selectively binds to," and "selective for" a particular antigen (e.g., a polypeptide target) or epitope on a particular antigen refer to binding that is measurably different from nonspecific or nonselective interactions. Specific binding can be measured, for example, by determining binding of a molecule compared to binding of a control molecule. Specific binding can also be determined by competition with a control molecule that mimics the antibody binding site on the target. Specific binding is then indicated if binding of the antibody to the target is competitively inhibited by the control molecule.

[0045]

[0063] An "affinity matured" antibody is one that has one or more alterations in one or more CDRs or FRs that result in an improvement in the affinity of the antibody for its antigen compared to a parent antibody that does not possess the alterations. In one embodiment, the affinity matured antibody has nanomolar or picomolar affinity for the target antigen. Affinity matured antibodies can be produced using various methods known in the art. For example, Marks et al. (Bio / Technology, 1992, 10:779-783, which is incorporated by reference in its entirety) describe affinity matured antibodies. H and V LAffinity maturation by domain shuffling has been described. Random mutagenesis of CDR residues and / or framework residues is described, for example, in Barbas et al. (Proc. Nat. Acad. Sci. USA, 1994, 91:3809-3813); Schier et al., Gene, 1995, 169:147-155; Yelton et al., J. Immunol., 1995, 155:1994-2004; Jackson et al., J. Immunol., 1995, 154:3310-33199; and Hawkins et al., J. Mol. Biol., 1992, 226:889-896. Each of these documents is incorporated by reference in its entirety.

[0046]

[0064] The term "amino acid" refers to the 20 common naturally occurring amino acids. Naturally occurring amino acids include alanine (Ala; A), arginine (Arg; R), asparagine (Asn; N), aspartic acid (Asp; D), cysteine ​​(Cys; C), glutamic acid (Glu; E), glutamine (Gln; Q), glycine (Gly; G), histidine (His; H), isoleucine (Ile; I), leucine (Leu; L), lysine (Lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y), and valine (Val; V), as well as the rare pyrrolysine and selenocysteine. Naturally occurring amino acids also include citrulline. Naturally encoded amino acids include post-translational variants of the 22 naturally occurring amino acids, such as prenylated amino acids, isoprenylated amino acids, myrisoylated amino acids, palmitoylated amino acids, N-linked glycosylated amino acids, O-linked glycosylated amino acids, phosphorylated amino acids, and acylated amino acids. The term "amino acid" also includes non-naturally occurring (or unnatural) or synthetic α, β, γ, or δ amino acids, including, but not limited to, those found in proteins, i.e., glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartate, glutamate, lysine, arginine, and histidine. In certain embodiments, the amino acid is in the L-configuration.Alternatively, the amino acid may be a derivative of alanyl, valinyl, leucinyl, isoleucinyl, prolinyl, phenylalaninyl, tryptophanyl, methioninyl, glycinyl, serinyl, threoninyl, cysteinyl, tyrosinyl, asparaginyl, glutaminyl, aspartoyl, glutaroyl, lysinyl, argininyl, histidinyl, β-alanyl, β-valinyl, β-leucinyl, β-isoleucinyl, β-prolinyl, β-phenylalaninyl, β-tryptophanyl, β-methioninyl, β-glycinyl, β-serinyl, β-threoninyl, β-cysteinyl, β-tyrosinyl, β-asparaginyl, β-glutaminyl, β-aspartoyl, β-glutaroyl, β-lysinyl, β-arginyl, or β-histidinyl. An unnatural amino acid is not a proteinogenic amino acid or a post-translationally modified variant thereof. In particular, the term unnatural amino acid refers to an amino acid that is not one of the 20 common amino acids or pyrrolysine or selenocysteine, or a post-translationally modified variant thereof.

[0047]

[0065] The term "conjugate" or "antibody conjugate" refers to an antibody linked to one or more payload moieties. The antibody may be any antibody described herein. The payload may be any payload described herein. The antibody may be directly linked to the payload via a covalent bond, or the antibody may be indirectly linked to the payload via a linker. Typically, the linker is covalently attached to the antibody and is also covalently attached to the payload. The term "antibody drug conjugate" or "ADC" refers to a conjugate in which at least one payload is a therapeutic moiety, such as a drug.

[0048]

[0066] A "pAMF" mutation refers to a mutant in which a phenylalanine residue, ie, paraazidomethyl-L-phenylalanine, has been added to or substituted into the polypeptide.

[0049]

[0067] The term "payload" refers to a molecular moiety that can be conjugated to an antibody. In certain embodiments, the payload is selected from the group consisting of a therapeutic moiety and / or a labeling moiety described herein.

[0050]

[0068] The term "linker" refers to a molecular moiety capable of forming at least two covalent bonds. Typically, a linker is capable of forming at least one covalent bond to an antibody and at least another covalent bond to a payload. In certain embodiments, a linker can form more than one covalent bond to an antibody. In certain embodiments, a linker may form more than one covalent bond to a payload, or may form covalent bonds with more than one payload. The remaining structure after the linker forms a bond with the antibody, payload, or both, i.e., the residue of the linker after one or more covalent bonds are formed, may still be referred to herein as a "linker." The term "linker precursor" refers to a linker having one or more reactive groups capable of forming a covalent bond with the antibody, payload, or both. In some embodiments, the linker is a cleavable linker. For example, a cleavable linker may be a linker that is released by a biodestabilizing function, which may or may not be genetically engineered. In some embodiments, the linker is a non-cleavable linker. For example, a non-cleavable linker may be a linker that is released upon antibody degradation.

[0051]

[0069] When referring to the compounds provided herein, the following terms have the following meanings unless otherwise indicated. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In the event that there are multiple definitions for terms herein, those in this section take precedence unless otherwise specified.

[0052]

[0070] As used herein, the term "alkyl," unless otherwise specified, refers to a saturated, straight-chain or branched hydrocarbon. In certain embodiments, an alkyl group is a primary, secondary, or tertiary hydrocarbon. In certain embodiments, an alkyl group contains 1 to 10 carbon atoms, i.e., C1 to C6. 10 It is alkyl. This term includes both substituted and unsubstituted alkyl groups, including, for example, halogenated alkyl groups. In some or any embodiment, alkyl is unsubstituted. In some or any embodiment, alkyl is substituted. In certain embodiments, alkyl is a fluorinated alkyl group. Non-limiting examples of the moiety that alkyl can be substituted with are selected from the group consisting of halogen (fluoro, chloro, bromo or iodo), hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate, which are unprotected or optionally protected, as known to those skilled in the art, for example, as taught in Greene, et al., Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991, which is incorporated herein by reference. In certain embodiments, the alkyl group is selected from the group consisting of methyl, CF3, CCl3, CFCl2, CF2Cl, ethyl, CH2CF3, CF2CF3, propyl, isopropyl, butyl, isobutyl, secbutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl, 3-methylpentyl, 2,2-dimethylbutyl, and 2,3-dimethylbutyl.

[0053]

[0071] As used herein, unless otherwise specified, the term "lower alkyl" refers to a saturated, straight-chain or branched hydrocarbon having 1 to 6 carbon atoms, i.e., C1-C6 alkyl. In certain embodiments, a lower alkyl group is a primary, secondary, or tertiary hydrocarbon. The term includes both substituted and unsubstituted moieties.

[0054]

[0072] As used herein, unless otherwise specified, the term "alkylene" refers to a divalent alkyl group, as defined herein. In some or any embodiments, the alkylene is unsubstituted.

[0055]

[0001] "Alkenyl" refers, in certain embodiments, to an olefinically unsaturated hydrocarbon group having up to about 11 carbon atoms or 2 to 6 carbon atoms which may be straight-chained or branched and having at least 1 or 1 to 2 sites of alkenyl unsaturation.

[0056]

[0002] "Alkenylene" refers to a divalent alkenyl as defined herein. Lower alkenylene is C2-C6-alkenylene.

[0057]

[0073] "Alkynyl" refers, in certain embodiments, to an acetylenically unsaturated hydrocarbon group having up to about 11 carbon atoms, or 2 to 6 carbon atoms which may be straight-chained or branched, and having at least 1 or 1 to 2 sites of alkynyl unsaturation. Non-limiting examples of alkynyl groups include acetylene, ethynyl (-C≡CH), propargyl (-CHC≡CH), and the like.

[0058]

[0074] "Alkynylene" refers to a divalent alkynyl as defined herein. Lower alkynylene is C2-C6-alkynylene.

[0059]

[0075] As used herein, unless otherwise specified, the term "aryl" refers to phenyl, biphenyl, or naphthyl. This term includes both substituted and unsubstituted moieties. Aryl groups can be substituted with any of the listed moieties, including, but not limited to, one or more moieties selected from the group consisting of halogen (fluoro, chloro, bromo, or iodo), alkyl, haloalkyl, hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate, unprotected or optionally protected, as known to those skilled in the art, for example, as taught in Greene, et al., Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991.

[0060]

[0076] As used herein, unless otherwise specified, the term "arylene" refers to a divalent aryl group, as defined herein.

[0061]

[0077] "Alkarylene" refers to an arylene group, as defined herein, where the aryl ring is substituted with one or two alkyl groups. "Substituted alkarylene" refers to an alkarylene, as defined herein, where the arylene group is further substituted as defined for aryl.

[0062]

[0078] "Aralkylene" refers to a -CH-arylene-, -arylene-CH-, or -CH-arylene-CH- group, where arylene is as defined herein. "Substituted aralkylene" refers to aralkylene, as defined herein, where the aralkylene group is substituted as defined for aryl.

[0063]

[0079] "Alkoxy" and "alkoxyl" refer to the group --OR', where R' is alkyl or cycloalkyl. Alkoxy groups include, by way of example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, 1,2-dimethylbutoxy, and the like.

[0064]

[0080] "Alkoxycarbonyl" refers to a -C(O)-alkoxy radical where alkoxy is as defined herein.

[0065]

[0081] "Amino" refers to the -NH2 radical.

[0066]

[0082] As used herein, unless otherwise specified, the term "alkylamino" refers to a group in which R' is C as defined herein. 1~10 In some or any embodiments, alkylamino refers to an -NHR' group that is alkyl. 1~6 It is alkylamino.

[0067]

[0083] As used herein, unless otherwise specified, the term "dialkylamino" refers to a group in which each R' is independently C as defined herein. 1~10 In some or any embodiments, dialkylamino refers to a -NR'R' group that is di-C 1~6 It is alkylamino.

[0068]

[0084] "Carboxyl" or "carboxy" refers to the -C(O)OH radical.

[0069]

[0085] As used herein, unless otherwise specified, the term "cycloalkyl" refers to a saturated cyclic hydrocarbon. In certain embodiments, a cycloalkyl group can be saturated, and / or bridged, and / or unbridged, and / or fused bicyclic groups. In certain embodiments, a cycloalkyl group contains 3 to 10 carbon atoms, i.e., C3 to C6. 10In some embodiments, the cycloalkyl is a cycloalkyl having 3 to 15 carbon atoms (C 3~15 ), 3~10 pieces (C 3~10 ), or 3 to 7 (C 3~7 In certain embodiments, the cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexylmethyl, cycloheptyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, decalinyl, or adamantyl.

[0070]

[0086] As used herein, the term "cycloalkylene" refers to a divalent cycloalkyl group, as defined herein. Lower cycloalkylene refers to C3-C6-cycloalkylene.

[0071]

[0087] As used herein, a "fused bicyclic aryl" is naphthyl.

[0072]

[0088] The terms "heterocyclyl" and "heterocyclic" refer to monovalent, monocyclic non-aromatic and / or polycyclic ring systems containing at least one non-aromatic ring, wherein one or more of the non-aromatic ring atoms are heteroatoms independently selected from O, S, and N, and the remaining ring atoms of the non-aromatic ring are carbon atoms; any aromatic ring atoms are optionally heteroatoms independently selected from O, S, and N, and the remaining ring atoms of the non-aromatic ring are carbon atoms. In certain embodiments, a heterocyclyl or heterocyclic group has 3 to 20, 3 to 15, 3 to 10, 3 to 8, 4 to 7, 4 to 11, or 5 to 6 ring atoms. The heterocyclyl group is attached to the remainder of the molecule through the non-aromatic ring. In certain embodiments, the heterocyclyl is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, and may include fused or bridged ring systems; the nitrogen or sulfur atoms may be optionally oxidized; the nitrogen atoms may be optionally quaternized; and some rings may be partially or fully saturated or aromatic. The heterocyclyl may be attached to the main structure at any heteroatom or carbon atom of its non-aromatic ring to produce a stable compound. Heterocycloalkyl refers to a heterocycle that is a monovalent, monocyclic or polycyclic, non-aromatic ring system. In some or any embodiments, the heterocycloalkyl is a monovalent, monocyclic or polycyclic, fully saturated ring system.Such heterocyclic and / or heterocycloalkyl radicals include 2,5-diazabicyclo[2.2.2]octanyl, 3,9-diazabicyclo[3.3.2]decanyl), azepinyl, benzodioxanyl, benzodioxolyl, benzofuranonyl, benzopyranonyl, benzopyranyl, benzotetrahydrofuranyl, benzotetrahydrothienyl, benzothiopyranyl, benzoxazinyl, β-carbolinyl, chromanyl, chromonyl, cinnolinyl, coumarinyl, decahydroisoquinolinyl, dihydrobenzothiazinyl, dihydrobenzisoxazinyl, dihydrofuryl, dihydroisoindolyl, dihydropyranyl, dihydropyrazolyl, dihydropyrazinyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, and dioxolanyl. , 1,4-dithianyl, furanonyl, imidazolidinyl, imidazolinyl, indolinyl, isobenzotetrahydrofuranyl, isobenzotetrahydrothienyl, isochromanyl, isocoumarinyl, isoindolinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, oxazolidinonyl, oxazolidinyl, oxiranyl, piperazinyl, piperidinyl, 4-piperidonyl, pyrazolidinyl, pyrazolinyl, pyrrolidinyl, pyrrolinyl, quinuclidinyl, tetrahydrofuryl, tetrahydroisoquinolinyl, tetrahydropyranyl, tetrahydrothienyl, thiamorpholinyl, thiazolidinyl, tetrahydroquinolinyl, and 1,3,5-trithianyl. In certain embodiments, heterocyclic rings may be optionally substituted as described herein. In some or any embodiments, heterocyclic and heterocycloalkyl are substituted with 1, 2, or 3 groups independently selected from halogen (fluoro, chloro, bromo, or iodo), alkyl, haloalkyl, hydroxyl, amino, alkylamino, and alkoxy. In some embodiments, heterocycloalkyl groups may contain 1, 2, 3, or 4 heteroatoms.Those skilled in the art will recognize that a 4-membered heterocycloalkyl may generally contain 1 or 2 heteroatoms, a 5- to 6-membered heterocycloalkyl may generally contain 1 or 2 heteroatoms, and a 7- to 10-membered heterocycloalkyl may generally contain 1, 2, 3, or 4 heteroatoms.

[0073]

[0089] "Heterocycloalkylene" refers to a divalent heterocycloalkyl, as defined herein.

[0074]

[0090] "N-linked heterocycloalkyl" or "N-linked heterocyclyl" refers to a heterocycloalkyl, as defined above, containing at least one nitrogen, where the heterocycloalkyl is attached to the main structure via a nitrogen atom in a non-aromatic ring. In some or any embodiments, the N-linked heterocycloalkyl and / or N-linked heterocyclyl are fully saturated.

[0075]

[0091] The term "heteroaryl" refers to a monovalent monocyclic aromatic and / or polycyclic aromatic group in which at least one aromatic ring contains one or more heteroatoms independently selected from O, S, and N within the ring. Each ring of a heteroaryl group can contain one or two O atoms, one or two S atoms, and / or one to four N atoms, provided that the total number of heteroatoms in each ring is four or less and each ring contains at least one carbon atom. In certain embodiments, a heteroaryl has 5 to 20, 5 to 15, or 5 to 10 ring atoms. A heteroaryl may be attached to the remainder of the molecule through a nitrogen or carbon atom. In some embodiments, monocyclic heteroaryl groups include, but are not limited to, furanyl, imidazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, imidazolyl, triazolyl, thiadiazolyl, thiazolyl, thienyl, tetrazolyl, triazinyl, and triazolyl. Bicyclic heteroaryl groups include, but are not limited to, benzofuranyl, benzimidazolyl, benzisoxazolyl, benzopyranyl, benzothiadiazolyl, benzothiazolyl, benzothienyl, benzotriazolyl, benzoxazolyl, furopyridyl, imidazopyridinyl, imidazothiazolyl, indolizinyl, indolyl, indazolyl, isobenzofuranyl, isobenzothienyl, isoindolyl, isoquinolinyl, isothiazolyl, naphthyridinyl, oxazolopyridinyl, phthalazinyl, pteridinyl, purinyl, pyridopyridyl, pyrrolopyridyl, quinolinyl, quinoxalinyl, quinazolinyl, thiadiazolopyrimidyl, and thienopyridyl. Tricyclic heteroaryl groups include, but are not limited to, acridinyl, benzindolyl, carbazolyl, dibenzofuranyl, perimidinyl, phenanthrolinyl, phenanthridinyl, phenarsazinyl, phenazinyl, phenothiazinyl, phenoxazinyl, and xanthenyl. In certain embodiments, heteroaryl can be optionally substituted as described herein.A "substituted heteroaryl" is a heteroaryl substituted as defined for aryl.

[0076]

[0092] The term "heteroarylene" refers to a divalent heteroaryl group, as defined herein. A "substituted heteroarylene" is a heteroarylene substituted as defined for aryl.

[0077]

[0093] "Partially saturated heteroaryl" refers to a polycyclic (e.g., bicyclic, tricyclic) fused ring system containing at least one non-aromatic ring and at least one aromatic ring, where one or more of the non-aromatic ring atoms and / or one or more of the aromatic ring atoms are independently a heteroatom selected from O, S, and N, and the remaining ring atoms are carbon atoms. A partially saturated heteroaryl group is attached to the remainder of the molecule via an aromatic ring. In certain embodiments, a partially saturated heteroaryl group has 6 to 20, 6 to 15, 6 to 10, 6 to 8, or 8 to 11 ring atoms. In certain embodiments, a partially saturated heteroaryl group has 8, 9, 10, or 11 (in some embodiments, 9 or 10) ring atoms. A partially saturated heteroaryl may be attached to the main structure at any heteroatom or carbon atom of the aromatic ring to produce a stable compound. In some or any embodiments, an oxo group may be present as a substituent on one of the ring atoms.Partially saturated heteroaryl radicals include benzodioxanyl, benzodioxolyl, benzofuranonyl, benzopyranonyl, benzopyranyl, benzotetrahydrofuranyl, benzotetrahydrothienyl, benzothiopyranyl, benzoxazinyl, chromanyl, chromonyl, cinnolinyl, coumarinyl, decahydroisoquinolinyl, dihydrobenzisothiazinyl, dihydrobenzisoxazinyl, dihydrofuryl, dihydroisoindolyl, dihydropyranyl, dihydropyrazolyl, dihydropyrazinyl, tetrahydropyrazinyl, dihydropyrazinonyl, dihydropyridinyl, tetrahydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, furanonyl, imidazolinyl, indolinyl, tetrahydroindolyl, isoindolinyl, tetrahydroiso

[0033] The aryl group may consist of or comprise one or more of: indolyl, isobenzotetrahydrofuranyl, isobenzotetrahydrothienyl, isochromanyl, isocoumarinyl, isoindolinyl, dihydroisoxazolyl, oxazinyl, dihydrooxazinyl, oxo-oxazolyl, dihydrooxazolyl, dihydropiperidonyl, dihydro-4-piperidonyl, dihydropyrazolyl, dihydropyrazolinyl, dihydropyrrolyl, azabicyclo[2.2.2]oct-2-enyl, dihydrofuryl, tetrahydroisoquinolinyl, dihydropyranyl, pyranyl, dihydrothienyl, oxathiazinyl, dihydrothiazolyl, tetrahydroquinolinyl, and 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl.In certain embodiments, the partially saturated heteroaryl radical is benzodioxanyl, benzodioxolyl, benzofuranonyl, benzopyranonyl, benzopyranyl, benzotetrahydrofuranyl, benzotetrahydrothienyl, benzothiopyranyl, benzoxazinyl, chromanyl, chromonyl, coumarinyl, dihydrobenzisothiazinyl, dihydrobenzisoxazinyl, dihydroisoindolyl, indolinyl, isobenzotetrahydrofuranyl, isobenzotetrahydrothienyl, isochromanyl, isocoumarinyl, isoindolinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, or 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl. In certain embodiments, the partially saturated heteroaryl may be optionally substituted as described herein.

[0078]

[0094] "Spiroheterocyclic" or "spiroheterocycle" or "spiroheterocycloalkyl" refers to a heterocycle, as defined herein, comprising two rings bonded to each other through a common atom. Non-limiting examples of spiroheterocycles include those that are bonded to another ring (e.g., ring B shown below) through a common atom:

[0079] [ka] The spiro heterocycloalkyl optionally includes, for example, 1 to 2 C 1~3 It may be substituted with alkyl.

[0080]

[0095] As used herein, and unless otherwise specified, the term "protecting group" refers to a group added to an oxygen, nitrogen, or phosphorus atom to prevent its further reaction or for other purposes. A wide variety of oxygen and nitrogen protecting groups are known to those skilled in the art of organic synthesis.

[0081]

[0096] "Pharmaceutically acceptable salt" refers to any salt of a compound provided herein that retains its biological properties and is not toxic or otherwise undesirable for pharmaceutical use. Such salts may be derived from a variety of organic and inorganic counterions well known in the art.Such salts include, but are not limited to, (1) hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, sulfamic acid, acetic acid, trifluoroacetic acid, trichloroacetic acid, propionic acid, hexanoic acid, cyclopentylpropionic acid, glycolic acid, glutaric acid, pyruvic acid, lactic acid, malonic acid, succinic acid, sorbic acid, ascorbic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, picric acid, cinnamic acid, mandelic acid, phthalic acid, lauric acid, methanesulfonic acid, ethanesulfonic acid, methyl ... Acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphoric acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, lauryl sulfuric acid, gluconic acid, benzoic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, cyclohexylsulfamido or (2) salts formed when an acidic proton present in the parent compound is replaced by (a) a metal ion, such as an alkali metal ion, alkaline earth ion, or aluminum ion, or an alkali metal or alkaline earth metal hydroxide, such as sodium, potassium, calcium, magnesium, aluminum, lithium, zinc, and barium hydroxide, or ammonia, or (b) an organic base, such as an aliphatic, alicyclic, or aromatic organic amine, such as ammonia, methylamine, dimethylamine, diethylamine, picoline, ethanolamine, diethanolamine, triethanolamine, ethylenediamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylene-diamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, N-methylglucamine piperazine, tris(hydroxymethyl)-aminomethane, tetramethylammonium hydroxide, and the like.

[0082]

[0097] Pharmaceutically acceptable salts further include, by way of example only and not limited to, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like, and if the compound contains a basic functional group, salts of non-toxic organic or inorganic acids, such as hydrohalides, e.g., hydrochlorides and hydrobromides, sulfates, phosphates, sulfamate, nitrates, acetates, trifluoroacetates, trichloroacetates, propionates, hexanoates, cyclopentylpropionates, glycolates, glutarates, pyruvates, lactates, malonates, succinates, sorbates, ascorbates, malates, maleates, fumarates, tartrates, citrates, benzoates, 3-(4-hydroxybenzoyl)benzoates, picrates, Examples of suitable salts include cinnamate, mandelate, phthalate, laurate, methanesulfonate (mesylate), ethanesulfonate, 1,2-ethanedisulfonate, 2-hydroxyethanesulfonate, benzenesulfonate (besylate), 4-chlorobenzenesulfonate, 2-naphthalenesulfonate, 4-toluenesulfonate, camphorate, camphorsulfonate, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylate, glucoheptonate, 3-phenylpropionate, trimethyl acetate, tert-butyl acetate, lauryl sulfate, gluconate, benzoate, glutamate, hydroxynaphthoate, salicylate, stearate, cyclohexylsulfamate, quinate, and muconate.

[0083]

[0098] The terms "substantially free" or "substantially absent" with respect to a composition refer to a composition that contains at least 85% or 90%, and in certain embodiments 95%, 98%, 99%, or 100% by weight of a specified enantiomer of the compound. In certain embodiments, in the methods and compounds provided herein, the compound is substantially free of the enantiomer.

[0084]

[0099] Similarly, the term "isolated" with respect to a composition refers to a composition that contains at least 85%, 90%, 95%, 98%, and 99% to 100% by weight of the compound, with the remainder containing other species or enantiomers.

[0085]

[0100] "Solvate" refers to a compound provided herein or a salt thereof that further includes a stoichiometric or non-stoichiometric amount of solvent bound by non-covalent intermolecular forces. When the solvent is water, the solvate is a hydrate.

[0086]

[0101] "Isotopic composition" refers to the amount of each isotope present for a given atom, and "natural isotopic composition" refers to the composition or abundance of the isotopes that naturally occur for a given atom. Atoms containing these natural isotopic compositions may also be referred to herein as "non-enriched" atoms. Unless otherwise specified, atoms of compounds described herein are intended to represent any stable isotope of that atom. For example, unless otherwise specified, if a position is specifically designated as "H" or "hydrogen", it is understood that the position has hydrogen with its natural isotopic composition.

[0087]

[0102] "Isotopic enrichment" refers to the percentage of a specific isotope incorporated into a molecule in place of the natural isotopic abundance of that atom.For example, 1% deuterium enrichment at a given position means that 1% of the molecules in a given sample contain deuterium at the specified position.Since the naturally occurring distribution of deuterium is approximately 0.0156%, the deuterium enrichment at any position in a compound synthesized using non-enriched starting materials is approximately 0.0156%.The isotopic enrichment of the compounds provided herein can be determined using conventional analytical methods known to those skilled in the art, including mass spectrometry and nuclear magnetic resonance spectroscopy.

[0088]

[0103] "Isotopically enriched" refers to an atom having an isotopic composition other than the natural isotopic composition of that atom. "Isotopically enriched" can also refer to a compound containing at least one atom having an isotopic composition other than the natural isotopic composition of that atom.

[0089]

[0104] As used herein, "alkyl," "alkylene," "alkylamino," "dialkylamino," "cycloalkyl," "aryl," "arylene," "alkoxy," "alkoxycarbonyl," "amino," "carboxyl," "heterocyclyl," "heterocycloalkyl," "heteroaryl," "heteroarylene," "partially saturated heteroaryl," "spiroheterocyclyl," "carboxyl," and "amino acid" groups optionally contain deuterium in one or more positions where a hydrogen atom would be present, and the deuterium composition of one or more atoms is other than the natural isotopic composition.

[0090]

[0105] Also, as used herein, "alkyl," "alkylamino," "dialkylamino," "cycloalkyl," "aryl," "alkoxy," "alkoxycarbonyl," "amino," "carboxyl," "heterocyclyl," "heteroaryl," "partially saturated heteroaryl," "spiroheterocyclyl," "carboxyl," and "amino acid" groups optionally contain carbon-13 in an amount other than its natural isotopic composition.

[0091]

[0106] As used herein, EC 50 refers to the dose, concentration, or amount of a particular test compound that elicits a dose-dependent response at 50% of the maximal expression of the particular response induced, elicited, or potentiated by that particular test compound.

[0092]

[0107] As used herein, IC 50 refers to the amount, concentration, or dose of a particular test compound that achieves 50% inhibition of a maximal response in an assay that measures such response.

[0093]

[0108] As used herein, the terms "subject" and "patient" are used interchangeably herein. The terms "subject" (singular and plural) refer to mammals, including non-primates (e.g., cows, pigs, horses, cats, dogs, rats, and mice) and primates (e.g., monkeys such as cynomolgus monkeys and chimpanzees, and humans), e.g., humans. In certain embodiments, the subject is resistant or non-responsive to current treatments for hepatitis C infection. In another embodiment, the subject is a farm animal (e.g., horse, cow, pig, etc.) or a pet (e.g., dog or cat). In certain embodiments, the subject is a human.

[0094]

[0109] As used herein, the terms "therapeutic agent" (singular and plural) refer to any agent that can be used in the treatment or prevention of a disorder or one or more symptoms thereof. In certain embodiments, the term "therapeutic agent" includes the compounds and / or antibody conjugates provided herein. In certain embodiments, a therapeutic agent is an agent that is known to be useful for, has been used for, or is currently being used to treat or prevent a disorder or one or more symptoms thereof.

[0095]

[0110] As used herein, the term "therapeutically effective amount" or "effective amount" refers to an amount of an antibody or composition that, when administered to a subject, is effective in treating a disease or disorder. In some embodiments, a therapeutically effective amount or effective amount refers to an amount of an antibody or composition that, when administered to a subject, is effective in preventing or ameliorating a disease or disease progression, or results in the amelioration of symptoms. A "therapeutically effective amount" will vary depending, among other things, on the compound, the disease and its severity, and the age, weight, etc., of the subject being treated.

[0096]

[0111] "Treating" or "treatment" of any disease or disorder, in certain embodiments, refers to ameliorating the disease or disorder present in a subject. In another embodiment, "treating" or "treatment" includes improving at least one physical parameter, which may be imperceptible to the subject. In yet another embodiment, "treating" or "treatment" includes modulating the disease or disorder, either physically (e.g., stabilization of a perceptible symptom) or physiologically (e.g., stabilization of a physical parameter), or both. In yet another embodiment, "treating" or "treatment" includes delaying or preventing the onset of the disease or disorder, or delaying or preventing the recurrence of the disease or disorder. In yet another embodiment, "treating" or "treatment" includes reducing or eliminating either the disease or disorder, or delaying the progression of the disease or disorder or one or more symptoms of the disease or disorder, or reducing the severity of the disease or disorder or one or more symptoms of the disease or disorder.

[0097]

[0112] As used herein, the term "inhibiting growth" (e.g., with reference to cells such as tumor cells) is intended to include measurably reducing cell growth (e.g., tumor cell growth) upon contact with an antibody or antibody conjugate compared to the growth of the same cell not contacted with the antibody or antibody conjugate. In some embodiments, growth can be inhibited by at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 99%, or 100%. Reduction in cell growth can occur by various mechanisms, including, but not limited to, antibody internalization, apoptosis, necrosis, and / or effector function-mediated activity.

[0098]

[0113] "Treating" or "treatment" of any disease or disorder refers, in certain embodiments, to ameliorating a disease or disorder present in a subject. In another embodiment, "treating" or "treatment" includes improving at least one physical parameter, which may not be apparent to the subject. In yet another embodiment, "treating" or "treatment" includes modulating the disease or disorder, either physically (e.g., stabilizing discernible symptoms) or physiologically (e.g., stabilizing physical parameters), or both. In yet another embodiment, "treating" or "treatment" includes delaying the onset of the disease or disorder.

[0099]

[0114] As used herein, the term "prophylactic agent" or "prophylactic agents" refers to any agent(s) that can be used in the prevention of a disorder or one or more symptoms thereof. In certain embodiments, the term "prophylactic agent" includes the compounds provided herein. In certain other embodiments, the term "prophylactic agent" does not refer to the compounds provided herein. For example, a prophylactic agent is an agent that is known to be useful for, or has been used, or is currently being used to prevent or inhibit the onset, development, progression, and / or severity of a disorder.

[0100]

[0115] As used herein, the phrase "prophylactically effective amount" refers to an amount of a treatment (e.g., a prophylactic agent) sufficient to result in the prevention or reduction of the development, recurrence, or onset of one or more symptoms associated with a disorder (or an amount sufficient to enhance or improve the prophylactic effect of another treatment (e.g., another prophylactic agent)).

[0101]

[0116] In some chemical structures depicted herein, certain substituents, chemical groups, and atoms may be represented by curved / wavy lines (e.g.,

[0102] [ka] ) are shown with, for example, but not limited to:

[0103] [ka] In some structures, such as, but not limited to, the curved / wavy line indicates an atom in the backbone of the conjugate or linker-payload structure to which the depicted chemical entity is attached.

[0104] [ka] In some structures, such as, the curved / wavy line indicates atoms in the antibody or antibody fragment to which the depicted chemical entity is attached as well as atoms in the backbone of the conjugate or linker-payload structure.

[0105]

[0117] The term "site-specific" refers to the modification of a polypeptide at a predetermined sequence position of the polypeptide. The modification is at a single, predictable residue of the polypeptide with little or no variation. In certain embodiments, a modified amino acid is introduced at that sequence position, e.g., recombinantly or synthetically. Similarly, a moiety may be "site-specifically" linked to a residue at a particular sequence position of the polypeptide. In certain embodiments, a polypeptide may contain more than one site-specific modification.

[0106] 2. Conjugates

[0118] Provided herein are immunostimulatory antibody-drug conjugates (iADCs). In certain embodiments, the iADCs are dual conjugates of an antibody with a TLR7 agonist and a cytotoxin. The conjugates comprise an antibody that recognizes a suitable antigen (e.g., a tumor antigen) that is covalently linked to a payload (e.g., a PA and IM described herein) directly or indirectly via a linker. In certain embodiments, the antibody is linked to one payload. In further embodiments, the antibody is linked to more than one payload. In certain embodiments, the antibody is linked to two, three, four, five, six, seven, eight, or more payloads.

[0107]

[0119] The payload may be any payload deemed useful by one of skill in the art. In certain embodiments, the payload is a therapeutic moiety. In certain embodiments, the payload is a diagnostic moiety, e.g., a label. Useful payloads are described in the sections and examples below.

[0108]

[0120] The linker may be any linker capable of forming at least one bond with the antibody and at least one bond with the payload. Useful linkers are described in the sections and examples below.

[0109]

[0121] Antibodies are typically proteins comprising multiple polypeptide chains. In certain embodiments, antibodies are heterotetramers comprising two identical light (L) chains and two identical heavy (H) chains. Each light chain may be linked to a heavy chain by one covalent disulfide bond. Each heavy chain may be linked to the other heavy chain by one or more covalent disulfide bonds. Each heavy chain and each light chain may also have one or more intrachain disulfide bonds. As known to those skilled in the art, each heavy chain typically comprises a variable domain (V H ) followed by several constant domains. Each light chain typically has a variable domain (V L) and constant domains. As is known to those skilled in the art, antibodies typically have a selective affinity for their target molecules, or antigens.

[0110]

[0122] The antibodies provided herein may have any antibody form known to those skilled in the art. The antibodies provided herein may be full-length or fragments. Representative full-length antibodies include IgA, IgA1, IgA2, IgD, IgE, IgG, IgG1, IgG2, IgG3, IgG4, IgM, etc. Representative fragments include Fv, Fab, Fc, scFv, scFv-Fc, etc.

[0111]

[0123] In certain embodiments, the antibody of the conjugate comprises one, two, three, four, five, or six CDR sequences described herein. In certain embodiments, the antibody of the conjugate comprises a heavy chain variable domain (V) as described herein. H In certain embodiments, the antibody of the conjugate comprises a light chain variable domain (V L In certain embodiments, the antibody of the conjugate comprises a heavy chain variable domain (V H ) and a light chain variable domain (V) as described herein L In certain embodiments, the antibody of the conjugate comprises a pair of heavy chain variable domains and a light chain variable domain (V H -V L In certain embodiments, the antibody of the conjugate comprises three heavy chain CDRs and three light chain CDRs (any V CDR pair) having sequences consisting of the heavy chain CDRs and light chain CDRs of any paired heavy chain variable domain and light chain variable domain described herein. H -V L It contains six CDRs (six pairs of CDRs).

[0112]

[0124] In certain embodiments, antibody conjugates may be formed from antibodies comprising one or more reactive groups. In certain embodiments, antibody conjugates may be formed from antibodies composed entirely of naturally encoded amino acids. Those skilled in the art will recognize that some naturally encoded amino acids contain reactive groups capable of conjugating to a payload or linker. Such reactive groups include cysteine ​​side chains, lysine side chains, and amino terminal groups. In such embodiments, the antibody conjugate may comprise a payload or linker linked to a residue of an antibody reactive group. In such embodiments, the payload precursor or linker precursor comprises a reactive group capable of forming a bond with an antibody reactive group. Exemplary reactive groups include maleimide groups, activated carbonates (including, but not limited to, p-nitrophenyl esters), activated esters (including, but not limited to, N-hydroxysuccinimide, p-nitrophenyl esters, and aldehydes). Particularly useful reactive groups include maleimides and succinimides, e.g., N-hydroxysuccinimide, for forming bonds with cysteine ​​and lysine side chains. Additional reactive groups are described in the following sections and examples.

[0113]

[0125] In a further embodiment, the antibody comprises one or more modified amino acids having a reactive group as described herein. Typically, the modified amino acid is not a naturally-encoded amino acid. Such modified amino acids may comprise a reactive group useful for forming a covalent bond with a linker precursor or a payload precursor. One skilled in the art can use the reactive group to link a polypeptide to any molecular entity capable of forming a covalent bond with the modified amino acid. Thus, provided herein is a conjugate comprising an antibody comprising a modified amino acid residue linked directly or indirectly via a linker to a payload. Representative modified amino acids are described in the following sections. Generally, the modified amino acid has a reactive group capable of forming a bond with a linker or payload having a complementary reactive group.

[0114]

[0126] In certain embodiments, the unnatural amino acid is placed at selected positions in the polypeptide chain of the antibody. These positions have been identified as providing optimal sites for substitution with the unnatural amino acid. Each site can hold the unnatural amino acid with optimal structure, function, and / or method for generating the antibody.

[0115]

[0127] In certain embodiments, the site-specific locations for substitutions provide stable antibodies. Stability can be measured by any technique apparent to one of skill in the art.

[0116]

[0128] In certain embodiments, the site-specific locations for substitutions provide antibodies with optimal functional properties. For example, an antibody may exhibit little or no loss of binding affinity to its target antigen compared to an antibody without the site-specific unnatural amino acid. In certain embodiments, an antibody may exhibit enhanced binding compared to an antibody without the site-specific unnatural amino acid.

[0117]

[0129] In certain embodiments, the site-specific locations for substitution provide antibodies that can be advantageously engineered. For example, in certain embodiments, the antibodies exhibit advantageous properties in their synthetic methods, as discussed below. In certain embodiments, the antibodies may exhibit little or no loss in yield during production compared to antibodies that do not have the site-specific unnatural amino acid. In certain embodiments, the antibodies can exhibit enhanced yield during production compared to antibodies that do not have the site-specific unnatural amino acid. In certain embodiments, the antibodies may exhibit little or no loss in tRNA silencing compared to antibodies that do not have the site-specific unnatural amino acid. In certain embodiments, the antibodies can exhibit enhanced tRNA silencing during production compared to antibodies that do not have the site-specific unnatural amino acid.

[0118]

[0130] In certain embodiments, the site-specific locations for substitutions provide antibodies with advantageous solubility. In certain embodiments, the antibodies may exhibit little or no loss in solubility compared to antibodies without the site-specific unnatural amino acid. In certain embodiments, the antibodies may exhibit enhanced solubility compared to antibodies without the site-specific unnatural amino acid.

[0119]

[0131] In certain embodiments, the site-specific locations for substitutions provide antibodies with advantageous expression. In certain embodiments, the antibodies may exhibit little or no loss of expression compared to antibodies without the site-specific unnatural amino acid. In certain embodiments, the antibodies may exhibit enhanced expression compared to antibodies without the site-specific unnatural amino acid.

[0120]

[0132] In certain embodiments, the site-specific locations for substitutions provide antibodies with favorable folding. In certain embodiments, the antibodies may exhibit little or no loss of correct folding compared to antibodies without the site-specific unnatural amino acid. In certain embodiments, the antibodies may exhibit enhanced folding compared to antibodies without the site-specific unnatural amino acid.

[0121]

[0133] In certain embodiments, the site-specific locations for substitution provide antibodies capable of advantageous conjugation. As described below, some unnatural amino acids have side chains or functional groups that facilitate conjugation of the antibody to a second agent, either directly or via a linker. In certain embodiments, the antibodies can exhibit enhanced conjugation efficiency compared to antibodies that do not have the same or other unnatural amino acids at other positions. In certain embodiments, the antibodies can exhibit enhanced conjugation yield compared to antibodies that do not have the same or other unnatural amino acids at other positions. In certain embodiments, the antibodies can exhibit enhanced conjugation specificity compared to antibodies that do not have the same or other unnatural amino acids at other positions.

[0122]

[0134] In some embodiments, one or more unnatural amino acids are positioned at selected site-specific positions in at least one polypeptide chain of an antibody. The polypeptide chain may be any polypeptide chain of an antibody, including, but not limited to, any light chain or any heavy chain. The site-specific positions may be located in any domain of an antibody, including any variable domain and any constant domain.

[0123]

[0135] In certain embodiments, the antibodies provided herein comprise one unnatural amino acid at a site-specific position. In certain embodiments, the antibodies provided herein comprise two unnatural amino acids at a site-specific position. In certain embodiments, the antibodies provided herein comprise three unnatural amino acids at a site-specific position. In certain embodiments, the antibodies provided herein comprise more than three unnatural amino acids at a site-specific position.

[0124]

[0136] In certain embodiments, the antibodies provided herein comprise one or more unnatural amino acids or post-translationally modified variants thereof at a position independently selected from the group consisting of heavy chain or light chain residues HC-F404, HC-K121, HC-Y180, HC-F241, HC-221, LC-T22, LC-S7, LC-N152, LC-K42, LC-E161, LC-D170, HC-S136, HC-S25, HC-A40, HC-S119, HC-S190, HC-K222, HC-R19, HC-Y52, or HC-S70, according to the Kabat, Chothia, or EU numbering scheme. In certain embodiments, the antibodies provided herein comprise one or more unnatural amino acids or post-translationally modified variants thereof at a position independently selected from the group consisting of HC-180, HC-222, LC-7, or LC-42, according to the Kabat, Chothia, or EU numbering scheme. In these designations, HC refers to a heavy chain residue and LC refers to a light chain residue. In certain embodiments, the unnatural amino acid is at HC-F404. In certain embodiments, the unnatural amino acid is at HC-Y180. In certain embodiments, the unnatural amino acid is at HC-F404 and HC-Y180. In certain embodiments, the unnatural amino acid is at HC-K222. In certain embodiments, the unnatural amino acid is at LC-S7. In certain embodiments, the unnatural amino acid is at LC-K42. In certain embodiments, the unnatural amino acid is at HC-Y180 and LC-K42. In certain embodiments, the unnatural amino acid is at HC-F404 and LC-K42. In certain embodiments, the unnatural amino acid is at HC-Y180, HC-F404, and LC-K42. In certain embodiments, the unnatural amino acid is at HC-Y180, HC-K222, LC-S7, and LC-K42. In certain embodiments, the unnatural amino acid is at HC-F241, HC-K121, and / or HC-S190. In certain embodiments, the unnatural amino acid is the same. In certain embodiments, the unnatural amino acid is different. In certain embodiments, the unnatural amino acid is a residue of formula (30) herein.

[0125]

[0137] In some embodiments, the antibody sequence may include a Q-tag sequence compatible with transglutaminase conjugation. In some embodiments, one or more glutamine residues are in a Q-tag independently selected from those described elsewhere herein. In such embodiments, a linker-payload bearing an amino group can be conjugated to the side chain of one or more glutamine (Q) residues of the antibody in the presence of transglutaminase.

[0126]

[0138] In certain embodiments, provided herein are compounds of formula (C1) or (C2):

[0127] [ka] or a pharmaceutically acceptable salt, solvate, stereoisomer, positional isomer, or tautomer thereof, wherein Ab is a residue of an antibody or antigen-binding fragment thereof; PA is the payload portion, IM is an immunostimulatory moiety, Each W 1 , W 2 , W 3 , W 4 , and W 5 is, in each occurrence, independently a single bond, absent, or a divalent attachment group; each EG, in each occurrence, is independently absent or an eliminator group; each RT is absent or a release trigger group in the backbone of formula (C1) or (C2), or RT is hydrogen or a release trigger group when attached to EG, an eliminator group; each HP, in each occurrence, is independently a single bond, absent, a monovalent hydrophilic group, or a divalent hydrophilic group; each SG, in each occurrence, is independently a single bond, is absent, or is a divalent spacer group; each R', in each occurrence, is independently a terminal conjugate group or a divalent residue of a terminal conjugate group; the subscript m is an integer selected from 1 to 30; The subscript n is an integer selected from 1-30.

[0128]

[0139] In some embodiments, n is an integer selected from 1 to 8. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 5. In some embodiments, n is 6. In some embodiments, n is 7. In some embodiments, n is 8.

[0129]

[0140] In some embodiments, m is an integer from 1 to 8. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4. In some embodiments, m is 5. In some embodiments, m is 6. In some embodiments, m is 7. In some embodiments, m is 8.

[0130]

[0141] Any combination of m and n is contemplated within the scope of the embodiments presented herein.

[0131] 2.1 Attachment groups

[0142] The attachment group facilitates the incorporation of an eliminator group, a release trigger group, a hydrophobic group, a spacer group, and / or a conjugate group into the compound. Useful attachment groups are known and apparent to those skilled in the art. Examples of useful attachment groups are provided herein. In certain embodiments, the attachment group is a W 1 , W 2 , W 3 , W 4 , or W 5In certain embodiments, the attachment group may comprise a divalent ketone, a divalent ester, a divalent ether, a divalent amide, a divalent amine, an alkylene, an arylene, a sulfide, a disulfide, a carbonylene, or a combination thereof. In certain embodiments, the attachment group may comprise -C(O)-, -O-, -C(O)NH-, -C(O)NH-alkyl-, -OC(O)NH-, -SC(O)NH-, -NH-, -NH-alkyl-, -C(O)N(CH)-, -C(O)N(CH)-alkyl-, -N(CH)-, -N(CH)-alkyl-, -N(CH)CHCHN(CH)-, -C(O)CHCHCHC(O)-, -S-, -SS-, -OCHCHO-, or vice versa (e.g., -NHC(O)-), or a combination thereof.

[0132] 2.2 Eliminator Group

[0143] The eliminator (leaving) group facilitates separation of the biologically active portion of a compound or conjugate described herein from the remainder of the compound or conjugate in vivo and / or in vitro. The eliminator group, in conjunction with a release trigger group, can also facilitate separation of the biologically active portion of a compound or conjugate described herein. For example, the eliminator group and the release trigger group can react in a release reaction to release the biologically active portion of a compound or conjugate described herein from the compound or conjugate in vivo and / or in vitro. When the release reaction is initiated by a release trigger agent, the eliminator group cleaves the biologically active portion, or a prodrug form of the biologically active portion, to form a stable, non-toxic entity that does not further affect the activity of the biologically active portion.

[0133]

[0144] In certain embodiments, the eliminator group is referred to herein as EG. Useful eliminator groups include those described herein. In certain embodiments, the eliminator group is:

[0134] [ka] where each R EG are independently selected from the group consisting of hydrogen, alkyl, biphenyl, -CF3, -NO2, -CN, fluoro, bromo, chloro, alkoxyl, alkylamino, dialkylamino, alkyl-C(O)O-, alkylamino-C(O)-, and dialkylamino-C(O)-. In each structure, the phenyl ring may contain one, two, three, or in some cases, four R EG In the second and third structures, one skilled in the art will recognize that EG is attached to an RT that is not within the backbone of formula (C1), as shown in the above description of formula (C1). In some embodiments, each R EG is independently selected from the group consisting of hydrogen, alkyl, biphenyl, -CF3, alkoxyl, alkylamino, dialkylamino, alkyl-C(O)O-, alkylamino-C(O)-, and dialkylamino-C(O)-. In a further embodiment, each R EG is independently selected from the group consisting of hydrogen, —NO, —CN, fluoro, bromo, and chloro. In certain embodiments, the eliminator group is

[0135] [ka] In certain embodiments, the eliminator group is

[0136] [ka] In certain embodiments, the eliminator group is

[0137] [ka] In certain embodiments, the eliminator group is

[0138] [ka] is.

[0139]

[0145] In some embodiments, the eliminator group is

[0140] [ka] wherein Z may be CH or N, and each R EG are independently selected from the group consisting of hydrogen, alkyl, biphenyl, -CF3, -NO2, -CN, fluoro, bromo, chloro, alkoxyl, alkylamino, dialkylamino, alkyl-C(O)O-, alkylamino-C(O)-, and dialkylaminoC-(O)-. In each structure, the phenyl ring may contain one, two, three, or in some cases, four R EG In the first and second structures, one skilled in the art will recognize that EG is attached to an RT that is not within the backbone of formula (C1), as shown in the above description of formula (C1). In some embodiments, each R EG is independently selected from the group consisting of hydrogen, alkyl, biphenyl, -CF3, alkoxyl, alkylamino, dialkylamino, alkyl-C(O)O-, alkylamino-C(O)-, and dialkylamino-C(O)-. In a further embodiment, R EG is selected from the group consisting of hydrogen, —NO, —CN, fluoro, bromo, and chloro. EG is hydrogen. In certain embodiments, the eliminator group is

[0141] [ka] In certain embodiments, the eliminator group is

[0142] [ka] In certain embodiments, the eliminator group is

[0143] [ka] is.

[0144] 2.3 Release trigger groups

[0146] The release trigger group facilitates separation of the biologically active portion of a compound or conjugate described herein from the remainder of the compound or conjugate in vivo and / or in vitro. The release trigger group, in conjunction with an eliminator group, can also facilitate separation of the biologically active portion of a compound or conjugate described herein. For example, the eliminator group and the release trigger group can react in a release reaction to release the biologically active portion of a compound or conjugate described herein from the compound or conjugate in vivo and / or in vitro. In certain embodiments, the release trigger agent can act through a biologically driven reaction with high tumor:non-tumor specificity, such as the proteolytic action of enzymes overexpressed in the tumor environment.

[0145]

[0147] In certain embodiments, the release trigger group is referred to herein as RT. In certain embodiments, RT is divalent and is attached within the backbone of formula (C1). In other embodiments, RT is monovalent and is attached to EG as shown above. Useful release trigger groups include those described herein. In certain embodiments, the release trigger group comprises a residue of a natural or unnatural amino acid residue or a sugar ring. In certain embodiments, the release trigger group is

[0146] [ka] is.

[0147]

[0148] Those skilled in the art will recognize that the first structure may be divalent and attached within the backbone of formula (C1) or as shown in formula (C2), and the second structure may be monovalent and attached to EG as shown in formula (C1) above. In certain embodiments, the release trigger group is:

[0148] [ka] In certain embodiments, the release-triggering group is

[0149] [ka] is.

[0150] In some embodiments, the release-triggering group is:

[0151] [ka] (where R1 is a bond to the remainder of the compound, or

[0152] [ka] and R2 is -CH3, -CH2CH2CO2H, or -(CH2)3NHCONH2), a protease-cleavable R1-Val-X1 peptide;

[0153] [ka] (wherein Z is OH or NH2) or a legumain-cleavable Ala-Ala-Asn (AAN) or Ala-Ala-Asp (AAD) peptide according to the structure

[0154] [ka] Those skilled in the art will recognize that the β-glucuronidase cleavable β-glucuronide has the structure

[0155] [ka] It will be appreciated that is a divalent structure and may be attached within the backbone of formula (C1) or as shown in formula (C2).

[0156] [ka] is monovalent and may be attached to EG as shown in formula (C1) above.

[0157] 2.4 Hydrophilic groups

[0150] The hydrophilic group promotes the hydrophilicity of the compounds described herein. It is believed that the increased hydrophilicity allows for greater solubility in aqueous solutions, such as those found in biological systems. The hydrophilic group can also function as a spacer group, as described in more detail herein.

[0158] In certain embodiments, the hydrophilic group is referred to herein as HP. Useful hydrophilic groups include those described herein. In certain embodiments, the hydrophilic group is a divalent poly(ethylene glycol). In certain embodiments, the hydrophilic group has the formula:

[0159] [ka] where m is an integer from 1 to 13, optionally from 1 to 4, optionally from 2 to 4, or optionally from 4 to 8.

[0160] In some embodiments, the hydrophilic group has the following formula:

[0161] [ka] It is a divalent poly(ethylene glycol) based on

[0162] In some other embodiments, the hydrophilic group has the following formula:

[0163] [ka] It is a divalent poly(ethylene glycol) based on

[0164] In other embodiments, the hydrophilic group has the following formula:

[0165] [ka] It is a divalent poly(ethylene glycol) based on

[0166] In other embodiments, the hydrophilic group has the following formula:

[0167] [ka] It is a divalent poly(ethylene glycol) based on

[0168] In some embodiments, the hydrophilic group has the formula:

[0169] [ka] The sulfonic acid displayed on the chain can be maintained by

[0170] 2.5 Spacer Groups

[0157] The spacer group facilitates the spacing between the conjugate group and other groups of the compounds described herein. This spacing can result in more efficient conjugation of the compounds described herein with a second compound and more efficient cleavage of active catabolites. The spacer group can also stabilize the conjugate group, improving the overall antibody-drug conjugate properties.

[0171] In certain embodiments, the spacer group is referred to herein as SG. Useful spacer groups include those described herein. In certain embodiments, the spacer group is

[0172] [ka] In certain embodiments, the spacer group, W 4 and the hydrophilic group together form a compound of the formula:

[0173] [ka] where m is an integer from 1 to 13, optionally from 1 to 4, optionally from 2 to 4, or optionally from 4 to 8.

[0174] In some embodiments, SG is:

[0175] [ka] is.

[0176] In some embodiments, the divalent poly(ethylene glycol) has the following formula:

[0177] [ka] It has.

[0178] In some other embodiments, the divalent poly(ethylene glycol) has the following formula:

[0179] [ka] It has.

[0180] In other embodiments, the divalent poly(ethylene glycol) has the following formula:

[0181] [ka] It has.

[0182] In other embodiments, the divalent poly(ethylene glycol) has the following formula:

[0183] [ka] It has.

[0184] In some embodiments, the hydrophilic group has the formula:

[0185] [ka] This allows the sulfonic acid to be retained on the chain.

[0186] 2.6 Conjugate Groups and Their Residues The conjugate group facilitates conjugation of a payload described herein with a second compound, such as an antibody described herein. In certain embodiments, the conjugate group is referred to herein as R. The conjugate group can react by any suitable reaction mechanism known to those of skill in the art. In certain embodiments, the conjugate group reacts by a [3+2] alkyne-azide cycloaddition reaction, an inverse electron demand Diels-Alder ligation reaction, a thiol-electrophilic reaction, or a carbonyl-oxyamine reaction, as described in detail herein. In certain embodiments, the conjugate group comprises an alkyne, a strained alkyne, a tetrazine, a thiol, a para-acetyl-phenylalanine residue, an oxyamine, a maleimide, or an azide. In certain embodiments, the conjugate group comprises

[0187] [ka] , -N3, or -SH, wherein R 201 is lower alkyl. In one embodiment, R 201 is methyl, ethyl, or propyl. In one embodiment, R 201 is methyl. Additional conjugate groups are described, for example, in U.S. Patent Application Publication No. 2014 / 0356385, U.S. Patent Application Publication No. 2013 / 0189287, U.S. Patent Application Publication No. 2013 / 0251783, U.S. Patent No. 8,703,936, U.S. Patent No. 9,145,361, U.S. Patent No. 9,222,940, and U.S. Patent No. 8,431,558.

[0188]

[0166] After conjugation, a divalent residue of the conjugate group is formed and attached to a residue of the second compound. The structure of the divalent residue is determined by the type of conjugation reaction used to form the conjugate.

[0189] In certain embodiments, when the conjugate is formed by a [3+2] alkyne-azide cycloaddition reaction, the divalent residue of the conjugate group comprises a triazole ring or a fused ring group containing a triazole ring. In certain embodiments, when the conjugate is formed by a strain-promoted [3+2] alkyne-azide cycloaddition (SPAAC) reaction, the divalent residue of the conjugate group comprises

[0190] [ka] is.

[0191] In certain embodiments, when the conjugate is formed by a tetrazine inverse electron demand Diels-Alder ligation reaction, the divalent residue of the conjugate group comprises a fused bicyclic ring having at least two adjacent nitrogen atoms in the ring. In certain embodiments, when the conjugate is formed by a tetrazine inverse electron demand Diels-Alder ligation reaction, the divalent residue of the conjugate group comprises

[0192] [ka] is.

[0193] In certain embodiments, when the conjugate is formed by a thiol-maleimide reaction, the divalent residue of the conjugate group comprises a succinimidylene and a sulfur linkage. In certain embodiments, when the conjugate is formed by a thiol-maleimide reaction, the divalent residue of the conjugate group comprises:

[0194] [ka] is.

[0195] In certain embodiments, the conjugate comprises the following group:

[0196] [ka] The reaction involved in forming the conjugate involves the following steps:

[0197] [ka] and the divalent residue of the resulting conjugate group comprises:

[0198] [ka] is.

[0199] In certain embodiments, when the conjugate is formed by a carbonyl-oxyamine reaction, the divalent residue of the conjugate group comprises a divalent residue of an unnatural amino acid. In certain embodiments, when the conjugate is formed by a carbonyl-oxyamine reaction, the divalent residue of the conjugate group comprises

[0200] [ka] is.

[0201] In certain embodiments, when the conjugate is formed by a carbonyl-oxyamine reaction, the divalent residue of the conjugate group comprises an oxime linkage. In certain embodiments, when the conjugate is formed by a carbonyl-oxyamine reaction, the divalent residue of the conjugate group comprises an oxime linkage.

[0202] [ka] is.

[0203] In some embodiments, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein EG comprises phenylene, carboxylene, amine, or a combination thereof. In one embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein EG is

[0204] [ka] where each R EG are independently selected from the group consisting of hydrogen, alkyl, biphenyl, -CF3, -NO2, -CN, fluoro, bromo, chloro, alkoxyl, alkylamino, dialkylamino, alkyl-C(O)O-, alkylamino-C(O)-, and dialkylamino-C(O)-. In each structure, the phenyl ring may contain one, two, three, or in some cases, four R EG In the second and third structures, one skilled in the art will recognize that EG is attached to RT, which is not within the backbone of Formula C1, as shown in the above description of Formula C1. In some embodiments, each R EG is independently selected from the group consisting of hydrogen, alkyl, biphenyl, -CF3, alkoxyl, alkylamino, dialkylamino, alkyl-C(O)O-, alkylamino-C(O)-, and dialkylamino-C(O)-. In a further embodiment, each R EG is independently selected from the group consisting of hydrogen, —NO 2 , —CN, fluoro, bromo, and chloro.

[0205] In some embodiments, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein EG comprises phenylene, carboxylene, amine, or a combination thereof. In one embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein EG is

[0206] [ka] wherein Z may be CH or N, and each R EG are independently selected from the group consisting of hydrogen, alkyl, biphenyl, -CF3, -NO2, -CN, fluoro, bromo, chloro, alkoxyl, alkylamino, dialkylamino, alkyl-C(O)O-, alkylamino-C(O)-, and dialkylamino-C(O)-. In each structure, the phenyl ring may contain one, two, three, or in some cases, four R EG In the second and third structures, one skilled in the art will recognize that EG is attached to RT, which is not within the backbone of Formula C1, as shown in the above description of Formula C1. In some embodiments, each R EG is independently selected from the group consisting of hydrogen, alkyl, biphenyl, -CF3, alkoxyl, alkylamino, dialkylamino, alkyl-C(O)O-, alkylamino-C(O)-, and dialkylamino-C(O)-. In a further embodiment, each R EG is independently selected from the group consisting of hydrogen, —NO, —CN, fluoro, bromo, and chloro. EG is hydrogen.

[0207] In some embodiments, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein RT comprises a residue of a natural or unnatural amino acid or a residue of a sugar. In one embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein RT is

[0208] [ka] Those skilled in the art will recognize that the first structure may be divalent and attached within the backbone as shown in formula (C2), and the second structure may be monovalent and attached to EG as shown in formula (C1) above.

[0209] In some embodiments, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein RT comprises a residue of a natural or unnatural amino acid or a residue of a sugar. In one embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein RT is

[0210] [ka] (where R1 is a bond to the remainder of the compound, or

[0211] [ka] and R2 is -CH3, -CH2CH2CO2H, or -(CH2)3NHCONH2);

[0212] [ka] (wherein Z is OH or NH2) or a legumain-cleavable Ala-Ala-Asn (AAN) or Ala-Ala-Asp (AAD) peptide having the structure:

[0213] [ka] Those skilled in the art will recognize that the β-glucuronidase cleavable β-glucuronide has the structure

[0214] [ka] It will be appreciated that is a divalent structure and may be attached within the backbone of formula (C1) or as shown in formula (C2).

[0215] [ka] is monovalent and may be attached to EG as shown in formula (C1) above.

[0216] In one embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein HP comprises poly(ethylene glycol). In one embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein HP is

[0217] [ka] wherein m is an integer selected from 1 to 13.

[0218] In one embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein SG is C1-C 10 alkylene, C4-C6 alkylene, carbonylene, or a combination thereof. In one embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein SG is

[0219] [ka] is.

[0220] In one embodiment, provided herein is a conjugate according to formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein W 1 , W 2 , W 3 , W 4 , and W 5 are each independently a single bond, absent, or comprise a divalent ketone, divalent ester, divalent ether, divalent amide, divalent amine, alkylene, arylene, sulfide, disulfide, carbonylene, or combinations thereof. In one embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein W 1 , W 2 , W 3 , W 4 , and W 5are each independently a single bond, absent, or include -C(O)-, -O-, -C(O)NH-, -C(O)NH-alkyl-, -OC(O)NH-, -SC(O)NH-, -NH-, -NH-alkyl-, -C(O)N(CH3)-, -C(O)N(CH3)-alkyl-, -N(CH3)-, -N(CH3)-alkyl-, -N(CH3)CH2CH2N(CH3)-, -C(O)CH2CH2CH2C(O)-, -S-, -SS-, -OCH2CHO-, or reverses thereof (e.g., -NHC(O)-), or combinations thereof.

[0221] In one embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein R' comprises a triazolyl ring. In one embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein R' is a triazolyl ring, or a fused ring group comprising a triazole ring. In one embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein R' is

[0222] [ka] is.

[0223] In one embodiment, provided herein is a conjugate according to formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein R' comprises a fused bicyclic ring having at least two adjacent nitrogen atoms in the ring. In one embodiment, provided herein is a conjugate according to formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein R' is

[0224] [ka] is.

[0225] In one embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein R' comprises a sulfur linkage. In one embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein R' is

[0226] [ka] is.

[0227] In one embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein R' comprises a divalent residue of an unnatural amino acid. In one embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein R' is

[0228] [ka] is.

[0229] In one embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, comprising an oxime linkage. In one embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein R' is

[0230] [ka] is.

[0231] In one embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, comprising an oxime linkage. In one embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein R' is

[0232] [ka] is.

[0233] In one embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein R' is:

[0234] [ka] is.

[0235] In one embodiment, provided herein is a compound according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, where Ab is a residue of any compound known to be useful for conjugation to a payload described herein, and an optional linker described herein. In one embodiment, provided herein is a compound according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, where Ab is a residue of an antibody chain, or an antigen-binding fragment thereof.

[0236] In one aspect, provided herein is an antibody conjugate comprising a payload as described herein and an optional linker as described herein linked to an antibody, wherein Ab is a residue of an antibody. In one embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein Ab is a residue of an antibody and R' comprises a triazole ring or a fused ring group comprising a triazole ring. In one embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein Ab is a residue of an antibody and R' is

[0237] [ka] is.

[0238] In one embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein Ab is a residue of an antibody or an antigen-binding fragment thereof, and R' comprises a fused bicyclic ring, the fused bicyclic ring having at least two adjacent nitrogen atoms in the ring. In one embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein Ab is a residue of an antibody or an antigen-binding fragment thereof, and R' is

[0239] [ka] is.

[0240] In one embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein Ab is a residue of a polypeptide and R' comprises a sulfur-linked divalent residue. In one embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein Ab is a residue of a polypeptide and R' is

[0241] [ka] is.

[0242] In one embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein Ab is a residue of a polypeptide and R comprises a divalent residue of a non-natural amino acid. In one embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein Ab is a residue of a polypeptide and R' is

[0243] [ka] is.

[0244] In one embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein Ab is a residue of a polypeptide and R' comprises an oxime linkage. In one embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein Ab is a residue of a polypeptide and R' is

[0245] [ka] is.

[0246] In one embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein Ab is a residue of a polypeptide and R' comprises an oxime linkage. In one embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein Ab is a residue of a polypeptide and R' is

[0247] [ka] is.

[0248] The linker linked to the drug compound (e.g., a cytotoxic drug) is herein an L-PA. The L-PA is then conjugated to an antibody construct, such as an antibody or antibody chain, or an antigen-binding fragment thereof, to form an antibody conjugate to PA. The linker linked to the immunomodulatory compound is herein an L-IM. The L-IM is conjugated to an antibody construct, such as an antibody or antibody chain, or an antigen-binding fragment thereof, to form an antibody conjugate to IM.

[0249] In one embodiment, provided herein is a conjugate according to any of the following formulas, where Ab represents a residue of an antibody or antigen-binding fragment thereof, PA represents a drug payload moiety, and IM represents an immunomodulator (e.g., immunostimulator) moiety, and positional isomers thereof. Those skilled in the art will recognize that Ab can be attached at more than one position. Each positional isomer, and mixtures thereof, is provided by the formula below, where:

[0250] [ka] indicates the bond to the linker-immunomodulator. Those skilled in the art will recognize that the linker in the formula shown for L-PA may also be the linker in the L-IM moiety. Those skilled in the art will recognize that the linker in the L-PA may be the same or different from the linker in the L-IM, and further, that the L-IM moiety in each formula may include positional isomers.

[0251] [ka]

[0252] [ka]

[0253] In one embodiment, provided herein is a conjugate according to any of the following formulas, where Ab represents a residue of an antibody, PA represents a payload moiety, and IM represents an immunomodulator moiety, and positional isomers thereof: Each positional isomer and mixtures thereof are provided by the formula:

[0254] [ka] indicates the bond to the linker-immunomodulator. Those skilled in the art will recognize that the linker in the formula shown for L-PA may also be the linker in the L-IM moiety. Those skilled in the art will recognize that the linker in the L-PA may be the same or different from the linker in the L-IM, and further, that the L-IM moiety in each formula may include positional isomers.

[0255] [ka]

[0256] In one embodiment, provided herein is a conjugate according to any of the following formulas, where Ab represents a residue of an antibody, PA represents a payload moiety, and IM represents an immunomodulator moiety, and positional isomers thereof: Each positional isomer and mixtures thereof are provided by the formula:

[0257] [ka] indicates the bond to the linker-immunomodulator. Those skilled in the art will recognize that the linker in the formula shown for L-PA may also be the linker in the L-IM moiety. Those skilled in the art will recognize that the linker in the L-PA may be the same or different from the linker in the L-IM, and further, that the L-IM moiety in each formula may include positional isomers.

[0258] [ka]

[0259] [ka]

[0260] In one embodiment, provided herein is a conjugate according to any of Formulas 101a-107, where Ab represents a residue of an antibody, PA represents a payload moiety, and IM represents an immunomodulator moiety, and positional isomers thereof. Each positional isomer and mixtures thereof are provided by the formula below, wherein:

[0261] [ka] indicates the bond to the linker-immunomodulator. Those skilled in the art will recognize that the linker in the formula shown for L-PA may also be the linker in the L-IM moiety. Those skilled in the art will recognize that the linker in the L-PA may be the same or different from the linker in the L-IM, and further, that the L-IM moiety in each formula may include positional isomers.

[0262] [ka]

[0263] [ka]

[0264] [ka]

[0265] In any of the above embodiments, the conjugate comprises m PA moieties, where m is an integer selected from 1 to 8. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4. In some embodiments, m is 5. In some embodiments, m is 6. In some embodiments, m is 7. In some embodiments, m is 8. One of ordinary skill in the art will recognize that Formula (101a) and Formula (101b) are positional isomers based on the nitrogen atom in the triazole to which the antibody is attached. Similarly, Formula (102a) and Formula (102b), Formula (103a) and Formula (103b), Formula (104a) and Formula (104b), and Formula (105a) and Formula (105b) are pairs of positional isomers. Furthermore, the L-IM moiety in each of the above formulas may also include positional isomers. In each of conjugates 101a-107, the L-IM moiety can be according to any of formulas 201a-207 below. In certain embodiments, provided herein are each conjugates of any pairwise combination of one or more of 101a-107 with one or more of 201a-207.

[0266] In one embodiment, provided herein is a conjugate according to any of the following formulas, where Ab represents a residue of an antibody or antigen-binding fragment thereof, PA represents a drug payload moiety, and IM represents an immunomodulator (e.g., immunostimulator) moiety, and positional isomers thereof. Those skilled in the art will recognize that Ab can be attached at more than one position. Each positional isomer and mixtures thereof are provided in the formula below, where:

[0267] [ka] indicates the linker-payload bond. Those skilled in the art will recognize that the linker in the formula shown for L-IM may also be the linker in the L-PA portion. Those skilled in the art will recognize that the linker in the L-PA may be the same or different from the linker in the L-IM, and further, that the L-IM portion of each formula may include positional isomers.

[0268] [ka]

[0269] [ka]

[0270] In one embodiment, provided herein is a conjugate according to any of the following formulas, where Ab represents a residue of an antibody, PA represents a payload moiety, and IM represents an immunomodulator moiety, and positional isomers thereof: Each positional isomer and mixtures thereof are provided by the formula:

[0271] [ka] indicates the bond to the linker-immunomodulator. Those skilled in the art will recognize that the linker in the formula shown for L-PA may also be the linker in the L-IM moiety. Those skilled in the art will recognize that the linker in the L-PA may be the same or different from the linker in the L-IM, and further, that the L-IM moiety in each formula may include positional isomers.

[0272] [ka]

[0273] In one embodiment, provided herein is a conjugate according to any of the following formulas, where Ab represents a residue of an antibody, PA represents a payload moiety, and IM represents an immunomodulator moiety, and positional isomers thereof: Each positional isomer and mixtures thereof are provided by the formula:

[0274] [ka] indicates the bond to the linker-immunomodulator. Those skilled in the art will recognize that the linker in the formula shown for L-PA may also be the linker in the L-IM moiety. Those skilled in the art will recognize that the linker in the L-PA may be the same or different from the linker in the L-IM, and further, that the L-IM moiety in each formula may include positional isomers.

[0275] [ka]

[0276] In one embodiment, provided herein is a conjugate according to any of Formulas 201a-207, where Ab represents a residue of an antibody, PA represents a payload moiety, and IM represents an immunomodulator moiety, and positional isomers thereof. Each positional isomer and mixtures thereof are provided by the formula below, wherein:

[0277] [ka] indicates the bond to the linker-immunomodulator. Those skilled in the art will recognize that the linker in the formula shown for L-PA may also be the linker in the L-IM moiety. Those skilled in the art will recognize that the linker in the L-PA may be the same or different from the linker in the L-IM, and further, that the L-IM moiety in each formula may include positional isomers.

[0278] [ka]

[0279] [ka]

[0280] [ka]

[0281] In any of the above embodiments, the conjugate comprises n PA moieties, where n is an integer selected from 1 to 8. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 5. In some embodiments, n is 6. In some embodiments, n is 7. In some embodiments, n is 8. One of skill in the art will recognize that Formula (201a) and Formula (201b) are positional isomers based on the nitrogen atom in the triazole to which the antibody is attached. Similarly, Formula (202a) and Formula (202b), Formula (203a) and Formula (203b), Formula (204a) and Formula (204b), and Formula (205a) and Formula (205b) are pairs of positional isomers. Furthermore, the L-IM moiety in each of the above formulas may also include positional isomers. In each of conjugates 201a-207, the L-PA moiety can be according to any of formulas 101a-107 above. In certain embodiments, provided herein are conjugates of any pairwise combination of one or more of 101a-107 with one or more of 201a-207.

[0282] In certain embodiments, provided herein are conjugates according to Formula 101 and Formula 201. In certain embodiments, provided herein are conjugates according to Formula 101 and Formula 202. In certain embodiments, provided herein are conjugates according to Formula 101 and Formula 203. In certain embodiments, provided herein are conjugates according to Formula 101 and Formula 204. In certain embodiments, provided herein are conjugates according to Formula 101 and Formula 205. In certain embodiments, provided herein are conjugates according to Formula 101 and Formula 206. In certain embodiments, provided herein are conjugates according to Formula 101 and Formula 207. In each embodiment, Formula 101, Formula 102, Formula 104, Formula 104, Formula 105, Formula 201, Formula 202, Formula 203, Formula 204, and Formula 205 each refer to either one or both positional isomers of each formula.

[0283] In certain embodiments, provided herein are conjugates according to Formula 102 and Formula 201. In certain embodiments, provided herein are conjugates according to Formula 102 and Formula 202. In certain embodiments, provided herein are conjugates according to Formula 102 and Formula 203. In certain embodiments, provided herein are conjugates according to Formula 102 and Formula 204. In certain embodiments, provided herein are conjugates according to Formula 102 and Formula 205. In certain embodiments, provided herein are conjugates according to Formula 102 and Formula 206. In certain embodiments, provided herein are conjugates according to Formula 102 and Formula 207. In embodiments, each of Formula 101, Formula 102, Formula 104, Formula 104, Formula 105, Formula 201, Formula 202, Formula 203, Formula 204, and Formula 205 refers to either one or both positional isomers of each formula.

[0284] In certain embodiments, provided herein are conjugates according to Formula 103 and Formula 201. In certain embodiments, provided herein are conjugates according to Formula 103 and Formula 202. In certain embodiments, provided herein are conjugates according to Formula 103 and Formula 203. In certain embodiments, provided herein are conjugates according to Formula 103 and Formula 204. In certain embodiments, provided herein are conjugates according to Formula 103 and Formula 205. In certain embodiments, provided herein are conjugates according to Formula 103 and Formula 206. In certain embodiments, provided herein are conjugates according to Formula 103 and Formula 207. In embodiments, each of Formula 101, Formula 102, Formula 104, Formula 104, Formula 105, Formula 201, Formula 202, Formula 203, Formula 204, and Formula 205 refers to either one or both positional isomers of each formula.

[0285] In certain embodiments, provided herein are conjugates according to Formula 104 and Formula 201. In certain embodiments, provided herein are conjugates according to Formula 104 and Formula 202. In certain embodiments, provided herein are conjugates according to Formula 104 and Formula 203. In certain embodiments, provided herein are conjugates according to Formula 104 and Formula 204. In certain embodiments, provided herein are conjugates according to Formula 104 and Formula 205. In certain embodiments, provided herein are conjugates according to Formula 104 and Formula 206. In certain embodiments, provided herein are conjugates according to Formula 104 and Formula 207. In embodiments, each of Formula 101, Formula 102, Formula 104, Formula 104, Formula 105, Formula 201, Formula 202, Formula 203, Formula 204, and Formula 205 refers to either one or both positional isomers of each formula.

[0286] In certain embodiments, provided herein are conjugates according to Formula 105 and Formula 201. In certain embodiments, provided herein are conjugates according to Formula 105 and Formula 202. In certain embodiments, provided herein are conjugates according to Formula 105 and Formula 203. In certain embodiments, provided herein are conjugates according to Formula 105 and Formula 204. In certain embodiments, provided herein are conjugates according to Formula 105 and Formula 205. In certain embodiments, provided herein are conjugates according to Formula 105 and Formula 206. In certain embodiments, provided herein are conjugates according to Formula 105 and Formula 207. In embodiments, each of Formula 101, Formula 102, Formula 104, Formula 104, Formula 105, Formula 201, Formula 202, Formula 203, Formula 204, and Formula 205 refers to either one or both positional isomers of each formula.

[0287] In certain embodiments, provided herein are conjugates according to Formula 106 and Formula 201. In certain embodiments, provided herein are conjugates according to Formula 106 and Formula 202. In certain embodiments, provided herein are conjugates according to Formula 106 and Formula 203. In certain embodiments, provided herein are conjugates according to Formula 106 and Formula 204. In certain embodiments, provided herein are conjugates according to Formula 106 and Formula 205. In certain embodiments, provided herein are conjugates according to Formula 106 and Formula 206. In certain embodiments, provided herein are conjugates according to Formula 106 and Formula 207. In embodiments, each of Formula 101, Formula 102, Formula 104, Formula 104, Formula 105, Formula 201, Formula 202, Formula 203, Formula 204, and Formula 205 refers to either one or both positional isomers of each formula.

[0288] In certain embodiments, provided herein are conjugates according to Formula 107 and Formula 201. In certain embodiments, provided herein are conjugates according to Formula 107 and Formula 202. In certain embodiments, provided herein are conjugates according to Formula 107 and Formula 203. In certain embodiments, provided herein are conjugates according to Formula 107 and Formula 204. In certain embodiments, provided herein are conjugates according to Formula 107 and Formula 205. In certain embodiments, provided herein are conjugates according to Formula 107 and Formula 206. In certain embodiments, provided herein are conjugates according to Formula 107 and Formula 207. In each embodiment, Formula 101, Formula 102, Formula 104, Formula 104, Formula 105, Formula 201, Formula 202, Formula 203, Formula 204, and Formula 205 each refer to either one or both positional isomers of each formula.

[0289] In certain embodiments, provided herein is an antibody conjugate according to any of Formulas 101a-105b and 201a-205b, wherein Ab comprises a residue of a non-natural amino acid according to Formula (30): In certain embodiments, provided herein is an antibody conjugate according to any of Formulas 101a-105b and 201a-205b, wherein Ab comprises a residue of a non-natural amino acid according to Formula (30): In certain embodiments, provided herein is an antibody conjugate according to any of Formulas 101a-105b and 201a-205b, wherein Ab comprises a residue of a non-natural amino acid according to Formula (30): In certain embodiments, provided herein is an antibody conjugate according to any of Formulas 101a-105b and 201a-205b, wherein Ab comprises a residue of a non-natural amino acid according to Formula (30): In certain embodiments, provided herein is an antibody conjugate according to Formulas 101a-105b and 201a-205b, wherein Ab comprises a residue of a non-natural amino acid according to Formula (30): In certain embodiments, provided herein is an antibody conjugate according to Formula In certain embodiments, provided herein is an antibody conjugate according to any of Formulas 101a-105b and 201a-205b, wherein Ab comprises a residue of a non-natural amino acid according to Formula (30) below at position 241 of the heavy chain according to the EU numbering system. In certain embodiments, provided herein is an antibody conjugate according to any of Formulas 101a-105b and 201a-205b, wherein Ab comprises a residue of a non-natural amino acid according to Formula (30) below at position 222 of the heavy chain according to the EU numbering system. In certain embodiments, provided herein is an antibody conjugate according to any of Formulas 101a-105b and 201a-205b, wherein Ab comprises a residue of a non-natural amino acid according to Formula (30) below at position 7 of the light chain according to the Kabat or Chothia numbering system. In certain embodiments, provided herein is an antibody conjugate according to any of Formulas 101a-105b and 201a-205b, wherein Ab comprises a residue of an unnatural amino acid according to Formula (30) below at light chain position 42 according to the Kabat or Chothia numbering system. In certain embodiments, PA is a cytotoxic compound described herein.

[0290] [ka]

[0291]

[0213] Those skilled in the art will recognize that amino acids such as formula (30) can be incorporated as residues into polypeptides and antibodies. For example, a residue of formula (30) can be represented by the following formula (30'):

[0292] [ka] Further modifications, for example at -N3, are also encompassed by the term residue herein.

[0293] In certain embodiments, provided herein is an antibody conjugate according to any of Formulas 101a-105b and 201a-205b, wherein Ab comprises a residue of a non-natural amino acid according to formula (56): ... Formulas 101a-105b and 201a-205b, wherein Ab comprises a residue of a non-natural amino acid according to formula (56): In certain embodiments, provided herein is an antibody conjugate according to Formulas 101a-105b and 201a-205b, wherein Ab comprises a residue of a non-natural amino acid according to formula (56): In certain embodiments, provided herein is an antibody conjugate according to Formula In certain embodiments, provided herein is an antibody conjugate according to any of Formulas 101a-105b and 201a-205b, wherein Ab comprises a residue of a non-natural amino acid according to Formula (56) below at position 241 of the heavy chain according to the EU numbering system. In certain embodiments, provided herein is an antibody conjugate according to any of Formulas 101a-105b and 201a-205b, wherein Ab comprises a residue of a non-natural amino acid according to Formula (56) below at position 222 of the heavy chain according to the EU numbering system. In certain embodiments, provided herein is an antibody conjugate according to any of Formulas 101a-105b and 201a-205b, wherein Ab comprises a residue of a non-natural amino acid according to Formula (56) below at position 7 of the light chain according to the Kabat or Chothia numbering system. In certain embodiments, provided herein is an antibody conjugate according to any of Formulas 101a-105b and 201a-205b, wherein Ab comprises a residue of an unnatural amino acid according to Formula (56) below at light chain position 42 according to the Kabat or Chothia numbering system. The unnatural amino acid according to Formula (56) is:

[0294] [ka]

[0295]

[0215] In certain embodiments, provided herein is an antibody conjugate according to any of Formulas 101a-105b and 201a-205b, wherein Ab comprises the unnatural amino acid residue para-azidomethyl-L-phenylalanine. In certain embodiments, provided herein is an antibody conjugate according to any of Formulas 101a-105b and 201a-205b, wherein Ab comprises the unnatural amino acid residue para-azidomethyl-L-phenylalanine at position 404 of the heavy chain according to the EU numbering system. In certain embodiments, provided herein is an antibody conjugate according to any of Formulas 101a-105b and 201a-205b, wherein Ab comprises the unnatural amino acid residue para-azidomethyl-L-phenylalanine at position 180 of the heavy chain according to the EU numbering system. In certain embodiments, provided herein is an antibody conjugate according to any of Formulas 101a-105b and 201a-205b, wherein Ab comprises the unnatural amino acid residue para-azidomethyl-L-phenylalanine at heavy chain position 241 according to the EU numbering system. In certain embodiments, provided herein is an antibody conjugate according to any of Formulas 101a-105b and 201a-205b, wherein Ab comprises the unnatural amino acid residue para-azidomethyl-L-phenylalanine at heavy chain position 222 according to the EU numbering system. In certain embodiments, provided herein is an antibody conjugate according to any of Formulas 101a-105b and 201a-205b, wherein Ab comprises the unnatural amino acid residue para-azidomethyl-L-phenylalanine at light chain position 7 according to the Kabat or Chothia numbering system. In certain embodiments, provided herein are antibody conjugates according to any of Formulas 101a-105b and 201a-205b, wherein Ab comprises the unnatural amino acid residue paraazidomethyl-L-phenylalanine at light chain position 42 according to the Kabat or Chothia numbering system. In certain embodiments, PA is any cytotoxic payload described herein. In some embodiments, IM is a compound of Formula (III) or any other immunomodulatory compound described herein.

[0296]

[0216] In certain embodiments, provided herein is an antibody conjugate according to any of Formulas 101a-105b and 201a-205b, wherein Ab comprises the unnatural amino acid residue paraacetyl-L-phenylalanine. In certain embodiments, provided herein is an antibody conjugate according to any of Formulas 101a-105b and 201a-205b, wherein Ab comprises the unnatural amino acid residue paraacetyl-L-phenylalanine at position 404 of the heavy chain according to the EU numbering system. In certain embodiments, provided herein is an antibody conjugate according to any of Formulas 101a-105b and 201a-205b, wherein Ab comprises the unnatural amino acid residue paraacetyl-L-phenylalanine at position 180 of the heavy chain according to the EU numbering system. In certain embodiments, provided herein is an antibody conjugate according to any of Formulas 101a-105b and 201a-205b, wherein Ab comprises the unnatural amino acid residue paraacetyl-L-phenylalanine at heavy chain position 241 according to the EU numbering system. In certain embodiments, provided herein is an antibody conjugate according to any of Formulas 101a-105b and 201a-205b, wherein Ab comprises the unnatural amino acid residue paraacetyl-L-phenylalanine at heavy chain position 222 according to the EU numbering system. In certain embodiments, provided herein is an antibody conjugate according to any of Formulas 101a-105b and 201a-205b, wherein Ab comprises the unnatural amino acid residue paraacetyl-L-phenylalanine at light chain position 7 according to the Kabat or Chothia numbering system. In certain embodiments, provided herein are antibody conjugates according to any of Formulas 101a-105b and 201a-205b, wherein Ab comprises the unnatural amino acid residue para-acetyl-L-phenylalanine at light chain position 42 according to the Kabat or Chothia numbering system. In certain embodiments, PA is any cytotoxic payload described herein. In some embodiments, IM is a compound of Formula (III) or any other immunomodulatory compound described herein.

[0297] In certain embodiments, provided herein are antibody conjugates according to any of Formula 106, Formula 107, Formula 206, and Formula 207, wherein Ab comprises a glutamine residue. The glutamine residue can be any glutamine residue suitable for conjugation. In certain embodiments, the glutamine residue is at position 195 of the heavy chain according to the EU numbering system. In certain embodiments, the antibody is deglycosylated or non-glycosylated. In certain embodiments, the antibody comprises a Q-tag as described herein. In certain embodiments, the Q-tag is at the C-terminus of one or more polypeptide chains. In certain embodiments, the Q-tag has the sequence LQR, or leucine-glutamine-arginine. In certain embodiments, the antibody comprises a Q-tag at any of positions 122, 294, 295, 296, 374, and 399 of the heavy chain according to the EU numbering system. In certain embodiments, the antibody contains an LQR at any of positions 122, 294, 295, 296, 374, and 399 of the heavy chain according to the EU numbering system. In these embodiments, the position number indicates the position of the leftmost amino acid residue of the Q tag, and other residues of the Q tag are substituted for subsequent residues in the antibody sequence. In certain embodiments, the antibody is conjugated to one or more amino termini of the heavy or light chain. In certain embodiments, the antibody contains more than one glutamine and / or amino terminus for conjugation. Conjugation at such sites can proceed using the enzyme transglutaminase according to standard techniques. Useful transglutaminase techniques are described, for example, in Jeger et al., 2010, Angew. Chem. Int. Ed. 49:9995-9997; Strop et al., Chemistry & Biology 2013:161-167, and in the Examples below.

[0298] In a first aspect, provided herein is an antibody conjugate comprising an antibody or antigen-binding fragment thereof covalently linked to a drug payload and further covalently linked to an immunomodulatory payload, i.e., an immunomodulatory drug-antibody conjugate (iADC). In some cases, the drug payload is a cytotoxic compound. In some examples, the cytotoxic compound is selected from the group consisting of alkylating agents, DNA crosslinking agents, antitumor antibiotics, antimetabolites, antimitotic agents (e.g., microtubule-disrupting agents), histone deacetylase (HDAC) inhibitors, telomerase inhibitors, and immunogenic cell death agents. In some cases, the immunomodulatory payload in the antibody conjugate is an immunostimulatory payload. In some cases, the immunomodulatory payload in the antibody conjugate is selected from the group consisting of toll-like receptor agonists, kinase inhibitors, growth factor inhibitors (e.g., EGFR inhibitors, PDGF inhibitors, VEGF inhibitors), calcineurin inhibitors, CRAC inhibitors, PARP1 antagonists, PPARγ agonists, Kvl.3 antagonists, PP2A agonists, MYD88 inhibitors, BCL-2 inhibitors, adenosine A2A receptor (A2ar) agonists, Toll-like receptor 7 / 8 (TLR7 / 8) agonists, Toll-like receptor 4 (TLR4) agonists, Toll-like receptor 9 (TLR9) agonists, calcium-activated potassium channel (Kca3.1) agonists, TGF-R1 inhibitors, TGF-R2 inhibitors, GLi 1 inhibitors, tankyrase (TNKS) antagonists, Traf2 and Nck interacting kinase (TNIK) antagonists, imide and vitamin D receptor (VDR) agonists.

[0299] In any of the preceding embodiments, the drug payload is linked to the antibody or antigen-binding fragment via a linker. The antibody conjugate of any one of the preceding claims, wherein the immunomodulatory payload is linked to the antibody or antigen-binding fragment via a linker.

[0300] In another aspect, provided herein are compounds of formula (I):

[0301] [ka] or a mixture of pharmaceutically acceptable salts, solvates, stereoisomers, tautomers, or positional isomers thereof, wherein Ab is an antibody or antigen-binding fragment thereof; each L is independently an optional linker; Each PA is independently a drug payload, Each IM is independently an immunomodulatory payload, the subscript n is an integer from 1 to 8; the subscript m is an integer from 1 to 8; Each bracketed group is covalently linked to Ab.

[0302] In some embodiments of Formula (I), L-PA is independently:

[0303] [ka] is.

[0304] In some embodiments of Formula (I), L-IM is independently:

[0305] [ka] is.

[0306]

[0223] In some embodiments, a compound of formula (II):

[0307] [ka] or a pharmaceutically acceptable salt, solvate, stereoisomer, tautomer, or mixture of positional isomers thereof, according to the structure: Each W 1 is, in each occurrence, independently a single bond, absent, or a divalent spacer; Each X, in each occurrence, is independently absent or

[0308] [ka] and the subscript b is an integer from 1 to 10; Each R A is absent or, in each occurrence, independently 1~3 alkyl, each RT is absent or, at each occurrence, independently a release-triggering group; each HP is absent or, in each occurrence, independently a hydrophilic group; Each W 6 is, at each occurrence, independently a peptide or absent; each SG, in each occurrence, is independently absent or a divalent spacer group; each R', in each occurrence, is independently a divalent residue of a conjugated group; the subscript n is an integer from 1 to 30; the subscript m is an integer from 1 to 30; Ab is an antibody or antigen-binding fragment thereof; PA is a cytotoxic compound payload, or a residue thereof, IM is an immunomodulatory payload, or a residue thereof.

[0309] In some embodiments of Formula (I) and / or Formula (II), SG, in each occurrence, is independently:

[0310] [ka] where the subscript d is an integer from 1 to 10, and each

[0311] [ka] denotes the attachment point to the rest of the equation.

[0312] In some embodiments of Formula (I) and / or Formula (II), SG, in each occurrence, is independently:

[0313] [ka] and each

[0314] [ka] In some embodiments of Formula (I) and / or Formula (II), the antibody conjugate of any one of claims 8 to 10, wherein W 1 If exists,

[0315] [ka] where the subscript e is an integer from 1 to 10, and each

[0316] [ka] denotes the attachment point to the rest of the equation.

[0317] In some embodiments of Formula (I) and / or Formula (II), W 1 If exists,

[0318] [ka] and each

[0319] [ka] denotes the attachment point to the rest of the equation.

[0320] In some embodiments of Formula (I) and / or Formula (II), W 6 When W is a peptide, the peptide may contain natural and / or unnatural amino acid residues. 6 When present, W is a tripeptide residue. 6 teeth,

[0321] [ka] and each

[0322] [ka] indicates the point of attachment to the rest of the formula. In some examples of formula (VI), W 6 When present, W is a dipeptide residue. 6 If exists,

[0323] [ka] and each

[0324] [ka] denotes the attachment point to the rest of the equation.

[0325] In some embodiments of Formula (I) and / or Formula (II), R T is, at each occurrence, independently:

[0326] [ka] and

[0327] [ka] denotes the attachment point to the rest of the equation.

[0328] In some embodiments of Formula (I) and / or Formula (II), HP, if present, at each occurrence is independently a PEG group. In some embodiments of Formula (I) and / or Formula (II), HP, if present, at each occurrence is independently

[0329] [ka] and the subscript b is an integer from 1 to 10;

[0330] [ka] denotes the attachment point to the rest of the equation.

[0331] In some embodiments of Formula (I) and / or Formula (II), R', in each occurrence, is independently:

[0332] [ka] and R 201 is C 1~6 alkyl, and each

[0333] [ka] denotes the attachment point to the rest of the equation,

[0334] [ka] indicates the point of attachment to the antibody or antigen-binding fragment thereof,

[0335] [ka] indicates the point of attachment to the antibody or antigen-binding fragment thereof via the sulfur atom of the cysteine ​​residue.

[0336]

[0231] In some embodiments of Formula (I) and / or Formula (II), the antibody or antigen-binding fragment thereof is selected from the group consisting of anti-BCMA, anti-Muc16, trastuzumab, sofitizumab, anti-GFP, and anti-FolRa, or an antigen-binding fragment thereof.

[0337] In some embodiments of Formula (I) and / or Formula (II), the antibody or antigen-binding fragment thereof comprises two or more unnatural amino acids suitable for conjugation.

[0338]

[0233] In some embodiments of Formula (I) and / or Formula (II), in the antibody or antigen-binding fragment thereof, at least one of the two or more unnatural amino acid residues is a pAMF residue.

[0339] In some embodiments of Formula (I) and / or Formula (II), the antibody or antigen-binding fragment thereof comprises a Y180 pAMF mutation, a F404 pAMF mutation, or both.

[0340] In some embodiments of Formula (I) and / or Formula (II), the antibody or antigen-binding fragment thereof is modified by substituting or adding one or more glutamine (Q) residues. In some such embodiments of Formula (I) and / or Formula (II), the one or more glutamine residues are selected from the group consisting of LLQGA (SEQ ID NO:44), YAHQAHY (SEQ ID NO:45), YRYRQ (SEQ ID NO:46), PNPQLPF (SEQ ID NO:47), PKPQQFM (SEQ ID NO:48), GQQQLG (SEQ ID NO:49), WALQRPH (SEQ ID NO:50), WELQRPY (SEQ ID NO:51), YPMQGWF (SEQ ID NO:52), LSLSQG (SEQ ID NO:53), GGGLLQGG (SEQ ID NO:54), GLLQG (SEQ ID NO:55), GSPLAQSHGG (SEQ ID NO:56), GLLQGGG (SEQ ID NO:57), GLL In a Q-tag selected from the group consisting of QGG (SEQ ID NO:58), GLLQ (SEQ ID NO:59), LLQLLQGA (SEQ ID NO:60), LLQGA (SEQ ID NO:61), LLQYQGA (SEQ ID NO:62), LLQGSG (SEQ ID NO:63), LLQYQG (SEQ ID NO:64), LLQLLQG (SEQ ID NO:65), SLLQG (SEQ ID NO:66), LLQLQ (SEQ ID NO:67), LLQLLQ (SEQ ID NO:68), LLQGR (SEQ ID NO:69), LLQGPA (SEQ ID NO:70), LLQGPP (SEQ ID NO:71), GGLLQGPP (SEQ ID NO:72), LLQGG (SEQ ID NO:73), LLQG (SEQ ID NO:74), and LQR. In some embodiments, the acyl donor glutamine-containing tag (Q-tag) comprises an amino acid sequence selected from the group consisting of LLQGPA (SEQ ID NO:70), LLQGPP (SEQ ID NO:71), or GGLLQGPP (SEQ ID NO:72). In some embodiments, the acyl donor glutamine-containing tag (Q-tag) comprises an amino acid sequence selected from the group consisting of LLQGG (SEQ ID NO: 73) and LLQGA (SEQ ID NO: 44). In some embodiments, the acyl donor glutamine-containing tag (Q-tag) comprises or consists of the amino acid sequence LQR. In some such embodiments of Formula (I) and / or Formula (II), one or more glutamine residues are in a Q-tag having the sequence LQR.

[0341] In one group of embodiments, in the antibody conjugates described herein, the ratio of cytotoxic compound:immunomodulatory compound is adjusted to provide optimal therapeutic effect. In some embodiments of Formula (I) and / or Formula (II), the ratio of cytotoxic compound:immunomodulatory compound is about 1 to 3:1, or greater than 3:1. In some embodiments of Formula (I) and / or Formula (II), the PA:IM ratio is about 1:1, 2:1, 3:1, or greater than 3:1.

[0342]

[0237] Embodiments of the PA and IM are described in more detail in the sections below. In some embodiments of Formula (I) and / or Formula (II), the PA and IM are as described in the Payload section below and herein.

[0343] In some embodiments of Formula (I) and / or Formula (II),

[0344] [ka] teeth,

[0345] [ka]

[0346] [ka]

[0347] [ka]

[0348] [ka] wherein each

[0349] [ka] denotes the attachment point to the rest of the equation.

[0350] In some embodiments of Formula (I) and / or Formula (II),

[0351] [ka] teeth,

[0352] [ka]

[0353] [ka]

[0354] [ka]

[0355] [ka] wherein each

[0356] [ka] denotes the attachment point to the rest of the equation.

[0357] In some embodiments of Formula (I) and / or Formula (II), PA is:

[0358] [ka] wherein each

[0359] [ka] denotes the attachment point to the rest of the equation.

[0360] In some embodiments of Formula (I) and / or Formula (II),

[0361] [ka] teeth,

[0362] [ka] or a pharmaceutically acceptable salt, solvate, stereoisomer, tautomer, or mixture of positional isomers thereof, wherein each

[0363] [ka] denotes the attachment point to the rest of the equation.

[0364] In some embodiments of Formula (I) and / or Formula (II), the antibody conjugate comprises:

[0365] [ka]

[0366] [ka]

[0367] [ka]

[0368] [ka] or a pharmaceutically acceptable salt, solvate, stereoisomer, tautomer, or positional isomer mixture thereof.

[0369] As used herein, when an antibody is conjugated to a linker precursor, for convenience, the conjugate may, in some or any embodiments, be one of the following:

[0370] [ka] As shown herein,

[0371] [ka] indicates the point of attachment to the rest of the molecule. The antibody may be attached to one of the two nitrogens of the triazole, thereby forming:

[0372] [ka] It will be understood by those skilled in the art that the compound forms two possible positional isomers as shown in Figure 1. Therefore, any of the positional isomers or mixtures of the possible positional isomers are provided herein. When more than two positional isomers are possible, all individual positional isomers and all mixtures thereof are provided herein.

[0373] For any of the preceding embodiments, antibody drug conjugates in which the antibody is selected from various therapeutic antibodies that have been approved for use, are in clinical trials, or are in development for clinical use are also contemplated as being within the scope of the embodiments presented herein. Such therapeutic antibodies include, but are not limited to, rituximab (Rituxan®, IDEC / Genentech / Roche) (see, e.g., U.S. Pat. No. 5,736,137), a chimeric anti-CD20 antibody approved to treat non-Hodgkin's lymphoma, HuMax-CD20, an anti-CD20 currently being developed by Genmab, the anti-CD20 antibody described in U.S. Pat. No. 5,500,362, AME-133 (Applied Molecular Evolution), hA20 (Immunomedics, Inc.), HumaLYM (Intracel), and PRO70769 (PCT Application No. PCT / US2003 / 040426), trastuzumab (Herceptin®, Genentech) (see, e.g., U.S. Pat. No. 5,677,171 ), a humanized anti-Her2 / neu antibody approved to treat breast cancer; pertuzumab (rhuMab-2C4, Omnitarg®), currently in development by Genentech; anti-Her2 antibodies (U.S. Pat. No. 4,753,894 ; Chimeric anti-EGFR antibodies in clinical trials for various cancers include cetuximab (Erbitux®, Imclone) (U.S. Patent No. 4,943,533; PCT Publication No. WO 96 / 40210); ABX-EGF (U.S. Patent No. 6,235,883), currently being developed by Abgenix-Immunex-Amgen; HuMax-EGFr (U.S. Patent No. 7,247,301), currently being developed by Genmab; 425, EMD55900, EMD62000, and EMD72000 (Merck KGaA) (U.S. Patent No. 5,558,864; Murthy, et al. (1987) Arch. Biochem. Biophys. 252(2): 549-60; Rodeck, et al. (1987) J. Cell. Biochem. 35(4): 315-20; Kettleborough, et al.al. (1991) Protein Eng. 4(7): 773-83); ICR62 (Institute of Cancer Research) (PCT publication number WO95 / 20045; Modjtahedi, et al. (1993) J. Cell. Biophys. 22(I-3): 129-46; Modjtahedi, et al. (1993) Br. J. Cancer 67(2): 247-53; Modjtahedi, et al. (1996) Br. J. Cancer 73(2): 228-35; Modjtahedi, et al. (2003) Int. J. Cancer 105(2): 273-80); Cuba (U.S. Patent No. 5,891,996, U.S. Patent No. 6,506,883; Mateo, et al. (1997) Immunotechnol. 3(1): 71-81); mAb-806 (Ludwig Institute for Cancer Research, Memorial Sloan-Kettering) (Jungbluth, et al. (2003) Proc. Natl. Acad. Sci. USA. 100(2): 639-44); KSB-102 (KS Biomedix); MR1-1 (IVAX, National Cancer Institute) (PCT Publication No. WO01 / 62931A2); and (Scancell) (PCT Publication No. WO01 / 88138); alemtuzumab (Campath®, Millennium), a humanized mAb currently approved for the treatment of B-cell chronic lymphocytic leukemia; Ortho Muromonab-CD3 (Orthoclone OKT3®), an anti-CD3 antibody developed by Biotech / Johnson & Johnson; IDEC / Scheringibritumomab tiuxetan (Zevalin®), an anti-CD20 antibody developed by AG; gemtuzumab ozogamicin (Mylotarg®), an anti-CD33 (p67 protein) antibody developed by Celltech / Wyeth; and anti-LFA-3 (LFA-3) antibody developed by Biogen.Alefacept (Amevive®), an Fc fusion; Abciximab (ReoPro®), developed by Centocor / Lilly; Basiliximab (Simulect®), developed by Novartis; Palivizumab (Synagis®), developed by Mediimmune; Infliximab (Remicade®), an anti-TNF alpha antibody developed by Centocor; Adalimumab (Humira®), an anti-TNF alpha antibody developed by Abbott; Humicade®, an anti-TNF alpha antibody developed by Celltech; Golimumab (CNTO-148), a fully human TNF antibody developed by Centocor; Etanercept (Enbrel®), a p75 TNF receptor Fc fusion developed by Immunex / Amgen; and the p55 TNF receptor Fc fusion previously developed by Roche. fusion, jenercept, ABX-CBL, an anti-CD147 antibody being developed by Abgenix, ABX-IL8, an anti-IL8 antibody being developed by Abgenix, ABX-MA1, an anti-MUC18 antibody being developed by Abgenix, Pemtumomab (R1549, 90Y-muHMFG1), an anti-MUC1 antibody being developed by Antisoma, Therex (R1550), an anti-MUC1 antibody being developed by Antisoma, AngioMab (AS1405), an anti-MUC1 antibody being developed by Antisoma, HuBC-1, an anti-MUC1 antibody being developed by Antisoma, Thioplatin (AS1407), an anti-alpha-4-beta-1 (VLA-4) and alpha-4-beta-7 antibody being developed by Biogen, Antegren® (natalizumab), an anti-VLA-1 integrin antibody being developed by Biogen, VLA-1, an anti-VLA-1 integrin antibody being developed by Biogen. mAb, an anti-lymphotoxin beta receptor (LTBR) antibody being developed by Biogen, LTBR mAb, Cambridge AntibodyCAT-152, an anti-TGF-β antibody being developed by Cambridge Antibody Technology; ABT874 (J695), an anti-IL-12p40 antibody being developed by Abbott; CAT-192, an anti-TGF-β1 antibody being developed by Cambridge Antibody Technology and Genzyme; CAT-213, an anti-eotaxin 1 antibody being developed by Cambridge Antibody Technology; LymphoStat-B®, an anti-Blys antibody being developed by Cambridge Antibody Technology and Human Genome Sciences Inc.; and TRAIL-R1, an anti-TRAIL-R1 antibody being developed by Cambridge Antibody Technology and Human Genome Sciences Inc. mAb, Avastin® bevacizumab (rhuMAb-VEGF), an anti-VEGF antibody being developed by Genentech, an anti-HER receptor family antibody being developed by Genentech, anti-tissue factor (ATF), an anti-tissue factor antibody being developed by Genentech, Xolair® (omalizumab), an anti-IgE antibody being developed by Genentech, Raptiva® (efalizumab), an anti-CD11a antibody being developed by Genentech and Xoma, MLN-02 antibody (formerly LDP-02) being developed by Genentech and Millennium Pharmaceuticals, HuMaX CD4, an anti-CD4 antibody being developed by Genmab, HuMax-IL15, an anti-IL15 antibody being developed by Genmab and Amgen, HuMax-Inflam, developed by Genmab and Medarex, Genmab, Medarex, and Oxford HuMax-Cancer, an anti-heparanase I antibody being developed by GcoSciences; HuMax-Lymphoma, being developed by Genmab and Amgen; HuMax-TAC, being developed by Genmab; and IDEC.IDEC-131, an anti-CD40L antibody being developed by IDEC Pharmaceuticals; IDEC-151 (clenoliximab), an anti-CD4 antibody being developed by IDEC Pharmaceuticals; IDEC-114, an anti-CD80 antibody being developed by IDEC Pharmaceuticals; IDEC-152, an anti-CD23 antibody being developed by IDEC Pharmaceuticals; an anti-macrophage chemotactic factor (MIF) antibody being developed by IDEC Pharmaceuticals; BEC2, an anti-idiotypic antibody being developed by Imclone; IMC-1C11, an anti-KDR antibody being developed by Imclone; DC101, an anti-flk-1 antibody being developed by Imclone; an anti-VE-cadherin antibody being developed by Imclone; CEA-Cide® (labetuzumab), an anti-carcinoembryonic antigen (CEA) antibody being developed by Immunomedics; and LymphoCi, an anti-CD22 antibody being developed by Immunomedics. de® (epratuzumab), AFP-Cide being developed by Immunomedics, MyelomaCide being developed by Immunomedics, LkoCide being developed by Immunomedics, ProstaCide being developed by Immunomedics, MDX-010, an anti-CTLA4 antibody being developed by Medarex, MDX-060, an anti-CD30 antibody being developed by Medarex, MDX-070 being developed by Medarex, MDX-018 being developed by Medarex, MedareX and Immuno-DesignedOsidem® (IDM-1), an anti-Her2 antibody being developed by Molecules; HuMax®-CD4, an anti-CD4 antibody being developed by MedareX and Genmab; HuMax-IL15, an anti-IL15 antibody being developed by MedareX and Genmab; CNTO148, an anti-TNFα antibody being developed by MedareX and Centocor / J&J; CNTO1275, an anti-cytochrome P450 antibody being developed by Centocor / J&J; MOR101 and MOR102, anti-intercellular adhesion molecule-1 (ICAM-1) (CD54) antibodies being developed by MorphoSys; MOR201, an anti-fibroblast growth factor receptor 3 (FGFR-3) antibody being developed by MorphoSys; Nuvion® (vicilizumab), an anti-CD3 antibody being developed by Protein Design Labs; Protein Design In another embodiment, therapeutic agents include HuZAF®, an anti-gamma interferon antibody being developed by Labs, anti-α5β1 integrin being developed by Protein Design Labs, anti-IL-12 being developed by Protein Design Labs, ING-1, an anti-Ep-CAM antibody being developed by Xoma, Xolair® (omalizumab), a humanized anti-IgE antibody being developed by Genentech and Novartis, and MLN01, an anti-beta2 integrin antibody being developed by Xoma. In another embodiment, therapeutic agents include KRN330 (Kirin); huA33 antibody (A33, Ludwig Institute for Cancer Research); CNTO95 (alpha V integrin, Centocor); MEDI-522 (alpha Vβ3 integrin, Medimmune); volociximab (alpha Vβ1 integrin, Biogen / PDL); human mAb216 (B cell glycosolated epitope, NCl); BiTE MT103 (bispecific CD19 x CD3, Medimmune); 4G7 x H22 (bispecific B cell x Fc gamma R1, Medarex / Merck KGa); rM28 (bispecific CD28 x MAPG, EP 1444268); MDX447 (EMD82633) (bispecific CD64 x EGFR, Medarex); catumaxomab (Removab) (bispecific EpCAM x anti-CD3, Trion / Fres); ertumaxomab (bispecific HER2 / CD3, Fresenius Biotech); oregovomab (OvaRex) (CA-125, ViRexx); Rencarex® (WX G250) (carbonic anhydrase IX, Wilex); CNTO888 (CCL2, Centocor); TRC105 (CD105 (endoglin), Tracon); BMS-663513 (CD137 agonist, Bristol Myers Squibb); MDX-1342 (CD19, Medarex); siplizumab (MEDI-507) (CD2, Medimmune); ofatumumab (Humax-CD20) (CD20, Genmab); rituximab (Rituxan) (CD20, Genentech); veltuzumab (hA20) (CD20, Immunomedics); epratuzumab (CD22, Amgen); lumiliximab (IDEC152) (CD23, Biogen); muromonab-CD3 (CD3, Ortho); HuM291 (CD3 fc receptor, PDL Biopharma); HeFi-1, CD30, NCl); MDX-060 (CD30, Medarex); MDX-1401 (CD30, Medarex); SGN-30 (CD30, Seattle Genentics); SGN-33 (lintuzumab) (CD33, Seattle Genentics); zanolimumab (HuMax-CD4) (CD4, Genmab); HCD122 (CD40, Novartis); SGN-40 (CD40, Seattle Genentics); Campath1h (alemtuzumab) (CD52, Genzyme); MDX-1411 (CD70, Medarex);hLL1 (EPB-1) (CD74.38, Immunomedics); galiximab (IDEC-144) (CD80, Biogen); MT293 (TRC093 / D93) (cleaved collagen, Tracon); HuLuc63 (CS1, PDL Pharma); ipilimumab (MDX-010) (CTLA4, Bristol Myers Squibb); tremelimumab (ticilimumab, CP-675,2) (CTLA4, Pfizer); HGS-ETR1 (mapatumumab) (DR4TRAIL-R1 agonist, Human Genome Science / Glaxo Smith) Kline; AMG-655 (DR5, Amgen); Apomab (DR5, Genentech); CS-1008 (DR5, Daiichi Sankyo Co., Ltd.); HGS-ETR2 (lexatumumab) (DR5TRAIL-R2 agonist, HGS); Cetuximab (Erbitux) (EGFR, Imclone); IMC-11F8 (EGFR, Imclone); Nimotuzumab (EGFR, YM Bio); Panitumumab (Vectabix) (EGFR, Amgen); Zalutumumab (HuMaxEGFr) (EGFR, Genmab); CDX-110 (EGFRvIII, AVANT Immunotherapeutics; adecatumumab (MT201) (Epcam, Merck); edrecolomab (Panorex, 17-1A) (Epcam, Glaxo / Centocor); MORAb-003 (folate receptor a, Morphotech); KW-2871 (ganglioside GD3, Kyowa); MORAb-009 (GP-9, Morphotech); CDX-1307 (MDX-1307) (hCGb, Celldex); trastuzumab (Herceptin) (HER2, Celldex); pertuzumab (rhuMAb 2C4) (HER2(DI), Genentech); apolizumab (HLA-DR beta chain, PDL Pharma); AMG-479 (IGF-1R, Amgen); anti-IGF-1R R1507 (IGF1-R, Roche); CP751871 (IGF1-R, Pfizer); IMC-A12 (IGF1-R, Imclone); BIIB022 (IGF-1R, Biogen);Mik-beta-1 (IL-2Rb (CD122), Hoffman LaRoche); CNTO328 (IL6, Centocor); Anti-KIR(1-7F9) (killer cell Ig-like receptor (KIR), Novo); Hu3S193 (Lewis(y), Wyeth, Ludwig Institute of Cancer Research); hCBE-11 (LTβR, Biogen); HuHMFG1 (MUC1, Antisoma / NCl); RAV12 (N-linked glycan epitope, Raven); CAL (parathyroid-related protein (PTH-rP), University of California); CT-011 (PD1, CureTech); MDX-1106 (ono-4538) (PD1, Medarex / Ono); MAb CT-011 (PD1, Curetech); IMC-3G3 (PDGFRa, Imclone); bavituximab (phosphatidylserine, Peregrine); huJ591 (PSMA, Cornell Research Foundation); muJ591 (PSMA, Cornell Research Foundation); GC1008 (TGFb(pan) inhibitor (IgG4), Genzyme); infliximab (Remicade) (TNFa, Centocor); A27.15 (transferrin receptor, Salk Institute, INSERN WO2005 / 111082); E2.3 (transferrin receptor, Salk Institute); bevacizumab (Avastin) (VEGF, Genentech); HuMV833 (VEGF, Tsukuba Research Lab, PCT Publication No. WO / 2000 / 034337, University of Texas); IMC-18F1 (VEGFR1, Imclone); IMC-1121 (VEGFR2, Imclone);

[0374] Examples of useful bispecific parent antibodies include, but are not limited to, those having one antibody against a tumor cell antigen and the other antibody against a cytotoxicity-inducing molecule, e.g., anti-FcγRI / anti-CD15, anti-p185 HER2 / FcγRIII (CD16), anti-CD3 / anti-malignant B cells (1D10), anti-CD3 / anti-p185 HER2 , anti-CD3 / anti-p97, anti-CD3 / anti-renal cell carcinoma, anti-CD3 / anti-OVCAR-3, anti-CD3 / L-D1 (anti-colon cancer), anti-CD3 / anti-melanocyte stimulating hormone analog, anti-EGF receptor / anti-CD3, anti-CD3 / anti-CAMA1, anti-CD3 / anti-CD19, anti-CD3 / MoV18, anti-neural cell adhesion molecule (NCAM) / anti-CD3, anti-folate binding protein (FBP) / anti-CD3, anti-pan-cancer-associated antigen (AMO) C-31) / anti-CD3; bispecific antibodies having one antibody that specifically binds to a tumor antigen and another antibody that binds to a toxin, e.g., anti-saporin / anti-Id-1, anti-CD22 / anti-saporin, anti-CD7 / anti-saporin, anti-CD38 / anti-saporin, anti-CEA / anti-ricin A chain, anti-interferon alpha (IFN-α) / anti-hybridoma idiotype, anti-CEA / anti-vinca alkaloid; enzyme-activated prodrugs bispecific antibodies for converting RAGS, e.g., anti-CD30 / anti-alkaline phosphatase (catalyzing the conversion of mitomycin phosphate prodrug to mitomycin alcohol); bispecific antibodies that can be used as fibrinolytic agents, e.g., anti-fibrin / anti-tissue plasminogen activator (tPA), anti-fibrin / anti-urokinase-type plasminogen activator (uPA); bispecific antibodies for targeting immune complexes to cell surface receptors, e.g., anti-low density lipoprotein (LDL) / anti-Fc receptor (e.g., FcγRI, FcγRII, or FcγRIII); bispecific antibodies for use in the treatment of infectious diseases, e.g., anti-CD3 / anti-herpes simplex virus (HSV), anti-T cell receptor:CD3 complex / anti-influenza, anti-FcγR / anti-HIV; bispecific antibodies for in vitro or in vivo tumor detection, e.g., anti-CEA / anti-EOTUBE, anti-CEA / anti-DPTA, anti-p185 HER2 / anti-hapten; bispecific antibodies as vaccine adjuvants (see Fanger, MW et al., Crit Rev Immunol. 1992; 12(34):101-24, incorporated herein by reference); and bispecific antibodies as diagnostic tools, such as anti-rabbit IgG / anti-ferritin, anti-horseradish peroxidase (HRP) / anti-hormone, anti-somatostatin / anti-substance P, anti-HRP / anti-FITC, anti-CEA / anti-β-galactosidase (see Nolan, O et R. O'Kennedy, Biochim Biophys Acta. 1990 Aug. 1; 1040(1):1-11, incorporated herein by reference). Examples of trispecific antibodies include anti-CD3 / anti-CD4 / anti-CD37, anti-CD3 / anti-CD5 / anti-CD37, and anti-CD3 / anti-CD8 / anti-CD37.

[0375] In any of the above-described embodiments, e.g., embodiments in which the antibody conjugate has a structure according to Formula (I), (II), (Xa-e), and / or (XIa-d), the bracketed structure can be covalently linked to one or more unnatural amino acids of the antibody, where the one or more unnatural amino acids are located at sites independently selected from the group consisting of HC-F241, HC-F404, HC-Y180, and LC-K42, and combinations thereof, according to the Kabat numbering scheme or the EU numbering scheme of Kabat. In some embodiments, the bracketed structure is covalently linked to one or more unnatural amino acids at site HC-F404 of the antibody. In some embodiments, the bracketed structure is covalently linked to one or more unnatural amino acids at site HC-Y180 of the antibody. In some embodiments, the bracketed structure is covalently linked to one or more unnatural amino acids at site HC-F241 of the antibody. In some embodiments, the bracketed structures are covalently linked to one or more unnatural amino acids at site LC-K42 of the antibody. In some embodiments, the bracketed structures are covalently linked to one or more unnatural amino acids at sites HC-F404 and HC-Y180 of the antibody. In some embodiments, the bracketed structures are covalently linked to one or more unnatural amino acids at sites HC-F241, HC-F404, and HC-Y180 of the antibody. In some embodiments, at least one bracketed structure is covalently linked to an unnatural amino acid at site HC-F404 of the antibody and at least one bracketed structure is covalently linked to an unnatural amino acid at site HC-Y180 of the antibody. In some embodiments, the bracketed structures are covalently linked to one or more unnatural amino acids at sites HC-Y180 and LC-K42 of the antibody. In some embodiments, the bracketed structure is covalently attached to one or more unnatural amino acids at positions HC-F404 and LC-K42 of the antibody.In some embodiments, the bracketed structure is covalently linked to one or more unnatural amino acids at positions HC-F404, HC-Y180, and LC-K42 of the antibody. In some embodiments, the unnatural amino acids at positions HC-F404, HC-Y180, and LC-K42 are the same unnatural amino acid. In some embodiments, the unnatural amino acids at positions HC-F404, HC-Y180, and LC-K42 are each independently selected from two different unnatural amino acids. For example, the unnatural amino acid at positions HC-F404 and HC-Y180 can be a first unnatural amino acid, while the unnatural amino acid at position LC-K42 can be a different unnatural amino acid. In some embodiments, the unnatural amino acid at positions HC-F404 and HC-Y180 is a residue according to Formula (30), while the unnatural amino acid at position LC-K42 is L-paraacetylphenylalanine. In certain embodiments, each unnatural amino acid is a residue according to formula (30).

[0376] 3. Payload

[0247] In addition to the payloads described above, the molecular payload may be any molecular entity that one skilled in the art would wish to conjugate to a polypeptide.

[0377] In certain embodiments, the payload is a therapeutic moiety (e.g., a PA described herein). In other embodiments, the antibody conjugate may be used to deliver an immunomodulator (e.g., an IM described herein) to or near its molecular target.

[0378] In some embodiments, the payload PA is a residue of a cytotoxic compound. Cytotoxic compounds include alkylating agents (e.g., cisplatin, cyclophosphamide), DNA cross-linking agents (e.g., pyrrolobenzodiazepines (PBDs) or dimers thereof), antitumor antibiotics (e.g., doxorubicin, hedamycin, septacidin), microtubule-disrupting and / or antimitotic agents (e.g., maytansinoids, hemiasterin, paclitaxel), antimetabolites (e.g., 5-fluorouracil, methotrexate), histone deacetylases, and the like. These include HDAC inhibitors (e.g., suberanilohydroxamic acid (SAHA)), telomerase inhibitors (e.g., BIBR1542), small molecules targeting the SF3b subunit of the spliceosomal U2 small nuclear ribonucleoprotein (snRNP) (splisostatin A, meayamycin, and pladienolide B) and / or immunogenic cell death inhibitors (e.g., anthracyclines, platinum-based chemotherapy agents, cyclophosphamide, mitoxantrone).

[0379] In some embodiments of Formula (I) and / or Formula (II), the payload (PA) is selected from the group consisting of altretamine, ansamitocin P3, auristatins (MMAE, MMAF), bendamustine hydrochloride, bleomycin, bortezomib, busulfan, cabazitaxel, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clofarabine, colchicine, combrestatin-A4, cytarabine, cyclophosphamide, dapagliflozin ... Carbazine, dactinomycin, daunorubicin hydrochloride, docetaxel, dolastatin 10, dolastatin 15, doxorubicin hydrochloride, eribulin mesylate, epirubicin, epothilone AF, etoposide, floxuridine, fludarabine, 5-fluorouracil, gemcitabine, hedamycin, hemiasterin (e.g., HTI-286, E7974), idarubicin, ifosfamide, irinotecan, ixabepilone, ixazomib, leucovorin , lomustine, losoxantrone, maytansinoids (e.g., DM1, DM4), meayamycin, mechlorethamine, melphalan, mercaptopurine, methotrexate, mitomycin, mitotane, mitoxantrone, nelarabine, nedaplatin, omacetaxine mepesuccinate, oxaliplatin, paclitaxel, pemetrexed disodium, pentostatin, pladienolide B, pixantrone, pralatrexate, procarbazine The cytotoxic compound is a residue of a cytotoxic compound selected from the group consisting of benzodiazepine hydrochloride, pyrrolobenzodiazepine (PBD, e.g., SG3199), radium dichloride, septacidin, splicesostatin A, streptozocin, suberanilohydroxamic acid (SAHA), SN-38, thioguanine, thiotepa, temozolomide, teniposide, topotecan hydrochloride, valrubicin, vincristine sulfate, vinblastine sulfate, vinedesine, and vinorelbine tartrate. In some such embodiments of Formula (I) and / or Formula (II), the cytotoxic compound is an immunogenic cell death agent. In some such embodiments, the immunogenic cell death agent is selected from the group consisting of mitoxantrone, oxaliplatin, cyclophosphamide, doxorubicin, daunorubicin, epirubicin, idarubicin, and bortezomib.

[0380] In some embodiments, the payload is an antimetabolite. The antimetabolite may be, for example, a purine antagonist (e.g., azothioprine or mycophenolate mofetil), a dihydroBCMA reductase inhibitor (e.g., methotrexate), acyclovir, gandicyclovir, zidovudine, vidarabine, ribavarin, azidothymidine, cytidine arabinoside, amantadine, dideoxyuridine, iododeoxyuridine, poscarnet, or trifluridine.

[0381] Depending on the initiating stimulus, cancer cell death induced by cytotoxic compounds can be immunogenic or non-immunogenic. Cytotoxic compounds vary in their ability to induce immunogenic cell death and, as a result, anti-cancer immunity. The term "immunogenic cell death" is used to characterize a specific form of cell death that stimulates an immune response to specific antigens released by dying cancer cells (A. Sistigu, et al., Semin. Immunopathol. 33(2011)369-383). Among the numerous antitumor agents, only a few cytotoxic compounds have been described to induce ICD. The criterion met by bonafide ICD inducers is that pretreatment of cancer cells with such compounds, followed by inoculation into immunocompetent mice, results in tumor rejection upon rechallenge with untreated tumor cells (L. Zitvogel, Immunity 39(2013)74-88). These tumor rejection after vaccination of mice bearing tumor cells treated with compound is associated with the establishment of immunological memory.The compounds that have been shown to induce high levels of ICD include various anthracyclines, such as doxorubicin, epirubicin, and idarubicin, which are commonly used against various malignant tumors (N. Casares, et al., J. Exp. Med. 202(2005)1691-1701; M. Obeid, et al., Nat. Med. 13(2007)54-61; J. Fucikova et al., Cancer Res. 71(2011)4821-4833). The alkylating agent oxaliplatin, a platinum derivative used in combination regimens to treat advanced colorectal cancer, induces ICD, whereas cisplatin does not (A. Tesniere et al., Oncogene 29(2010)482-491; I. Martins et al., Oncogene 30(2011)1147-1158). Other bona fide ICD inducers are the topoisomerase II inhibitor mitoxantrone and the alkylating agent cyclophosphamide, both of which are used to treat several cancer types and autoimmune diseases.Bortezomib, a proteasome inhibitor approved for multiple myeloma and mantle cell lymphoma, also induces ICD (G. Schiavoni et al., Cancer Res. 71(2011)768-778; A. Sistigu et al., Semin. Immunopathol. 33(2011)369-383; M. Obeid et al., Nat. Med. 13(2007)54-61).

[0382] These therapeutic agents share the ability to induce specific "danger signals" or "damage-associated molecular patterns" (DAMPs) in tumor cells. ICD is characterized by endoplasmic reticulum stress, which leads to cell surface expression of calreticulin, followed by the release of soluble mediators HMGB1 and ATP (representing DAMPs) and type I interferons. The role of these markers in ICD has been demonstrated using RNA interference or neutralizing antibodies against calreticulin or HMGB1, respectively, followed by rescue with recombinant calreticulin or HMGB1 protein (M. Obeid et al., Nat. Med. 13(2007)54-61; A. Tesniere et al., Oncogene 29(2010)482-491). The induction of all four markers appears necessary to predict in vivo ICD response (L. Bezu et al., Front. Immunol. 6(2015)187). The various redox states of HMGB1 protein may also contribute to different immune functions, including leukocyte recruitment versus activation (R. Kang et al., Clin. Cancer Res. 19(2013)4046-4057). Cellular and molecular mechanisms involved in sensing danger signals involve receptors expressed by dendritic cells, including CD91 (for calreticulin), TLR4 (for HMGB1), and P2RY2 / P2RX7 (for ATP) (DV Krysko et al., Nat. Rev. Cancer 12(2012)860-875).

[0383]

[0254] Some tubulin inhibitors used as cytotoxic agents in ADCs have been reported to induce ICD. For example, when auristatin is delivered in the context of an ADC (SGN-35), it has been reported to induce markers of ICD, including calreticulin, and activate dendritic cells in vitro and in vivo (SJ Gardai et al., Cancer Res. 75 (2015) Abstract No. 2469). Anthracyclines are a class of cytotoxic drugs used as chemotherapy and in ADCs. Doxorubicin is a potent inducer of ICD as a free payload, and anthracycline-conjugated ADCs have been shown to have potent ICD activity (D'Amico L et al., J Immunother Cancer. 2019 Jan 21;7(1):16). Maytansinoids, cytotoxic agents commonly used in ADCs, have also been shown to induce ICD in the ADC setting (Bauzon M, et al., Oncoimmunology. 2019 Jan 22;8(4):e1565859).

[0384] Thus, ICD is a mechanism by which standard chemotherapy can stimulate the immune system and induce a strong inflammatory response in tumors. Certain cytotoxic agents activate dendritic cell maturation, leading to MHC-mediated tumor antigen cross-presentation and ultimately antigen-specific CD8+ delivery to tumors. + Induce the sequential production of secretory markers that lead to T cell recruitment. In particular, treatment regimens containing anthracycline (doxorubicin) and oxaliplatin appear attractive for combination with immuno-oncology compounds, as both compounds have been associated with the potent induction of immunogenic tumor cell death, thereby potentially enhancing anti-tumor immune responses (A. Sistigu et al., Semin. Immunopathol. 33 (2011) 369-383). Methods for assaying immunogenic cell death are described herein and in the Examples section.

[0385] In one group of embodiments, the cytotoxic agent is an immunogenic cell death agent. Cytotoxic agents capable of intrinsically inducing ICD include, but are not limited to, maytansinoids, hemiasterin, auristatin, mitoxantrone (and / or, for example, losoxantrone (DuP941), pixantrone (BBR2778)), oxaliplatin (and / or other platins, for example, carboplatin, cisplatin, nedaplatin), cyclophosphamide, anthracyclines (for example, doxorubicin, daunorubicin, epirubicin, and idarubicin), and bortezomib (and / or other boronic acid-containing agents, for example, ixazomib).

[0386] In certain embodiments, the cytotoxic agent is a maytansinoid, another group of antitubulin agents. For example, in specific embodiments, the maytansinoid may be maytansine or DM-1 (ImmunoGen, Inc.; see also Chari et al., 1992, Cancer Res. 52:127-131).

[0387] In some embodiments, the payload is an auristatin, such as auristatin E or a derivative thereof. For example, the auristatin E derivative may be an ester formed between auristatin E and a keto acid. For example, auristatin E can react with paraacetylbenzoic acid or benzoylvaleric acid to produce AEB and AEVB, respectively. Other exemplary auristatin derivatives include AFP (auristatin phenylalanine phenylenediamine), MMAF (monomethyl auristatin F), and MMAE (monomethyl auristatin E). The synthesis and structure of auristatin derivatives are described in U.S. Patent Application Publication Nos. 2003-0083263, 2005-0238649, and 2005-0009751; WO04 / 010957, WO02 / 088172, and U.S. Patent Nos. 6,323,315; 6,239,104; 6,034,065; 5,780,588; 5,665,860; 5,663,149; Nos. 5,635,483; 5,599,902; 5,554,725; 5,530,097; 5,521,284; 5,504,191; 5,410,024; 5,138,036; 5,076,973; 4,986,988; 4,978,744; 4,879,278; 4,816,444; and 4,486,414.

[0388] In some embodiments, the payload is hemiasterlin. Hemiasterlin suitable for use in the antibody-drug conjugates described herein is described, for example, in WO2016 / 2016 / 123582, which is incorporated herein by reference in its entirety.

[0389] In some embodiments of Formula (I) and / or Formula (II), the cytotoxic compound is a maytansinoid, hemiasterin, an anthracycline, and / or a pyrrolobenzodiazepine. In some such embodiments of Formula (I) and / or Formula (II), the maytansinoid is:

[0390] [ka] In other such embodiments of Formula (I) and / or Formula (II), hemiasterlin is:

[0391] [ka] In further such embodiments of Formula (I) and / or Formula (II), the pyrrolobenzodiazepine is a monomer or a dimeric derivative thereof. In some such embodiments, the pyrrolobenzodiazepine is

[0392] [ka] is.

[0393] In some embodiments of Formula (I) and / or Formula (II), the immunomodulatory payload (IM) is:

[0394] [ka] 4-Amino-2-butoxy-7,8-dihydro-8-[[3-(1-pyrrolidinylmethyl)phenyl]methyl]-6(5H)-pteridinone (Besatolimod, GS9620, CAS number 1228585-88-3), 1-(2-methylpropyl)-1H-imidazole[4,5-c]quinolin-4-amine (Imiquimod, CAS number 99011-02-6), 1-(4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl)-2-methylpropanol quinolin-2-ol (resquimod, R848, CAS number 144875-48-9), 4-amino-2-[(ethylamino)methyl]-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol (gardiquimod, CAS number 1020412-43-4), N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide (3M-001), 2-propylthiazolo[4,5-c]quinolin-1-yl N-(1-(4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-yl)methanesulfonamide (CAS number 642473-62-9, 3M-011, or 854A), and N-(4-( and a residue of an immunomodulatory compound selected from the group consisting of 4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl)methanesulfonamide (CAS No. 532959-63-0, 3M-852A, PF-4878691), 2-methyl-1-(2,2,4-trimethylpent-4-en-1-yl)-1H-imidazo[4,5-c]quinolin-4-amine (S-34240), loxoribine, CL264, ssRNA40, and SM-276001.

[0395] In some other embodiments of Formula (I) and / or Formula (II), the immunomodulatory payload is represented by Formula (III):

[0396] [ka] or a pharmaceutically acceptable salt, solvate, or N-oxide residue thereof, wherein R 1a , R 1b , R 2a , and R 2b is, in each occurrence, independently hydrogen and C 1~6 alkyl, Ring A is a cycloalkyl, heterocycloalkyl, monocyclic aryl, monocyclic heteroaryl, fused bicyclic aryl, or fused bicyclic heteroaryl, where the heterocycloalkyl and each heteroaryl contains 1, 2, 3, or 4 heteroatoms selected from N, S, and O; Ring B contains 1 to 2 R 3 is a 4-membered N-linked heterocycloalkyl further substituted with 3 is, in each occurrence independently, -N(R 3a )2, -OR 3b , -C(R 3c )2NH2, C 1~6 alkyl, heterocycloalkyl, heteroaryl, or partially saturated heteroaryl, or two R attached to the same carbon 3 together with the carbon atom to which they are attached form a spiroheterocycloalkyl, wherein the heterocycloalkyl, spiroheterocycloalkyl, heteroaryl, and partially saturated heteroaryl contain 1, 2, 3, or 4 heteroatoms selected from N, S, and O, and optionally 1 to 2 C 1~3 further substituted with alkyl, or Ring B contains 1 to 3 R 3 and R is a 5-6 membered N-linked heterocycloalkyl further substituted with 3 is, in each occurrence independently, -N(R 3a )2, -OR 3b , -C(R 3c)2NH2, heterocycloalkyl, heteroaryl, or partially saturated heteroaryl, or two R attached to the same carbon 3 together with the carbon atom to which they are attached form a spiroheterocycloalkyl, where the heterocycloalkyl, spiroheterocycloalkyl, heteroaryl, and partially saturated heteroaryl contain 1, 2, 3, or 4 heteroatoms selected from N, S, and O, and optionally 1 to 2 C 1~3 further substituted with alkyl, or Ring B contains 1 to 3 R 3 or 1 to 3 R 3 wherein the heterocycloalkyl and heteroaryl contain 1, 2, 3, or 4 heteroatoms selected from N, S, and O; and R 3 is, in each occurrence independently, -N(R 3a )2, -OR 3b , -C(R 3c )2NH2, C 1~6 alkyl, heterocycloalkyl, heteroaryl, or partially saturated heteroaryl, or two R attached to the same carbon 3 together with the carbon atom to which they are attached form a spiroheterocycloalkyl, wherein the heterocycloalkyl, spiroheterocycloalkyl, heteroaryl, and partially saturated heteroaryl contain 1, 2, 3, or 4 heteroatoms selected from N, S, and O, and optionally 1 to 2 C 1~3 further substituted with alkyl, R 3a is, in each occurrence, independently hydrogen, C 1~6 selected from alkyl, —C(═O)—CH2NH2, and cycloalkyl; R 3b is, in each occurrence, independently hydrogen,

[0397] [ka] and -CH2-aryl-CH2NH2; R 3c may, in each occurrence, independently represent hydrogen and C 1~6 alkyl, or two R 3c together with the carbon atom to which they are attached form a cycloalkyl; R 4 is C 1~6 is alkyl, R 5 halo, hydroxy, alkoxy, amino, C 1~6 Alkylamino, C 1~6 Dialkylamino, C 1~6 C optionally substituted with cycloalkyl, aryl, or heteroaryl 1~6 Cycloalkyl or C 1~6 alkyl, and heteroaryl containing 1, 2, 3, or 4 heteroatoms selected from N, S, and O, and cycloalkyl, aryl, and heteroaryl are optionally further substituted with halo, hydroxy, alkyl, or haloalkyl; where the immunomodulatory payload (IM) is R 3 or the amino group of ring B.

[0398] In some other embodiments of formula (I) and / or formula (II), the immunomodulatory payload is of formula (III'):

[0399] [ka] or a pharmaceutically acceptable salt, solvate, or N-oxide residue thereof, wherein R 1a , R 1b , R 2a , and R 2b is, in each occurrence, independently hydrogen and C 1~6 alkyl, Ring A is a cycloalkyl, heterocycloalkyl, monocyclic aryl, monocyclic heteroaryl, fused bicyclic aryl, or fused bicyclic heteroaryl, where the heterocycloalkyl and each heteroaryl contains 1, 2, 3, or 4 heteroatoms independently selected from N, S, and O; Ring B contains 1 to 2 R 3 and R is a 4-membered N-linked heterocycloalkyl substituted with 3 is, in each occurrence independently, -N(R 3a )2, -OR 3b , -C(R 3c )2NH2, C 1~6 alkyl, heterocycloalkyl, heteroaryl, or partially saturated heteroaryl, or two R attached to the same carbon 3 together with the carbon atom to which they are attached form a spiroheterocycloalkyl, where R 3 The heterocycloalkyl, spiroheterocycloalkyl, heteroaryl, and partially saturated heteroaryl of the formula (I) contain 1, 2, 3, or 4 heteroatoms independently selected from N, S, and O, and optionally 1 to 2 C 1~3 is substituted with alkyl, or Ring B contains 1 to 3 R 3 5-6 membered N-linked heterocycloalkyl substituted with 1-3 R 3 is a 5-6 membered N-linked heteroaryl substituted with R 3 is, in each occurrence independently, -N(R 3a )2, -OR 3b , -C(R 3c )2NH2, heterocycloalkyl, heteroaryl, or partially saturated heteroaryl, or two R attached to the same carbon 3 together with the carbon atom to which they are attached form a spiroheterocycloalkyl, and R 3 The heterocycloalkyl, spiroheterocycloalkyl, heteroaryl, and partially saturated heteroaryl of the formula (I) contain 1, 2, 3, or 4 heteroatoms independently selected from N, S, and O, and optionally 1 to 2 C 1~3is substituted with alkyl, or Ring B contains 1 to 3 R 3 7-10 membered N-linked heterocycloalkyl substituted with 1-3 R 3 and R is a 5-10 membered N-linked heteroaryl substituted with 3 is, in each occurrence independently, -N(R 3a )2, -OR 3b , -C(R 3c )2NH2, C 1~6 alkyl, heterocycloalkyl, heteroaryl, or partially saturated heteroaryl, or two R attached to the same carbon 3 together with the carbon atom to which they are attached form a spiroheterocycloalkyl, where R 3 The heterocycloalkyl, spiroheterocycloalkyl, heteroaryl, and partially saturated heteroaryl of the formula (I) contain 1, 2, 3, or 4 heteroatoms independently selected from N, S, and O, and optionally 1 to 2 C 1~3 is substituted with alkyl, R 3a is, in each occurrence, independently hydrogen, C 1~6 selected from alkyl, —C(═O)—CH2NH2, and cycloalkyl; R 3b is, in each occurrence, independently hydrogen,

[0400] [ka] wherein q1 is 1, 2, or 3, and —CH2-aryl-CH2NH2; R 3c is, in each occurrence, independently hydrogen, and C 1~6 alkyl, or two R 3c together with the carbon atom to which they are attached form a cycloalkyl; R 4 But C 1~6 is alkyl, R 5 But C 3~6Cycloalkyl or C 1~6 alkyl, which are each selected from halo, hydroxy, alkoxy, amino, C 1~6 Alkylamino, C 1~6 Dialkylamino, C 3~6 one, two, or three R independently selected from cycloalkyl, aryl, and heteroaryl; 5a group, where heteroaryl contains 1, 2, 3, or 4 heteroatoms independently selected from N, S, and O, and R 5a C 3~6 Any of the cycloalkyl, aryl, and heteroaryl groups are optionally substituted with 1, 2, or 3 groups independently selected from halo, hydroxy, alkyl, and haloalkyl.

[0401] In some embodiments of the compounds of Formula (III) and / or Formula (III'),

[0402] [ka] teeth,

[0403] [ka] where each

[0404] [ka] indicates the point of attachment to the rest of the formula. In some such embodiments, in one example, R 5 is pentyl,

[0405] [ka] is one or more of the groups shown above.

[0406] In some or any of the preceding embodiments of the compounds of Formula (IP), Formula (I), Formula (II) and / or Formula (III), R 1a , R 1b , R 2a , and R 2b is hydrogen and R 5 is pentyl, and ring B is a ring consisting of two R atoms which, together with the atoms to which they are attached, form a spiroheterocycloalkyl. 3 In some of such embodiments, spiroheterocycloalkyl is selected from spiroazetidinyl, spiromorpholinyl, spiro-(gemdimethyl)morpholinyl, or spiro-piperidinyl, optionally substituted as described herein. In some or any of the preceding embodiments of the compounds of Formula (IP), Formula (I), Formula (II), and / or Formula (III), R 1a , R 1b , R 2a , and R 2b is hydrogen and R 5 is pentyl, and ring B is each -OH, -NH2, -CH3,

[0407] [ka] and one to two R independently selected from combinations thereof. 3 In some or any of the preceding embodiments of the compounds of Formula (IP), Formula (I), Formula (II), and / or Formula (III), R 1a , R 1b , R 2a , and R 2b is hydrogen and R 5 is pentyl and ring B is

[0408] [ka] In some or any of the preceding embodiments of the compounds of Formula (IP), Formula (I), Formula (II), and / or Formula (III), R 1a , R 1b , R 2a , and R 2b is hydrogen and R 5 is pentyl, and Ring B is R 3 and N-linked azetidine substituted with any combination of:

[0409] In some or any of the preceding embodiments of the compounds of Formula (IP), Formula (I), Formula (II) and / or Formula (III), R 1a , R 1b , R 2a , and R 2b is hydrogen and R 5 is pentyl, and ring B is a ring consisting of two R atoms which, together with the atoms to which they are attached, form a spiroheterocycloalkyl. 3 In some of such embodiments, the spiroheterocycloalkyl is an azetidinyl ring, or a piperidinyl ring. In some of the compounds of Formula (IP), Formula (I), Formula (II), and / or Formula (III), or any of the preceding embodiments, R 1a , R 1b , R 2a , and R 2b is hydrogen and R 5 is pentyl and Ring B is an N-linked piperidinyl ring substituted with a partially saturated heteroaryl. In some or any of the preceding embodiments of the compounds of Formula (IP), Formula (I), Formula (II) and / or Formula (III), R 1a , R 1b , R 2a , and R 2b is hydrogen and R 5 is pentyl and ring B is C 1~3In some or any of the preceding embodiments of the compounds of Formula (IP), Formula (I), Formula (II), and / or Formula (III), R 1a , R 1b , R 2a , and R 2b is hydrogen and R 5 is pentyl, and ring B is a ring having 1 to 2 R 3 In some such embodiments, ring B is an N-linked heteroaryl substituted with 1-2 R 3 In some or any preceding embodiments of the compounds of Formula (IP), Formula (I), Formula (II), and / or Formula (III), R 3 In some or any of the preceding embodiments of the compounds of Formula (IP), Formula (I), Formula (II), and / or Formula (III), R 1a , R 1b , R 2a , and R 2b is hydrogen and R 5 is pentyl, and Ring B is R 3 is an N-linked ring substituted with any combination of:

[0410] In some or any of the preceding embodiments of the compounds of Formula (IP), Formula (I), Formula (II), and / or Formula (III), R 1a , R 1b , R 2a , and R 2b is hydrogen and R 5 is pentyl, and ring A is a group

[0411] [ka] a phenyl ring substituted with one methoxy group ortho to

[0412] [ka] indicates the point of attachment to the remainder of the formula. In some or any of the preceding embodiments of the compounds of Formula (IP), Formula (I), Formula (II), and / or Formula (III), R 1a , R 1b , R 2a , and R 2b is hydrogen and R 5 is pentyl, and ring A is a group

[0413] [ka] a phenyl ring substituted with two methoxy groups ortho to

[0414] [ka] denotes the attachment point to the rest of the equation.

[0415] In some embodiments, provided herein are conjugates according to formula (Xa), (Xb), (Xc), (Xd), or (Xe), wherein L and PA are as described herein:

[0416] [ka]

[0417] [ka]

[0418] In some examples of formulae (Xa), (Xb), (Xc), (Xd), and (Xe), SG is absent or

[0419] [ka] where the subscript d is an integer selected from 1 to 10, and each

[0420] [ka] indicates the point of attachment to the rest of the equation. In some cases, SG is

[0421] [ka] where each

[0422] [ka] denotes the attachment point to the rest of the equation.

[0423] In some examples of formulas (Xa), (Xb), (Xc), (Xd), and (Xe), W 1 If exists,

[0424] [ka] where the subscript e is an integer selected from 1 to 10, and each

[0425] [ka] indicates the attachment point to the rest of the equation. In some cases, W 1 If exists,

[0426] [ka] where each

[0427] [ka] denotes the attachment point to the rest of the equation.

[0428] In some examples of formulas (Xa), (Xb), (Xc), (Xd), and (Xe), W 6 When W is a residue of a peptide, the residue of the peptide may include natural and / or unnatural amino acid residues. In some examples of formulas (Xa), (Xb), (Xc), (Xd), and (Xe), W 6 When present, W is a tripeptide residue. 6 teeth,

[0429] [ka] where each

[0430] [ka] indicates the point of attachment to the rest of the equation. In some examples of equations (Xa), (Xb), (Xc), (Xd), and (Xe), W 6 When present, W is a dipeptide residue. 6 If exists,

[0431] [ka] where each

[0432] [ka] denotes the attachment point to the rest of the equation.

[0433] In some examples of formulas (Xa), (Xb), (Xc), (Xd), and (Xe), RT is

[0434] [ka] where:

[0435] [ka] denotes the attachment point to the rest of the equation.

[0436] In some examples of formula (Xa), (Xb), (Xc), (Xd), and (Xe), HP, when present, is a PEG group. In some examples of formula (VI), HP, when present, is

[0437] [ka] where the subscript b is an integer selected from 1 to 10;

[0438] [ka] denotes the attachment point to the rest of the equation.

[0439] In some examples of formulae (Xa), (Xb), (Xc), (Xd), and (Xe), R' is

[0440] [ka] where R 201 is C 1~6 alkyl, and each

[0441] [ka] denotes the attachment point to the rest of the equation,

[0442] [ka] indicates the point of attachment to the antibody or antigen-binding fragment thereof,

[0443] [ka] indicates the point of attachment to the antibody or antigen-binding fragment thereof via the sulfur atom of the cysteine ​​residue.

[0444] In some embodiments, an immunomodulatory compound (IM) suitable for the conjugates described herein is a Toll-like receptor agonist, e.g., a TLR7 agonist. In some embodiments of Formula (I) and / or Formula (II),

[0445] In some embodiments of Formula (I) and / or Formula (II), IM is:

[0446] [ka]

[0447] [ka]

[0448] [ka]

[0449] [ka] and wherein each of the compounds of formula (III) or (III') is selected from the group consisting of

[0450] [ka] denotes the attachment point to the rest of the equation.

[0451] In some other embodiments of Formula (I) and / or Formula (II), the immunomodulatory payload is represented by Formula (IV):

[0452] [ka] or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof, wherein X a and X b One of them is -N= and the other is -N(R a )- and R a is C1-C6-alkyl, cycloalkyl, or cycloalkyl-alkyl, X c and X d are independently C1-C6-alkylene; R b is hydrogen, quinolinyl, or —C(O)OCH3.

[0453] In some or any embodiments, the immunostimulatory payload is according to formula (IV) or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof, wherein X a and X b One of them is -N= and the other is -N(R a )- and X c and X d are independently C1-C6-alkylene, and R a is C1-C6-alkyl, and R b is hydrogen.

[0454] In some or any embodiments, the immunostimulatory payload of formula (IV) is according to formula (IVa) or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof:

[0455] [ka] In the formula, R a , R b , X c , and X d is as defined above or in any embodiment herein.

[0456] In some or any embodiments, the immunostimulatory payload of formula (IV) is according to formula (IVb) or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof:

[0457] [ka] In the formula, R a , R b , X c , and X d is as defined above or in any embodiment herein.

[0458] In some or any embodiments, an immunostimulatory payload of formula (IV), (IVa), or (IVb) is provided, wherein R b In some or any embodiments, an immunostimulatory payload of formula (IV), (IVa), or (IVb) is provided, wherein X c In some or any embodiments, an immunostimulatory payload of formula (IV), (IVa), or (IVb) is provided, wherein X d In some or any embodiments, an immunostimulatory payload of formula (IV), (IVa), or (IVb) is provided, wherein X c and X d and each is CH2. In some or any embodiments, an immunostimulatory payload of formula (IV), (IVa), or (IVb) is provided, wherein R ais C1-C6-alkyl. In some or any embodiments, an immunostimulatory payload of formula (IV), (IVa), or (IVb) is provided, wherein R a is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, sec-pentyl, or iso-pentyl. In some or any embodiments, an immunostimulatory payload of formula (IV), (IVa), or (IVb) is provided, wherein R b is hydrogen and X c In some or any embodiments, an immunostimulatory payload of formula (IV), (IVa), or (IVb) is provided, wherein R b is hydrogen and X d In some or any embodiments, an immunostimulatory payload of formula (IV), (IVa), or (IVb) is provided, wherein R b is hydrogen and X c and X d In some or any embodiments, an immunostimulatory payload of formula (IV), (IVa), or (IVb) is provided, wherein R b is hydrogen and X c and X d is CH2 and R a is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, sec-pentyl, or iso-pentyl. In some or any embodiments, an immunostimulatory payload of formula (I), (II), or (III) is provided, wherein R b is hydrogen and X c and X d is CH2 and R a is n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, sec-pentyl, or iso-pentyl.

[0459]

[0281] Formula (IVc)

[0460] [ka] or a pharmaceutically acceptable salt, tautomer, stereoisomer, and / or mixture of stereoisomers thereof.

[0461]

[0282] In some embodiments, provided herein are compounds of formula (XIa), (XIb), (XIc), or (XId):

[0462] [ka]

[0463] [ka] wherein L and PA are as described herein.

[0464] In some examples of any of formula (XIa), (XIb), (XIc), or (XId), SG is absent or

[0465] [ka] where the subscript d is an integer selected from 1 to 10, and each

[0466] [ka] indicates the point of attachment to the rest of the equation. In some cases, SG is

[0467] [ka] and each

[0468] [ka] denotes the attachment point to the rest of the equation.

[0469] In some examples of formula (XIa), (XIb), (XIc), or (XId), W 1 If exists,

[0470] [ka] and the subscript e is an integer selected from 1 to 10, and each

[0471] [ka] indicates the attachment point to the rest of the equation. In some cases, W 1 If exists,

[0472] [ka] and each

[0473] [ka] denotes the attachment point to the rest of the equation.

[0474] In some examples of formula (XIa), (XIb), (XIc), or (XId), W 6 When W is a residue of a peptide, the residue of the peptide may include natural and / or unnatural amino acid residues. In some examples of formulas (XIa), (XIb), (XIc), and (XId), W 6 When present, W is a tripeptide residue. 6 teeth,

[0475] [ka] where each

[0476] [ka] indicates the point of attachment to the rest of the formula. In some examples of formulas (XIa), (XIb), (XIc), and (XId), W 6 When present, W is a dipeptide residue. 6 If exists,

[0477] [ka] and each

[0478] [ka] denotes the attachment point to the rest of the equation.

[0479] In some examples of formulas (XIa), (XIb), (XIc), and (XId), RT is

[0480] [ka] and

[0481] [ka] denotes the attachment point to the rest of the equation.

[0482] In some examples of formula (XIa), (XIb), (XIc), and (XId), HP, when present, is a PEG group. In some examples of formula (VI), HP, when present, is

[0483] [ka] and the subscript b is an integer selected from 1 to 10;

[0484] [ka] denotes the attachment point to the rest of the equation.

[0485] In some examples of formulae (XIa), (XIb), (XIc) and (XId), R' is

[0486] [ka] where R 201 is C 1~6 alkyl, and each

[0487] [ka] denotes the attachment point to the rest of the equation,

[0488] [ka] indicates the point of attachment to the antibody or antigen-binding fragment thereof,

[0489] [ka] indicates the point of attachment to the antibody or antigen-binding fragment thereof via the sulfur atom of the cysteine ​​residue.

[0490] Further examples of immunomodulatory (or immunomodulatory) compounds include, but are not limited to, kinase inhibitors (e.g., phosphoinositide 3-kinase (PI3K) inhibitors (e.g., duvelisib, idelalisib), Bruton's tyrosine kinase (BTK) inhibitors (e.g., ibrutinib, acalabrutinib), Janus kinase (JAK) inhibitors (e.g., ruxolitinib, tofacitinib), mitogen-activated protein kinase (MAPK, MEK), extracellular signal-regulated kinase (ERK) inhibitors (as originally designated), c-jun inhibitors, N-terminal kinase (JNK) inhibitors, anaplastic lymphoma kinase (ALK) inhibitors, mammalian target of rapamycin (mTOR) inhibitors, SRC proto-oncogene, non-receptor tyrosine kinase (Src) inhibitors (e.g., dasatinib, saracatinib, bosutinib, and KX01), interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors (e.g., CA-4948), receptor tyrosine kinase (cKIT) kinase inhibitors, apoptosis signal-regulating kinase 1 (ASK1, MAP3K5) inhibitors, p38 mitogen-activated protein kinase (p38) inhibitors, Bcr-Abl tyrosine kinase (TK1) inhibitors (e.g., imitanib), Aurora kinase inhibitors (e.g., barasertib (AZD1152), alisertib (MLN8237), danusertib ( PHA-739358), tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR) (c-Met) inhibitors (e.g., sunitinib), cyclin-dependent kinase 4 / 6 (CDK4 / 6) inhibitors (e.g., palbociclib (Ibrance®), ribociclib), or other suitable kinase inhibitors), calcineurin inhibitors, CRAC inhibitors, PARP1 antagonists, PPARγ agonists, Kvl.3 antagonists, PP2A agonists, MYD88 inhibitors, BCL-2 inhibitors (e.g., ABT-199 (venetoclax, RG7601, GDC-0199), adenosine A2A receptor (A2ar) agonists, (Toll-like receptor 7 / 8 (TLR7 / 8) agonists, calcium-activated potassium channel (Kca3.1) agonists, TGF-R1 inhibitors, TGF-R2 inhibitors, epidermal growth factor receptor (EGFR) antagonists (e.g., gefitinib, erlotinib, afatinib, brigatinib, icotinib), platelet-derived growth factor (PDGF) inhibitors, vascular endothelial growth factor (VEGF) inhibitors, GLi 1 inhibitors, tankyrase (TNKS) antagonists, Traf2 and Nck-interacting kinase (TNIK) antagonists, imides (e.g., lenalidomide, thalidomide, and pomalidomide), and vitamin D receptor (VDR) agonists.

[0491]

[0290] In some embodiments, inhibitors of TGFpRl kinase include those described in U.S. Patent Application Publication No. 2018 / 0127426, U.S. Patent No. 8,080,568, WO2012 / 002680, WO2009 / 009059, WO2007 / 076127, WO2007076086, WO2006026306, Bioorg. Med. Chem., 2014, 22, 2724-2732 and J. Med. Chem. 2014, 57, 4213-4238, the disclosures of which are incorporated herein by reference.

[0492]

[0291] In some embodiments, inhibitors of TGFPR2 kinase include those disclosed in WO2015 / 136073, Bioorg. Med. Chem. Lett., 2013, 23, 3248-3252, Acta Cryst., 2016, D72, 658-674, WO2016 / 020864, ​​U.S. Patent Application Publication No. 2014 / 0249135, U.S. Patent Application Publication No. 20120225061, and compounds such as 3-amino-6-(4-(aminomethyl)phenyl)-N-(4-morpholinopyridin-3-yl)pyrazine-2-carboxamide, the disclosures of which are incorporated herein by reference.

[0493]

[0292] In some embodiments, inhibitors of TNKS include those disclosed in CN107226808, EP3313177, U.S. Patent No. 9,505,749, U.S. Patent Application Publication No. 2015 / 0045368, WO2014 / 036022, WO2017 / 076484, WO2018 / 046933, WO2018 / 003962, Eur. J. Med. Chem., 2017, 142, 506-522, the disclosures of which are incorporated herein by reference.

[0494]

[0293] In some embodiments, inhibitors of TNIK include those disclosed in U.S. Patent Application Publication No. 2016 / 0264555, WO2015 / 083833, U.S. Patent Application Publication No. 2010 / 0216795, U.S. Patent Application Publication No. 20100137386, Med. Chem. Commun., 2015, 6, 1564-1572 and Bioorg. Med. Chem. Lett., 2013, 23, 569-573, the disclosures of which are incorporated herein by reference.

[0495] Binding of an immunomodulatory compound to its target or protein target can inhibit the function of a protein target expressed in myofibroblasts, immune cells, or both. Binding of an immunomodulatory compound to its target or target protein can increase the activity of a protein expressed in myofibroblasts, immune cells, or both.

[0496]

[0295] Some non-limiting examples may include immunomodulatory compounds that are agonists of the adenine receptor A2Ra, such as CGS-21680, or that increase the activity of the phosphatase PP2A or sphingosine-1 analogs, such as FTY720, and derivative analogs. Some non-limiting examples of immunomodulatory compounds include protein kinase inhibitors of mTOR kinase in immune cells, such as rapamycin; inhibitors of TGFPR2 kinase in myofibroblasts, immune cells, or both, such as 3-amino-6-(4-(aminomethyl)phenyl)-N-(4-morpholinopyridin-3-yl)pyrazine-2-carboxamide; inhibitors of one or both of PI3Kγ and PI3K5 in immune cells, such as duvelisib, TG100713, and PF04691502; and inhibitors of TNIK in myofibroblasts, immune cells, or both, such as KY-05009 and NCB-0846 [4-((2-((4-(aminomethyl)-1H-benzo[d]imidazol-6-yl)amino)quinazolin-8-yl)oxy)cyclohexan-1-ol].

[0497] In some additional embodiments, the immunomodulatory agent is an agent that modulates components of the immune system, resulting in enhanced anti-tumor activity of the conjugate. Such agents include, but are not limited to, agonists of Toll-like receptors (e.g., Poly-ICLC (Hiltonol), GLA, MEDI9197, VTX-2337 (Motolimid), CpG (SD-101), and IMO-2125); agonists of the STING (stimulator of interferon genes) pathway (e.g., MK-1454, ADU-S100, and SB11285); activators of RIG-I-like receptor (RLR) signaling (e.g., RGT100). inhibitors of adenosinergic signaling (e.g., inhibitors of CD73, CD39 and A2R, e.g., AB680, AB928, A000830, CPI-444), inhibitors of IDO-1 (indoleamine 2,3-dioxygenase 1) (e.g., GDC-0919 (navoximod), BMS-986205, and epacadostat); and small molecule blockers of the PD-1 pathway (e.g., CA-170, BMS-8, BMS-202, and AUNP12).

[0498] In some embodiments, the immunomodulatory agent is an anti-multiple myeloma agent. Examples of such immunomodulatory agents include, for example, lenalidomide, pomalidomide, and proteasome inhibitors. Examples of such proteasome inhibitors include, for example, bortezomib, carfilzomib, and ixazomib.

[0499] In some embodiments, the immunomodulatory compound is an immunostimulatory compound.

[0500] In some embodiments, the immunomodulatory compound is not a cytokine. In some embodiments, the immunomodulatory compound is not an interleukin. In some embodiments, the immunomodulatory compound is not interleukin 2 (IL2). In some embodiments, the immunomodulatory compound may be replaced with a cytokine, or an interleukin or IL2.

[0501] In additional embodiments, the antibody conjugate can have a payload selected from the group consisting of: a label, a dye, a polymer, a water soluble polymer, polyethylene glycol, a derivative of polyethylene glycol, a photocrosslinker, a cytotoxic compound, a radionuclide, a drug, an affinity label, a photoaffinity label, a reactive compound, a resin, a second protein or polypeptide or polypeptide analog, an antibody or antibody fragment, a metal chelator, a cofactor, a fatty acid, a carbohydrate, a polynucleotide, DNA, RNA, an antisense polynucleotide, a peptide, a water soluble dendrimer, a cyclodextrin, an inhibitory ribonucleotide, a hydroxybenzoate ... The payload may be a nucleic acid, a biomaterial, a nanoparticle, a spin label, a fluorophore, a metal-containing moiety, a radioactive moiety, a novel functional group, a group that interacts covalently or non-covalently with other molecules, a photocaged moiety, a photoisomerizable moiety, biotin, a derivative of biotin, a biotin analog, a moiety incorporating a heavy atom, a chemically cleavable group, a photocleavable group, an extended side chain, a carbon-linked sugar, a redox-active agent, an aminothioacid, a toxic moiety, an isotope-labeled moiety, a biophysical probe, a phosphorescent group, a chemiluminescent group, an electron-dense group, a magnetic group, an intercalating group, a chromophore, an energy transfer agent, a biologically active agent, a detectable label, a small molecule, or any combination thereof. In one embodiment, the payload is a label, a dye, a polymer, a cytotoxic compound, a radionuclide, a drug, an affinity label, a resin, a protein, a polypeptide, a polypeptide analog, an antibody, an antibody fragment, a metal chelator, a cofactor, a fatty acid, a carbohydrate, a polynucleotide, DNA, RNA, a peptide, a fluorophore, or a carbon-linked sugar. In another embodiment, the payload is a label, a dye, a polymer, a drug, an antibody, an antibody fragment, DNA, RNA, or a peptide.

[0502] In certain embodiments, the conjugate comprises one or more water-soluble polymers. A wide variety of macromolecular polymers and other molecules can be linked to the polypeptides described herein to modulate the biological properties of the polypeptides and / or provide new biological properties to the polypeptides. Such macromolecular polymers may be linked to the polypeptides via naturally encoded amino acids, non-naturally encoded amino acids, or any functional substituents of natural or modified amino acids, or any substituents or functional groups added to natural or modified amino acids. The molecular weight of the polymer may range widely, including, but not limited to, from about 100 Da to about 100,000 Da or more.

[0503] The polymer selected may be water-soluble so that the protein to which it is attached does not precipitate in an aqueous environment, such as a physiological environment. The polymer may be branched or unbranched. Preferably, for therapeutic use of the final product preparation, the polymer will be pharmaceutically acceptable.

[0504] In certain embodiments, the ratio of polyethylene glycol molecules to polypeptide molecules will vary. Similarly, their concentrations in the reaction mixture will vary. Generally, the optimal ratio (in terms of reaction efficiency, with minimal excess unreacted protein or polymer) can be determined by the molecular weight of the selected polyethylene glycol and the available number of available reactive groups. With respect to molecular weight, typically, the higher the molecular weight of the polymer, the fewer the number of polymer molecules that can be attached to the protein. Similarly, polymer branching should be taken into consideration when optimizing these parameters. Generally, the higher the molecular weight (or the more branches), the higher the polymer:protein ratio.

[0505]

[0304] The water-soluble polymer may be of any structural form, including, but not limited to, linear, branched, or branched. Typically, the water-soluble polymer is a poly(alkylene glycol) such as poly(ethylene glycol) (PEG), although other water-soluble polymers can also be used. PEG is used as an example to illustrate certain embodiments.

[0506] PEG is a well-known water-soluble polymer that is commercially available or can be prepared by ring-opening polymerization of ethylene glycol according to methods well known in the art (Sandler and Karo, Polymer Synthesis, Academic Press, New York, Vol. 3, pages 138-161). The term "PEG" is used broadly to encompass any polyethylene glycol molecule, regardless of size or terminal modification of the PEG, and has the formula: X'O-(CHCHO). n and n is 2 to 10,000; and X is H or C. 1~4 Terminal modifications include, but are not limited to, alkyl, and Y is the point of attachment to the polypeptide.

[0507] In some cases, PEG terminates at one end with hydroxy or methoxy, i.e., X is H or CH ("methoxy PEG"). Alternatively, PEG may terminate with a reactive group, thereby forming a bifunctional polymer. Exemplary reactive groups include those commonly used to react with functional groups found in the 20 common amino acids, including maleimide groups, activated carbonates (including but not limited to p-nitrophenyl esters), activated esters (including but not limited to N-hydroxysuccinimide, p-nitrophenyl esters, and aldehydes), and functional groups that are inert toward the 20 common amino acids but specifically react with complementary functional groups present in non-naturally encoded amino acids, including but not limited to azide groups and alkyne groups. Note that the other end of PEG, represented by Y in the formula above, will be attached to the polypeptide either directly or indirectly through a naturally occurring or non-naturally encoded amino acid. For example, Y may be an amide, carbamate, or urea linkage with an amine group of the polypeptide, including but not limited to the epsilon amine of lysine or the N-terminus. Alternatively, Y may be a maleimide bond to a thiol group (including, but not limited to, the thiol group of cysteine). Alternatively, Y may be a linkage to a residue that is not generally accessible through the 20 common amino acids. For example, an azide group on PEG may react with an alkyne group on a polypeptide to form a Huisgen [3+2] cycloaddition product. Alternatively, an alkyne group on PEG may react with an azide group present on a non-naturally encoded amino acid, such as a modified amino acid described herein, to form a similar product. In some embodiments, strong nucleophiles (including, but not limited to, hydrazine, hydrazide, hydroxylamine, semicarbazide) can react with an aldehyde or ketone group present on a non-naturally encoded amino acid to form a hydrazone, oxime, or semicarbazone, which can be further reduced, if desired, in some cases by treatment with a suitable reducing agent.Alternatively, strong nucleophiles can be incorporated into the polypeptide via a non-naturally encoded amino acid and used to preferentially react with ketone or aldehyde groups present on the water-soluble polymer.

[0508] PEGs of any molecular weight can be used as desired, including, but not limited to, from about 100 daltons (Da) to 100,000 Da, or even larger if desired (including, but not limited to, 0.1-50 kDa or 10-40 kDa in some cases). Branched PEGs can also be used, including, but not limited to, PEG molecules with each chain having a MW in the range of 1-100 kDa (including, but not limited to, 1-50 kDa or 5-20 kDa). A wide range of PEG molecules are described, including, but not limited to, the Shearwater Polymers, Inc. catalog and the Nektar Therapeutics catalog. These catalogs are incorporated herein by reference.

[0509] Generally, at least one terminus of the PEG molecule is available for reaction with an antibody. For example, PEG can be attached to a non-naturally encoded amino acid as described herein using PEG derivatives bearing alkyne and azide moieties for reaction with amino acid side chains. When the non-naturally encoded amino acid contains an azide, the PEG will typically contain either an alkyne moiety to effect formation of a [3 + 2] cycloaddition product, or an activated PEG species (i.e., ester, carbonate) containing a phosphine group to effect formation of an amide linkage. Alternatively, when the non-naturally encoded amino acid contains an alkyne, the PEG will typically contain an azide moiety to effect formation of a [3 + 2] Huisgen cycloaddition product. When the non-naturally encoded amino acid contains a carbonyl group, the PEG will typically contain a strong nucleophile (including, but not limited to, a hydrazide, hydrazine, hydroxylamine, or semicarbazide functionality) to effect formation of a hydrazone, oxime, and semicarbazone linkage, respectively. In another alternative, the reverse orientation of the reactive groups described herein can be used. That is, the azide moiety of the non-naturally encoded amino acid can be reacted with an alkyne-containing PEG derivative.

[0510]

[0309] In some embodiments, the polypeptide variant having a PEG derivative comprises a chemical functionality that is reactive with a chemical functionality present in the side chain of a non-naturally encoded amino acid.

[0511] In certain embodiments, the payload is an azide- or acetylene-containing polymer comprising a water-soluble polymer backbone having an average molecular weight of about 800 Da to about 100,000 Da. The polymer backbone of the water-soluble polymer may be poly(ethylene glycol). However, it should be understood that a wide variety of water-soluble polymers are also suitable for use, including, but not limited to, poly(ethylene) glycol and other related polymers including poly(dextran) and poly(propylene glycol), and the use of the term PEG or poly(ethylene glycol) is intended to encompass and include all such molecules. The term PEG includes poly(ethylene glycol) in all its forms, including, but not limited to, bifunctional PEG, multi-armed PEG, derivatized PEG, scleral PEG, branched PEG, pendant PEG (i.e., PEG or related polymers having one or more functional groups pendant to the polymer backbone), or PEG with degradable linkages therein.

[0512] The polymer backbone may be linear or branched. Branched polymer backbones are generally known in the art. Typically, a branched polymer has a central branch core moiety and multiple linear polymer chains connected to the central branch core. PEG is commonly used in branched forms, which can be prepared by adding ethylene oxide to various polyols, such as glycerol, glycerol oligomers, pentaerythritol, and sorbitol. The central branch moiety may also be derived from several amino acids, such as lysine. Branched poly(ethylene glycol)s have the basic form R(-PEG-OH) mWherein R is derived from a core moiety such as glycerol, glycerol oligomer, or pentaerythritol, and m represents the number of arms. Also, multi-arm PEG molecules such as those described in U.S. Patent Nos. 5,932,462, 5,643,575; 5,229,490; 4,289,872; U.S. Patent Application Publication No. 2003 / 0143596; WO96 / 21469; and WO93 / 21259 can be used as the polymer backbone. Each of these documents is incorporated herein by reference in its entirety.

[0513]

[0312] The branched PEG is PEG(-YCHZ2). n where Y is a linking group and Z is an activated end group connected to CH by a chain of atoms of defined length.

[0514]

[0313] Yet another form of branching, pendant PEG, has reactive groups, such as carboxyl, along the PEG backbone rather than at the end of the PEG chain.

[0515] In addition to these forms of PEG, polymers can also be prepared with weak or degradable linkages in the backbone. For example, PEG can be prepared with ester linkages in the polymer backbone that are susceptible to hydrolysis. As shown herein, this hydrolysis results in the polymer being cleaved into lower molecular weight fragments: -PEG-CO2-PEG-+H2O→PEG-CO2H+HO-PEG-. Those skilled in the art will understand that the term poly(ethylene glycol) or PEG refers to or includes all forms known in the art, including, but not limited to, those disclosed herein.

[0516] Many other polymers are also suitable for use. In some embodiments, polymer backbones of water-soluble polymers having from 2 to about 300 termini are particularly suitable. Examples of suitable polymers include, but are not limited to, other poly(alkylene glycols), such as poly(propylene glycol) (“PPG”), their copolymers (including, but not limited to, copolymers of ethylene glycol and propylene glycol), their terpolymers, and mixtures thereof. The molecular weight of each chain of the polymer backbone can vary, but typically ranges from about 800 Da to about 100,000 Da, often from about 6,000 Da to about 80,000 Da.

[0517]

[0316] Those skilled in the art will recognize that the foregoing list of substantially water-soluble scaffolds is by no means exhaustive but merely illustrative, and that all polymeric materials having the qualities described herein are contemplated as suitable for use.

[0518] In some embodiments, the polymer derivatives are "multifunctional," meaning that the polymer backbone has at least two termini, and possibly as many as about 300 termini, that are functionalized or activated with functional groups. Multifunctional polymer derivatives include, but are not limited to, linear polymers having two termini, each of which is bonded to a functional group that may be the same or different.

[0519] 4. Linker In certain embodiments, the antibody may be linked to the payload by one or more linkers capable of reacting with the antibody amino acids and with the payload group. The linker(s) may be any linker apparent to one skilled in the art.

[0520]

[0319] The term "linker" is used herein to refer to a group or bond that is usually formed as a result of a chemical reaction and is typically a covalent bond.

[0521] Useful linkers include those described herein. In certain embodiments, the linker is any bivalent or polyvalent linker known to those skilled in the art. Useful bivalent linkers include alkylene, substituted alkylene, heteroalkylene, substituted heteroalkylene, arylene, substituted arylene, heteroarylene, and substituted heteroarylene. In certain embodiments, the linker is C 1~10 Alkylene or C 1~10 In some embodiments, C is heteroalkylene. 1~10 The heteroalkylene is PEG.

[0522] In certain embodiments, the linker is hydrolytically stable. A hydrolytically stable linkage means that the linkage is substantially stable in water and does not react with water at useful pH values ​​under conditions, including but not limited to, physiological conditions, for extended periods of time, perhaps even indefinitely. In certain embodiments, the linker is hydrolytically unstable. A hydrolytically unstable or degradable linkage means that the linkage is degradable in water or in aqueous solutions, including, for example, blood. An enzymatically unstable or degradable linkage means that the linkage can be degraded by one or more enzymes.

[0523] As is understood in the art, PEG and related polymers may contain degradable linkages in the polymer backbone or in linker groups between the polymer backbone and one or more of the terminal functional groups of the polymer molecule. For example, ester linkages formed by the reaction of PEG carboxylic acids or activated PEG carboxylic acids with alcohol groups on biologically active agents generally hydrolyze under physiological conditions to release the agent.

[0524]

[0323] Other hydrolytically degradable linkages include, but are not limited to, carbonate linkages; imine bonds resulting from the reaction of an amine and an aldehyde; phosphate ester linkages formed by reacting an alcohol with a phosphate group; hydrazone linkages, which are the reaction product of a hydrazide and an aldehyde; acetal linkages, which are the reaction product of an aldehyde and an alcohol; orthoester linkages, which are the reaction product of a formate and an alcohol; peptide linkages formed by an amine group, including but not limited to, those at the terminus of a polymer, such as PEG, and a carboxyl group of a peptide; and oligonucleotide linkages formed by a phosphoramidite group, including but not limited to, those at the terminus of a polymer, and a 5' hydroxyl group of an oligonucleotide.

[0525] Many different cleavable linkers are known to those skilled in the art. See U.S. Patent Nos. 4,618,492, 4,542,225, and 4,625,014. Mechanisms for releasing agents from such linker groups include, for example, irradiation of a photolabile bond and acid-catalyzed hydrolysis. For example, U.S. Patent No. 4,671,958 describes immunoconjugates containing linkers whose target site is cleaved in vivo by proteolytic enzymes of a patient's complement system. The length of the linker can be predetermined or selected depending on the desired spatial relationship between the polypeptide and the molecule linked to it. Those skilled in the art will be able to determine a suitable method for attaching a given agent to a polypeptide in light of the numerous reported methods for attaching various radiodiagnostic compounds, radiotherapeutic compounds, drugs, toxins, and other agents to polypeptides.

[0526]

[0325] The linker may have a wide range of molecular weights or lengths. Linkers with larger or smaller molecular weights can be used to provide the desired spatial relationship or conformation between the polypeptide and the linking entity. Linkers with longer or shorter molecular lengths can also be used to provide the desired space or flexibility between the polypeptide and the linking entity. Similarly, linkers with specific shapes or conformations can be used to impart specific shapes or conformations to the polypeptide or linking entity either before or after the polypeptide reaches its target. The functional groups present at each end of the linker can be selected to modulate the release of the polypeptide or payload under desired conditions. Such optimization of the spatial relationship between the polypeptide and the linking entity can provide the molecule with new, modulated, or desired properties.

[0527]

[0326] In some embodiments, provided herein are water-soluble bifunctional linkers having a dumbbell structure comprising: a) an azide, alkyne, hydrazine, hydrazide, hydroxylamine, or carbonyl-containing moiety at least at a first end of the polymer backbone; and b) at least a second functional group at a second end of the polymer backbone. The second functional group may be the same as or different from the first functional group. In some embodiments, the second functional group is not reactive with the first functional group. In some embodiments, provided are water-soluble compounds comprising at least one arm of a branched molecular structure. For example, the branched molecular structure may be a dendritic structure.

[0528] In some embodiments, the linker is derived from a linker precursor selected from the group consisting of N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), N-succinimidyl 4-(2-pyridyldithio)pentanoate (SPP), N-succinimidyl 4-(2-pyridyldithio)butanoate (SPDB), N-succinimidyl-4-(2-pyridyldithio)-2-sulfo-butanoate (sulfo-SPDB), N-succinimidyl iodoacetate (SIA), N-succinimidyl(4-iodoacetyl)aminobenzoate (SIAB), maleimide PEG. NHS, N-succinimidyl 4-(maleimidomethyl)cyclohexanecarboxylate (SMCC), N-sulfosuccinimidyl 4-(maleimidomethyl)cyclohexanecarboxylate (sulfo-SMCC), or 2,5-dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraoxo-4,7,10,13-tetraazaheptadecan-1-oate (CX1-1). In certain embodiments, the linker is derived from the linker precursor N-succinimidyl 4-(maleimidomethyl)cyclohexanecarboxylate (SMCC).

[0529] In some embodiments, the linker is derived from a linker precursor selected from the group consisting of dipeptides, tripeptides, tetrapeptides, and pentapeptides. In such embodiments, the linker can be cleaved by a protease. Representative dipeptides include, but are not limited to, valine-citrulline (vc or val-cit), alanine-phenylalanine (AF or ala-phe), phenylalanine-lysine (FK or phe-lys), phenylalanine-homolysine (phe-homolys), and N-methyl-valine-citrulline (Me-val-cit). Representative tripeptides include, but are not limited to, glycine-valine-citrulline (gly-val-cit), glycine-glycine-glycine (gly-gly-gly), and glycine-methoxyethoxyethyl)serine-valine (gly-val-citalanine OMESerValAla).

[0530] In some embodiments, the linker comprises a self-immolative spacer. In certain embodiments, the self-immolative spacer comprises p-aminobenzyl. In some embodiments, p-aminobenzyl alcohol is attached to the amino acid unit via an amide bond, creating a carbamate, methylcarbamate, or carbonate between the benzyl alcohol and the payload (Hamann et al. (2005) Expert Opin. Ther. Patents (2005) 15:1087-1103). In some embodiments, the linker comprises p-aminobenzyloxycarbonyl (PAB). Other examples of self-immolative spacers include, but are not limited to, aromatic compounds electronically similar to the PAB group, such as 2-aminoimidazole-5-methanol derivatives (U.S. Patent No. 7,375,078; Hay et al. (1999) Bioorg. Med. Chem. Lett. 9:2237) and ortho- or para-aminobenzyl acetals. In some embodiments, spacers that undergo cyclization upon amide bond hydrolysis can be used, such as substituted and unsubstituted 4-aminobutyric acid amides (Rodrigues et al. (1995) Chemistry Biology 2:223), appropriately substituted bicyclo[2.2.1] and bicyclo[2.2.2] ring systems (Storm et al. (1972) J. Amer. Chem. Soc. 94:5815), and 2-aminophenylpropionic acid amide (Amsberry, et al. (1990) J. Org. Chem. 55:5867). The linkage between a drug and the α-carbon of a glycine residue is another example of a self-immolative spacer that may be useful in conjugates (Kingsbury et al. (1984) J. Med. Chem. 27:1447).

[0531] In certain embodiments, linker precursors can be combined to form larger linkers. For example, in certain embodiments, the linker comprises the dipeptide valine-citrulline and p-aminobenzyloxycarbonyl. These are also referred to as citValCit--PAB linkers.

[0532] In certain embodiments, the payload may be linked to a linker, sometimes referred to herein as a linker-payload, where one or more linker groups are capable of reacting with antibody amino acid groups. The one or more linkers may be any linker apparent to one of skill in the art or may be those shown herein.

[0533] Linker precursors can be prepared as described in the Examples section herein and / or by standard techniques, or may be obtained from commercial sources. See, e.g., WO2019 / 055931, WO2019 / 055909, WO2017 / 132617, and WO2017 / 132615, each of which is incorporated by reference in its entirety.

[0534]

[0333] Additional linkers are disclosed herein, for example, linker precursors (A)-(N) described below.

[0535] 5. Antibody specificity The conjugate comprises an antibody that selectively binds to a human antigen. In some embodiments, the antibody binds to a homolog of a human antigen. In some aspects, the antibody binds to a homolog of a human antigen derived from a species selected from monkey, mouse, dog, cat, rat, cow, horse, goat, and sheep. In some aspects, the homolog is a cynomolgus monkey homolog. In some aspects, the homolog is a mouse or mouse homolog.

[0536] In some embodiments, the antibody comprises a light chain. In some aspects, the light chain is a kappa light chain. In some aspects, the light chain is a lambda light chain.

[0537] In some embodiments, the antibody comprises a heavy chain. In some aspects, the heavy chain is IgA. In some aspects, the heavy chain is IgD. In some aspects, the heavy chain is IgE. In some aspects, the heavy chain is IgG. In some aspects, the heavy chain is IgM. In some aspects, the heavy chain is IgG1. In some aspects, the heavy chain is IgG2. In some aspects, the heavy chain is IgG3. In some aspects, the heavy chain is IgG4. In some aspects, the heavy chain is IgA1. In some aspects, the heavy chain is IgA2.

[0538] In some embodiments, the antibody is an antibody fragment. In some aspects, the antibody fragment is an Fv fragment. In some aspects, the antibody fragment is a Fab fragment. In some aspects, the antibody fragment is a F(ab')2 fragment. In some aspects, the antibody fragment is a Fab' fragment. In some aspects, the antibody fragment is an scFv (sFv) fragment. In some aspects, the antibody fragment is an scFv-Fc fragment.

[0539] In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a polyclonal antibody.

[0540] In some embodiments, the antibody is a chimeric antibody. In some embodiments, the antibody is a humanized antibody. In some embodiments, the antibody is a human antibody. In some embodiments, the antibody is an affinity matured antibody.

[0541] The antibody conjugates provided herein may be useful in the treatment of various diseases and conditions, including cancer. In some embodiments, the antibody conjugates provided herein may be useful in the treatment of solid tumor cancer.

[0542] 6. Glycosylation mutants In certain embodiments, antibodies may be altered to increase, decrease, or eliminate the extent of glycosylation. Glycosylation of polypeptides is typically either "N-linked" or "O-linked."

[0543] "N-linked" glycosylation refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tripeptide sequences in a polypeptide creates a potential glycosylation site.

[0544]

[0343] "O-linked" glycosylation refers to the attachment of one of the sugars N-acetylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine can also be used.

[0545] Addition or deletion of N-linked glycosylation sites to an antibody can be accomplished by altering the amino acid sequence to create or remove one or more of the tripeptide sequences described above. Addition or deletion of O-linked glycosylation sites can be accomplished by adding, deleting, or substituting one or more serine or threonine residues within or to the sequence of the antibody (if applicable).

[0546] 7. Modified Amino Acids

[0345] When the antibody conjugate comprises a modified amino acid, the modified amino acid may be any modified amino acid deemed suitable by the practitioner. In certain embodiments, the modified amino acid comprises a reactive group useful for forming a covalent bond with a linker precursor or a payload precursor. In certain embodiments, the modified amino acid is an unnatural amino acid. In certain embodiments, the reactive group is selected from the group consisting of amino, carboxy, acetyl, hydrazino, hydrazide, semicarbazide, sulfanyl, azide, and alkynyl. Modified amino acids are also described, for example, in WO2013 / 185115 and WO2015 / 006555. Each of these documents is incorporated herein by reference in its entirety.

[0547] The terms "residue of an amino acid" and "amino acid residue" refer to the product of amide or peptide coupling of an amino acid to a suitable coupling partner, e.g., a water molecule is expelled after amide or peptide coupling of an amino acid, resulting in a product having the amino acid residue incorporated therein. In some embodiments, the amino acid residue is

[0548] [ka] where R a is the side chain of an amino acid. In some embodiments, the amino acid residue is

[0549] [ka] where R b is a residue in the side chain of an amino acid, for example, the C(O) residue of C(O)OH in the side chain of aspartic acid, or the NH residue of NH2 in the side chain of lysine.

[0550] The terms "residue of a peptide" and "peptide residue" refer to the product of amide or peptide coupling of an amino acid to a suitable coupling partner, e.g., a water molecule is expelled after amide or peptide coupling of an amino acid, resulting in a product having a peptide residue incorporated therein. In some embodiments, the peptide residue is

[0551] [ka] where n is 2 or more, and R a is the side chain of an amino acid. In some embodiments, the peptide residue is

[0552] [ka] where n is 2 or more, and R b is a residue in the side chain of an amino acid, for example, the C(O) residue of C(O)OH in the side chain of aspartic acid, or the NH residue of NH2 in the side chain of lysine. In some embodiments, n is 2 to 50, 2 to 25, 2 to 10, 1 to 5, or 2 to 3. In some embodiments, n is 2. In some embodiments, n is 3.

[0553]

[0348] In certain embodiments, the amino acid residue has the following formula:

[0554] [ka] Either by: Those skilled in the art will recognize that antibodies are generally composed of L-amino acids. However, in the case of unnatural amino acids, the present methods and compositions provide the practitioner with the ability to use L-, D-, or racemic unnatural amino acids at site-specific positions. In certain embodiments, the unnatural amino acids described herein include the D-form of natural amino acids and the racemic form of natural amino acids.

[0555] In the above formula, the wavy line indicates the bond connecting to the rest of the antibody polypeptide chain. Such unnatural amino acids can be incorporated into the polypeptide chain in exactly the same way as natural amino acids are incorporated into the same polypeptide chain. In certain embodiments, the unnatural amino acid is incorporated into the polypeptide chain via an amide bond, as shown in the formula.

[0556] In the above formula, R represents any functional group, without limitation, as long as the amino acid residue is not identical to a natural amino acid residue. In certain embodiments, R may be a hydrophobic group, a hydrophilic group, a polar group, an acidic group, a basic group, a chelating group, a reactive group, a therapeutic moiety, or a labeling moiety. In certain embodiments, R may be R 1z NR 2z R 3z , R 1z C(=O)R 2z , R 1z C(=O)OR 2z , R 1z N3, R 1z In such embodiments, R 1z is selected from the group consisting of a bond, alkylene, heteroalkylene, arylene, and heteroarylene. 2z and R 3z are each independently selected from the group consisting of hydrogen, alkyl, and heteroalkyl.

[0557] In some embodiments, the non-naturally encoded amino acid comprises a side chain functional group that reacts efficiently and selectively with functional groups not found in the 20 common amino acids (including, but not limited to, azide, ketone, aldehyde, and aminooxy groups) to form stable conjugates. For example, an antigen-binding polypeptide comprising a non-naturally encoded amino acid comprising an azide functional group can be reacted to form a stable conjugate with a polymer (including, but not limited to, poly(ethylene glycol)), or with a second polypeptide that alternatively comprises an alkyne moiety, resulting in the selective reaction of the azide and alkyne functional groups to form a Huisgen [3+2] cycloaddition product.

[0558] Representative non-naturally encoded amino acids that may be suitable for use in the present invention and are useful for reaction with water-soluble polymers include, but are not limited to, those with carbonyl, aminooxy, hydrazine, hydrazide, semicarbazide, azide, and alkyne reactive groups. In some embodiments, the non-naturally encoded amino acid comprises a saccharide moiety. Examples of such amino acids include N-acetyl-L-glucosaminyl-L-serine, N-acetyl-L-galactosaminyl-L-serine, N-acetyl-L-glucosaminyl-L-threonine, N-acetyl-L-glucosaminyl-L-asparagine, and O-mannosaminyl-L-serine. Examples of such amino acids also include those in which the naturally occurring N- or O-linkage between the amino acid and the saccharide is replaced with a covalent linkage not normally found in nature, including, but not limited to, an alkene, an oxime, a thioether, and an amide. Examples of such amino acids also include saccharides not normally found in naturally occurring proteins, such as 2-deoxy-glucose and 2-deoxygalactose.

[0559] Many of the non-naturally encoded amino acids provided herein are commercially available, for example, from Sigma-Aldrich (St. Louis, Missouri, USA), Novabiochem (a division of EMD Biosciences, Darmstadt, Germany), or Peptech (Burlington, Massachusetts, USA). Those that are not commercially available are optionally synthesized as provided herein or using standard methods known to those of skill in the art. For organic synthesis techniques, see, for example, Organic Chemistry by Fessendon and Fessendon (1982, Second Edition, Willard Grant Press, Boston Mass.); Advanced Organic Chemistry by March (Third Edition, 1985, Wiley and Sons, New York); and Advanced Organic Chemistry by Carey and Sundberg (Third Edition, Parts A and B, 1990, Plenum Press, New York). See also U.S. Patent Application Publication Nos. 2003 / 0082575 and 2003 / 0108885, which are incorporated by reference. In addition to unnatural amino acids comprising unnatural side chains, unnatural amino acids that may be suitable for use in the present invention optionally include, but are not limited to, structures of Formulas II and III:

[0560] [ka] where Z typically comprises OH, NH, SH, NH-R", or S-R", X and Y can be the same or different and typically comprise S or O, and R and R" are optionally the same or different and are typically independently selected from the same list of R group components described above for the unnatural amino acids having Formula I, as well as hydrogen. For example, unnatural amino acids of the invention optionally comprise substitutions at the amino or carboxyl group, as shown by Formulas II and III. Unnatural amino acids of this type include, but are not limited to, α-hydroxy acids, α-thioacids, α-aminothiocarboxylates, with side chains corresponding to the common 20 naturally occurring amino acids or unnatural side chains. Additionally, substitutions at the α-carbon optionally include L-amino acids, D-amino acids, or α-α-disubstituted amino acids, such as, but not limited to, D-glutamate, D-alanine, D-methyl-O-tyrosine, and aminobutyric acid. Other structural alternatives include cyclic amino acids such as proline analogs and 3-, 4-, 6-, 7-, 8-, and 9-membered ring proline analogs; P and y amino acids such as substituted β-alanine and γ-aminobutyric acid.

[0561]

[0354] Many unnatural amino acids are based on natural amino acids, such as tyrosine, glutamine, and phenylalanine, and are suitable for use in the present invention. Tyrosine analogs include, but are not limited to, para-substituted tyrosines, ortho-substituted tyrosines, and meta-substituted tyrosines, where substituted tyrosines include, but are not limited to, keto groups (including but not limited to, acetyl groups), benzoyl groups, amino groups, hydrazine, hydroxylamine, thiol groups, carboxy groups, isopropyl groups, methyl groups, C6-C8 20These include straight-chain or branched hydrocarbons, saturated or unsaturated hydrocarbons, O-methyl groups, polyether groups, nitro groups, or alkynyl groups. Additionally, polysubstituted aryl rings are also contemplated. Glutamine analogs that may be suitable for use in the present invention include, but are not limited to, α-hydroxy derivatives, γ-substituted derivatives, cyclic derivatives, and amide-substituted glutamine derivatives. Exemplary phenylalanine analogs that may be suitable for use in the present invention include, but are not limited to, para-substituted phenylalanine, ortho-substituted phenylalanine, and meta-substituted phenylalanine, with substituents including, but not limited to, hydroxy, methoxy, methyl, allyl, aldehyde, azido, iodo, bromo, keto (including, but not limited to, acetyl), benzoyl, or alkynyl groups. Specific examples of unnatural amino acids that may be suitable for use in the present invention include, but are not limited to, p-acetyl-L-phenylalanine, O-methyl-L-tyrosine, L-3-(2-naphthyl)alanine, 3-methyl-phenylalanine, O-4-allyl-L-tyrosine, 4-propyl-L-tyrosine, tri-O-acetyl-GlcNAcβ-serine, L-Dopa, fluorinated phenylalanine, isopropyl-L-phenylalanine, p-azido-L-phenylalanine, p-azido-methyl-L-phenylalanine, p-acyl-L-phenylalanine, p-benzoyl-L-phenylalanine, L-phosphoserine, phosphonoserine, phosphonotyrosine, p-iodo-phenylalanine, p-bromophenylalanine, p-amino-L-phenylalanine, isopropyl-L-phenylalanine, and p-propargyloxy-phenylalanine. Examples of structures of various unnatural amino acids that may be suitable for use in the present invention are provided, for example, in WO2002 / 085923, entitled "In vivo incorporation of unnatural amino acids."For additional methionine analogs, see also Kiick et al., (2002) Incorporation of azides into recombinant proteins for chemoselective modification by the Staudinger ligation, PNAS 99:19-24.

[0562] Many of the unnatural amino acids suitable for use in the present invention are commercially available, for example, from Sigma (USA) or Aldrich (Milwaukee, Wisconsin, USA). Those that are not commercially available are optionally synthesized as provided herein, as provided in various publications, or using standard methods known to those of skill in the art. For organic synthesis techniques, see, for example, Organic Chemistry by Fessendon and Fessendon (1982, Second Edition, Willard Grant Press, Boston Mass.); Advanced Organic Chemistry by March (Third Edition, 1985, Wiley and Sons, New York); and Advanced Organic Chemistry by Carey and Sundberg (Third Edition, Parts A and B, 1990, Plenum Press, New York). Additional publications describing the synthesis of unnatural amino acids include, for example, WO 2002 / 085923 entitled "In vivo incorporation of unnatural amino acids"; Matsoukas et al., (1995) J. Med. Chem., 38, 4660-4669; King, F. E. & Kidd, D. A. A. (1949) A New Synthesis of Glutamine and of γ-Dipeptides of Glutamic Acid from Phthylated Intermediates. J. Chem. Soc., 3315-3319; Friedman, O. M. & Chatterji, R. (1959) Synthesis of Derivatives of Glutamine as Model Substrates for Anti-Tumor Agents. J. Am. Chem. Soc. 81, 3750-3752; Craig, J. C. et al.(1988)Absolute Configuration of the Enantiomers of 7-Chloro-4[[4-(diethylamino)-1-methylbutyl]amino]quinoline(Chloroquine).J.Org.Chem.53,1167-1170;Azoulay,M.,Vilmont,M.&Frappier,F.(1991)Glutamine analogues as Potential Antimalarials,Eur.J.Med.Chem.26,201-5;Koskinen,A.M.P.&Rapoport,H.(1989)Synthesis of 4-Substituted Prolines as Conformationally Constrained Amino Acid Analogues.J.Org.Chem.54,1859-1866;Christie,B.D.&Rapoport,H.(1985)Synthesis of Optically Pure Pipecolates from L-Asparagine. Application to the Total Synthesis of (+)-Apovincamine through Amino Acid Decarbonylation and Iminium Ion Cyclization.J.Org.Chem.1989:1859-1866;Barton et al.,(1987)Synthesis of Novel a-Amino-Acids and Derivatives Using Radical Chemistry: Synthesis of L- and D-a-Amino-Adipic Acids,L-a-aminopimelic Acid and Appropriate Unsaturated Derivatives.Tetrahedron Lett.43:4297-4308;およびSubasinghe et al., (1992) Quisqualic acid analogues: synthesis of beta-heterocyclic 2-aminopropanoic acid derivatives and their activity at a novel quisqualate-sensitized site. J. Med. Chem. 35:4602-7. See also U.S. patent application Ser. No. 10 / 744,899, filed Dec. 22, 2003, entitled "Protein Arrays," and Ser. No. 60 / 435,821, filed Dec. 22, 2002.

[0563]

[0356] Amino acids with carbonyl reactive groups allow for a variety of reactions for linking molecules (including, but not limited to, PEG or other water-soluble molecules) by, among other things, nucleophilic addition or aldol condensation reactions.

[0564]

[0357] Representative carbonyl-containing amino acids are:

[0565] [ka] where n is 0-10; R1 is alkyl, aryl, substituted alkyl, or substituted aryl; R2 is H, alkyl, aryl, substituted alkyl, and substituted aryl; R3 is H, an amino acid, a polypeptide, or an amino-terminus modification group; and R4 is H, an amino acid, a polypeptide, or a carboxy-terminus modification group. In some embodiments, n is 1, R1 is phenyl, R2 is a simple alkyl (i.e., methyl, ethyl, or propyl), and the ketone moiety is positioned para to the alkyl side chain. In some embodiments, n is 1, R1 is phenyl, and R2 is a simple alkyl (i.e., methyl, ethyl, or propyl), and the ketone moiety is positioned meta to the alkyl side chain.

[0566] In some instances, non-naturally encoded amino acids bearing adjacent hydroxyl and amino groups can be incorporated into polypeptides as "shielded" aldehyde functionalities. For example, 5-hydroxylysine bears a hydroxyl group adjacent to the epsilon amine. Reaction conditions for generating the aldehyde typically involve the addition of a molar excess of sodium metaperiodate under mild conditions to avoid oxidation at other sites within the polypeptide. The pH of the oxidation reaction is typically about 7.0. A typical reaction involves the addition of about a 1.5 molar excess of sodium metaperiodate to a buffered solution of the polypeptide, followed by incubation in the dark for about 10 minutes. See, e.g., U.S. Patent No. 6,423,685, which is incorporated herein by reference.

[0567]

[0359] The carbonyl functionality can selectively react with hydrazine-, hydrazide-, hydroxylamine-, or semicarbazide-containing reagents under mild conditions in aqueous solution to form the corresponding hydrazone, oxime, or semicarbazone linkages, respectively, which are stable under physiological conditions. See, for example, Jencks, WP, J. Am. Chem. Soc. 81, 475-481 (1959); Shao, J. and Tam, JP, J. Am. Chem. Soc. 117: 3893-3899 (1995). Furthermore, the unique reactivity of the carbonyl group allows for selective modification in the presence of other amino acid side chains. See, e.g., Cornish, VW, et al., J. Am. Chem. Soc. 118:8150-8151 (1996); Geoghegan, KF & Stroh, JG, Bioconjug. Chem. 3:138-146 (1992); Mahal, LK, et al., Science 276:1125-1128 (1997).

[0568]

[0360] Non-naturally encoded amino acids containing nucleophilic groups such as hydrazine, hydrazide, or semicarbazide can react with a variety of electrophilic groups to allow the formation of conjugates (including, but not limited to, PEG or other water-soluble polymers).

[0569]

[0361] Representative hydrazine-, hydrazide-, or semicarbazide-containing amino acids include:

[0570] [ka] where n is 0-10; R1 is alkyl, aryl, substituted alkyl, substituted aryl, or absent; X is O, N, S, or absent; R2 is H, an amino acid, a polypeptide, or an amino terminus modification group; and R3 is H, an amino acid, a polypeptide, or a carboxy terminus modification group.

[0571] In some embodiments, n is 4, R1 is not present, and X is N. In some embodiments, n is 2, R1 is not present, and X is not present. In some embodiments, n is 1, R1 is phenyl, X is O, and the oxygen atom is positioned para to the aliphatic group on the aryl ring.

[0572]

[0363] Hydrazide-, hydrazine-, and semicarbazide-containing amino acids are available from commercial sources. For example, L-glutamate-γ-hydrazide is available from Sigma Chemical (St. Louis, Missouri). Other amino acids that are not commercially available can be prepared by those skilled in the art. See, for example, U.S. Patent No. 6,281,211, which is incorporated herein by reference.

[0573] Polypeptides containing non-naturally encoded amino acids bearing hydrazide, hydrazine, or semicarbazide functionalities can react efficiently and selectively with a variety of molecules containing aldehydes or other functional groups with similar chemical reactivity. See, e.g., Shao, J. and Tam, J., J. Am. Chem. Soc. 117:3893-3899 (1995). Due to their unique reactivity, hydrazide, hydrazine, and semicarbazide functional groups are significantly more reactive toward aldehydes, ketones, and other electrophilic groups than the nucleophilic groups present in the 20 common amino acids (including, but not limited to, the hydroxyl groups of serine or threonine, or the amino groups of lysine and the N-terminus).

[0574] Non-naturally encoded amino acids containing an aminooxy (also called hydroxylamine) group can react with various electrophilic groups to form conjugates (including, but not limited to, PEG or other water-soluble polymers). Similar to hydrazines, hydrazides, and semicarbazides, the enhanced nucleophilicity of the aminooxy group allows for efficient and selective reaction with a variety of molecules containing aldehydes or other functional groups with similar chemical reactivity. See, for example, Shao, J. and Tam, J., J. Am. Chem. Soc. 117:3893-3899 (1995); H. Hang and C. Bertozzi, Acc. Chem. Res. 34:727-736 (2001). However, while the reaction with a hydrazine group results in the corresponding hydrazone, the reaction of an aminooxy group with a carbonyl-containing group, such as a ketone, generally yields an oxime.

[0575]

[0366] Representative amino acids containing an aminooxy group are:

[0576] [ka] where n is 0-10, R1 is alkyl, aryl, substituted alkyl, or substituted aryl, or not present, X is O, N, S, or not present, m is 0-10, Y=C(O) or not present, R2 is H, an amino acid, a polypeptide, or an amino-terminus modification group, and R3 is H, an amino acid, a polypeptide, or a carboxy-terminus modification group. In some embodiments, n is 1, R1 is phenyl, X is O, m is 1, and Y is present. In some embodiments, n is 2, R1 and X are not present, m is 0, and Y is not present.

[0577] Aminoxy-containing amino acids can be prepared from readily available amino acid precursors (homoserine, serine, and threonine). For example, see M. Carrasco and R. Brown, J. Org. Chem. 68: 8853-8858 (2003). Certain aminoxy-containing amino acids, such as L-2-amino-4-(aminooxy) butyric acid, have been isolated from natural sources (Rosenthal, G. et al., Life Sci. 60: 1635-1641 (1997)). Those skilled in the art can prepare other aminoxy-containing amino acids.

[0578] Azide and alkyne functional groups are extremely useful for the selective modification of polypeptides and other biological molecules due to their unique reactivity. Organic azides, particularly aliphatic azides, and alkynes are generally stable to common reactive chemical conditions. In particular, both azide and alkyne functional groups are inert toward the side chains (i.e., R groups) of the 20 common amino acids found in naturally occurring polypeptides. However, upon close proximity, the "spring-loaded" nature of the azide and alkyne groups is exploited, allowing them to react selectively and efficiently via a Huisgen [3 + 2] cycloaddition reaction to generate the corresponding triazoles. See, eg, Chin J., et al., Science 301:964-7 (2003); Wang, Q., et al., J. Am. Chem. Soc. 125, 3192-3193 (2003); Chin, JW, et al., J. Am. Chem. Soc. 124: 9026-9027 (2002).

[0579]

[0369] Because the Huisgen cycloaddition reaction involves a selective cycloaddition reaction rather than a nucleophilic substitution (see, for example, Padwa, A., in COMPREHENSIVE ORGANIC SYNTHESIS, Vol. 4, (ed. Trost, BM, 1991), pp. 1069-1109; Huisgen, R. in 1,3-DIPOLAR CYCLOADDITION CHEMISTRY, (ed. Padwa, A., 1984), pp. 1-176), the incorporation of non-naturally encoded amino acids bearing azide- and alkyne-containing side chains allows the resulting polypeptide to be selectively modified at the position of the non-naturally encoded amino acid. Cycloaddition reactions involving azide- or alkyne-containing antibodies can be carried out under aqueous conditions at room temperature by adding a catalytic amount of Cu(II) (including, but not limited to, in the form of a catalytic amount of CuSO) in the presence of a reducing agent to reduce Cu(II) to Cu(I) in situ. See, e.g., Wang, Q., et al., J. Am. Chem. Soc. 125, 3192-3193 (2003); Tornoe, CW, et al., J. Org. Chem. 67:3057-3064 (2002); Rostovtsev, et al., Angew. Chem. Int. Ed. 41:2596-2599 (2002). Representative reducing agents include, but are not limited to, ascorbate, metallic copper, quinine, hydroquinone, vitamin K, glutathione, cysteine, Fe, and the like. 2+ , Co 2+ , and the applied potential.

[0580] In some cases, when a Huisgen [3+2] cycloaddition reaction between an azide and an alkyne is desired, the antigen-binding polypeptide comprises a non-naturally encoded amino acid comprising an alkyne moiety and the water-soluble polymer to be attached to the amino acid comprises an azide moiety. Alternatively, the reverse reaction (i.e., between an azide moiety on the amino acid and an alkyne moiety present on the water-soluble polymer) can also be performed.

[0581]

[0371] Additionally, the azide functional group can selectively react with water-soluble polymers containing aryl esters and appropriately functionalized with arylphosphine moieties to generate amide linkages. The arylphosphine group reduces the azide in situ, and the resulting amine then efficiently reacts with a neighboring ester linkage to generate the corresponding amide. See, for example, E. Saxon and C. Bertozzi, Science 287, 2007-2010 (2000). The azide-containing amino acid can be either an alkyl azide (including, but not limited to, 2-amino-6-azido-1-hexanoic acid) or an aryl azide (p-azido-phenylalanine).

[0582]

[0372] Representative water-soluble polymers containing aryl ester and phosphine moieties include:

[0583] [ka] where X can be O, N, S, or absent, Ph is phenyl, W is a water-soluble polymer, and R can be H, alkyl, aryl, substituted alkyl, and substituted aryl groups. Representative R groups include, but are not limited to, -CH, -C(CH), -OR, -NR, -SR, -halogen, -C(O)R, -CONR, -R', -S(O)R, -S(O)NR, -R', -CN, and -NO. R and R each independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, including, but not limited to, aryl substituted with one to three halogens, substituted or unsubstituted alkyl, alkoxy, or thioalkoxy groups, or arylalkyl groups. When a compound of the invention includes more than one R group, for example, each of the R groups is independently selected, as are each R and R' groups when more than one of such groups is present. When R" and R"' are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring. For example, -NR'R" is intended to include, but is not limited to, 1-pyrrolidinyl and 4-morpholinyl. From the above discussion of substituents, one of skill in the art will understand that the term "alkyl" is intended to include groups that contain carbon atoms bonded to groups other than hydrogen groups, such as haloalkyl (including, but not limited to, -CF3 and -CH2CF3) and acyl (including, but not limited to, -C(O)CH3, -C(O)CF3, and -C(O)CHOCH3).

[0584]

[0373] The azide functional group can also be selectively reacted with water-soluble polymers that contain a thioester and are appropriately functionalized with an arylphosphine moiety to generate an amide linkage. The arylphosphine group reduces the azide in situ, and the resulting amine then reacts efficiently with the thioester linkage to generate the corresponding amide. Exemplary water-soluble polymers containing a thioester and a phosphine moiety include:

[0585] [ka] where n is 1-10, X can be O, N, S, or absent, Ph is phenyl, and W is a water-soluble polymer.

[0586]

[0374] Representative alkyne-containing amino acids are:

[0587] [ka] where n is 0-10, R1 is alkyl, aryl, substituted alkyl, substituted aryl, or not present, X is O, N, S, or not present, m is 0-10, R2 is H, an amino acid, a polypeptide, or an amino-terminus modification group, and R3 is H, an amino acid, a polypeptide, or a carboxy-terminus modification group. In some embodiments, n is 1, R1 is phenyl, X is not present, m is 0, and the acetylene moiety is positioned para to the alkyl side chain. In some embodiments, n is 1, R1 is phenyl, X is O, m is 1, and the propargyloxy group is positioned para to the alkyl side chain (i.e., O-propargyl-tyrosine). In some embodiments, n is 1, R1 and X are not present, and m is 0 (i.e., propargylglycine).

[0588] Alkyne-containing amino acids are commercially available. For example, propargylglycine is commercially available from Peptech (Burlington, Massachusetts). Alternatively, alkyne-containing amino acids can be prepared according to standard methods. For example, p-propargyloxyphenylalanine can be synthesized as described in Deiters, A., et al., J. Am. Chem. Soc. 125:11782-11783 (2003), and 4-alkynyl-L-phenylalanine can be synthesized as described in Kayser, B., et al., Tetrahedron 53(7):2475-2484 (1997). Those skilled in the art can prepare other alkyne-containing amino acids.

[0589]

[0376] Representative azide-containing amino acids are:

[0590] [ka] where n is 0-10; R1 is alkyl, aryl, substituted alkyl, substituted aryl, or absent; X is O, N, S, or absent; m is 0-10; R2 is H, an amino acid, a polypeptide, or an amino terminus modification group; and R3 is H, an amino acid, a polypeptide, or a carboxy terminus modification group. In some embodiments, n is 1, R1 is phenyl, X is not present, m is 0, and the azide moiety is positioned para to the alkyl side chain. In some embodiments, n is 0-4, R1 and X are not present, and m=0. In some embodiments, n is 1, R1 is phenyl, X is O, m is 2, and the P-azidoethoxy moiety is positioned para to the alkyl side chain.

[0591] Azide-containing amino acids are available from commercial sources. For example, 4-azidophenylalanine can be obtained from Chem-Impex International, Inc. (Wood Dale, Illinois). For azide-containing amino acids that are not commercially available, the azide group can be relatively easily prepared using standard methods known to those skilled in the art, including, but not limited to, replacing a suitable leaving group (including, but not limited to, a halide, mesylate, or tosylate) or ring-opening a suitably protected lactone. See, for example, Advanced Organic Chemistry by March (Third Edition, 1985, Wiley and Sons, New York).

[0592] Due to its unique reactivity, beta-substituted aminothiol functional groups are extremely useful for the selective modification of polypeptides and other biological molecules containing aldehyde groups by the formation of thiazolidines. See, for example, J. Shao and J. Tam, J. Am. Chem. Soc. 1995, 117(14) 3893-3899. In some embodiments, beta-substituted aminothiol amino acids can be incorporated into antibodies and then reacted with water-soluble polymers containing aldehyde functionality. In some embodiments, water-soluble polymers, drug conjugates, or other payloads can be coupled to antibody polypeptides containing beta-substituted aminothiol amino acids by the formation of thiazolidines.

[0593] Specific examples of useful unnatural amino acids include, but are not limited to, the following: p-acetyl-L-phenylalanine, O-methyl-L-tyrosine, L-3-(2-naphthyl)alanine, 3-methyl-phenylalanine, O-4-allyl-L-tyrosine, 4-propyl-L-tyrosine, tri-O-acetyl-GlcNAc b-serine, L-Dopa, fluorinated phenylalanine, isopropyl-L-phenylalanine, p-azido-methyl-L-phenylalanine, p-azido-L-phenylalanine, p-acyl-L-phenylalanine, p-benzoyl-L-phenylalanine, L-phosphoserine, phosphonoserine, phosphonotyrosine, p-iodo-phenylalanine, p-bromophenylalanine, p-amino-L-phenylalanine, isopropyl-L-phenylalanine, and p-propargyloxy-phenylalanine. Further useful examples include N-acetyl-L-glucosaminyl-L-serine, N-acetyl-L-galactosaminyl-L-serine, N-acetyl-L-glucosaminyl-L-threonine, N-acetyl-L-glucosaminyl-L-asparagine, and O-mannosaminyl-L-serine.

[0594] In certain embodiments, the unnatural amino acid is selected from p-acetyl-phenylalanine, p-ethynyl-phenylalanine, p-propargyloxyphenylalanine, p-azido-methyl-phenylalanine, and p-azido-phenylalanine. One particularly useful unnatural amino acid is p-azidophenylalanine. This amino acid residue is known to those skilled in the art to facilitate a Huisgen [3+2] cycloaddition reaction (the so-called "click" chemistry) with, for example, a compound bearing an alkynyl group. This reaction allows those skilled in the art to easily and quickly conjugate the unnatural amino acid to an antibody at a site-specific position.

[0595] In certain embodiments, the first reactive group is an alkynyl moiety (including but not limited to, the unnatural amino acid p-propargyloxyphenylalanine, where the propargyl group is sometimes referred to as an acetylene moiety) and the second reactive group is an azide moiety, and [3+2] cycloaddition chemistry can be used. In certain embodiments, the first reactive group is an azide moiety (including but not limited to, the unnatural amino acid p-azido-L-phenylalanine) and the second reactive group is an alkynyl moiety.

[0596] In the formula above, each L represents a bivalent linker. The bivalent linker may be any bivalent linker known to those of skill in the art. Generally, the bivalent linker is capable of forming a covalent bond with the functional moiety R and a similar reactive group (e.g., the alpha carbon) of the unnatural amino acid. Useful bivalent linkers include bond, alkylene, substituted alkylene, heteroalkylene, substituted heteroalkylene, arylene, substituted arylene, heteroarylene, and substituted heteroarylene. In certain embodiments, L is C 1~10 Alkylene or C 1~10 It is heteroalkylene.

[0597]

[0383] Unnatural amino acids used in the methods and compositions described herein have at least one of the following four properties: (1) at least one functional group in the side chain of the unnatural amino acid has at least one feature and / or activity and / or reactivity that is orthogonal to the chemical reactivity of the 20 common genetically encoded amino acids (i.e., alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine) or that is at least orthogonal to the chemical reactivity of a naturally occurring amino acid that is present in a polypeptide that includes the unnatural amino acid; (2) the introduced unnatural amino acid is substantially chemically inert relative to the 20 common genetically encoded amino acids; (3) the unnatural amino acid preferably can be stably incorporated into a polypeptide with stability comparable to that of a naturally occurring amino acid or under typical physiological conditions, and more preferably, such incorporation is in (4) the unnatural amino acid contains an oxime functional group, or preferably a functional group that can be converted to an oxime group by reaction with a reagent under conditions that do not destroy the biological properties of the polypeptide containing the unnatural amino acid (unless, of course, destruction of such biological properties is the goal of the modification / conversion), or the conversion can occur under aqueous conditions at a pH between about 4 and about 8, or the reactive site on the unnatural amino acid is an electrophilic site. Any number of unnatural amino acids can be introduced into a polypeptide. The unnatural amino acid can also contain a protected or blocked oxime, or a protecting or blocking group that can be converted to an oxime group after deprotection of the protecting group or deblocking of the blocking group. The unnatural amino acid can also contain a protected or blocked carbonyl or dicarbonyl group that can be converted to a carbonyl or dicarbonyl group after deprotection of the protecting group or deblocking of the blocking group, thereby available to react with a hydroxylamine or oxime to form an oxime group.

[0598] In further embodiments, unnatural amino acids that can be used in the methods and compositions described herein include, but are not limited to, amino acids comprising photoactivatable crosslinkers, spin-labeled amino acids, fluorescent amino acids, metal-binding amino acids, metal-containing amino acids, radioactive amino acids, amino acids with novel functional groups, amino acids that interact covalently or non-covalently with other molecules, photocaged and / or photoisomerizable amino acids, amino acids comprising biotin or biotin analogs, glycosylated amino acids such as sugar-substituted serines, other carbohydrate-modified amino acids, keto-containing amino acids, aldehyde-containing amino acids, amino acids comprising polyethylene glycol or other polyethers, heavy atom-substituted amino acids, chemically cleavable and / or photocleavable amino acids, amino acids with elongated side chains compared to natural amino acids, including, but not limited to, polyethers, or long chain hydrocarbons comprising, but not limited to, more than about 5 or more than about 10 carbons, carbon-linked sugar-containing amino acids, redox-active amino acids, aminothioacid containing amino acids, and amino acids comprising one or more toxic moieties.

[0599] In some embodiments, the unnatural amino acid comprises a saccharide moiety. Examples of such amino acids include N-acetyl-L-glucosaminyl-L-serine, N-acetyl-L-galactosaminyl-L-serine, N-acetyl-L-glucosaminyl-L-threonine, N-acetyl-L-glucosaminyl-L-asparagine, and O-mannosaminyl-L-serine. Examples of such amino acids also include those in which the naturally occurring N- or O-linkage between the amino acid and the saccharide is replaced with a covalent linkage not normally found in nature, including, but not limited to, an alkene, an oxime, a thioether, and an amide. Examples of such amino acids also include saccharides not normally found in naturally occurring proteins, such as 2-deoxyglucose and 2-deoxygalactose.

[0600] Chemical moieties incorporated into antibodies through the incorporation of unnatural amino acids offer various advantages and polypeptide manipulation. For example, the unique reactivity of carbonyl or dicarbonyl functional groups (including keto or aldehyde functional groups) allows for the selective modification of antibodies in vivo and in vitro with any of several hydrazine- or hydroxylamine-containing reagents. Heavy atom unnatural amino acids can be useful, for example, for phasing X-ray structural data. Site-specific introduction of heavy atoms using unnatural amino acids also provides selectivity and flexibility in selecting the position of the heavy atom. Photoreactive unnatural amino acids (including, but not limited to, amino acids with benzophenone and aryl azide (including, but not limited to, phenyl azide) side chains) enable, for example, efficient in vivo and in vitro photocrosslinking of polypeptides. Examples of photoreactive unnatural amino acids include, but are not limited to, p-azido-phenylalanine and p-benzoyl-phenylalanine. Antibodies bearing photoreactive unnatural amino acids can then be crosslinked at will by excitation of the photoreactive groups, providing temporal control. In a non-limiting example, the methyl group of the unnatural amino can be replaced with an isotopically labeled methyl group, which can be used to probe local structure and dynamics using, but not limited to, nuclear magnetic resonance and vibrational spectroscopy.

[0601] Amino acids with electrophilic reactive groups allow for a variety of reactions to link molecules through a variety of chemical reactions, including, but not limited to, nucleophilic addition reactions. Such electrophilic reactive groups include carbonyl or dicarbonyl groups (including keto or aldehyde groups), carbonyl- or dicarbonyl-like groups (which have similar reactivity to, and are structurally similar to, carbonyl or dicarbonyl groups), shielded carbonyl or dicarbonyl groups (which can be readily converted to, carbonyl or dicarbonyl groups), or protected carbonyl or dicarbonyl groups (which have similar reactivity to, carbonyl or dicarbonyl groups upon deprotection). Such amino acids include those having the structure of formula (AA):

[0602] [ka] wherein A is optional and, when present, is lower alkylene, substituted lower alkylene, lower cycloalkylene, substituted lower cycloalkylene, lower alkenylene, lower alkynylene, lower heteroalkylene, substituted heteroalkylene, lower heterocycloalkylene, substituted lower heterocycloalkylene, arylene, substituted arylene, heteroarylene, substituted heteroarylene, alkarylene, substituted alkarylene, aralkylene, or substituted aralkylene; B is optional and, when present, is lower alkylene, substituted lower alkylene, lower alkenylene, substituted lower alkenylene, lower heteroalkylene, substituted lower heteroalkylene, -O-, -O-(alkylene or substituted alkylene)-, -S-, -S-(alkylene or substituted alkylene)-, -S(O) k -, where k is 1, 2, or 3; -S(O) k(alkylene or substituted alkylene)-, -C(O)-, -NS(O)2-, -OS(O)2-, -C(O)-(alkylene or substituted alkylene)-, -C(S)-, -C(S)-(alkylene or substituted alkylene)-, -N(R'')-, -NR''-(alkylene or substituted alkylene)-, -C(O)N(R'')-, -CON(R'')-(alkylene or substituted alkylene)-, -CSN(R'')-, -CSN(R'')-(alkylene or substituted alkylene)-, -N(R'')CO-(alkylene or substituted alkylene)-, -N(R'')C(O)O-, -S(O) k N(R'')-, -N(R'')C(O)N(R'')-, -N(R'')C(S)N(R'')-, -N(R'')S(O) k a linker selected from the group consisting of N(R")-, -N(R")-N=, -C(R")-N=, -C(R")-N(R")-, -C(R")-N=N(R")-, -C(R")-N=N-, and -C(R")-N(R")-N(R")-; wherein each R″ in B is independently H, alkyl, or substituted alkyl; and J is

[0603] [ka] wherein R is H, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl; each R" in J is independently H, alkyl, substituted alkyl, or a protecting group; or if more than one R" group is present, two R" optionally form a heterocycloalkyl; R1 is H, an amino protecting group, resin, amino acid, polypeptide, or polynucleotide; R2 is OH, an ester protecting group, resin, amino acid, polypeptide, or polynucleotide; each of R3 and R4 is independently H, halogen, lower alkyl, or substituted lower alkyl; or R3 and R4 or two R3 groups optionally form a cycloalkyl or heterocycloalkyl; or -ABJR groups taken together together form a bicyclic or tricyclic cycloalkyl or heterocycloalkyl containing at least one carbonyl group that contains a dicarbonyl group, a protected carbonyl group that contains a protected dicarbonyl group, or a masked carbonyl group that contains a masked dicarbonyl group; or the -J R groups together form a monocyclic or bicyclic cycloalkyl or heterocycloalkyl containing at least one carbonyl group that contains a dicarbonyl group, a protected carbonyl group that contains a protected dicarbonyl group, or a masked carbonyl group that contains a masked dicarbonyl group, with the proviso that when A is phenylene and each R is H, B is present and when A is -(CH)- and each R is H, B is not -NHC(O)(CHCH)-; and when A and B are absent and each R is H, R is not methyl. Such unnatural amino acids may be in the form of a salt or may be incorporated into unnatural amino acid polypeptides, polymers, polysaccharides, or polynucleotides, and may optionally be post-translationally modified.

[0604]

[0388] In certain embodiments, the compound of Formula (AA) is stable in aqueous solution under weakly acidic conditions for at least one month. In certain embodiments, the compound of Formula (AA) is stable under weakly acidic conditions for at least two weeks. In certain embodiments, the compound of Formula (AA) is stable under weakly acidic conditions for at least five days. In certain embodiments, such acidic conditions are pH 2-8.

[0605] In certain embodiments of a compound of Formula (AA), B is lower alkylene, substituted lower alkylene, —O-(alkylene or substituted alkylene)-, —C(R″)═NN(R″)-, —N(R″)CO-, —C(O)-, —C(R″)═N-, —C(O)-(alkylene or substituted alkylene)-, —CON(R″)-(alkylene or substituted alkylene)-, —S(alkylene or substituted alkylene)-, —S(O)(alkylene or substituted alkylene)-, or —S(O)2(alkylene or substituted alkylene)-. In certain embodiments of a compound of Formula (AA), B is -O(CH)-, -CH=N-, -CH=N-NH-, -NHCH-, -NHCO-, -C(O)-, -C(O)-(CH)-, -CONH-(CH)-, -SCH-, -S(=O)CH-, or -S(O)CH-. In certain embodiments of a compound of Formula (AA), R is C alkyl or cycloalkyl. In certain embodiments of a compound of Formula (AA), R is -CH, -CH(CH), or cyclopropyl. In certain embodiments of a compound of Formula (AA), R is H, tert-butyloxycarbonyl (Boc), 9-fluorenylmethoxycarbonyl (Fmoc), N-acetyl, tetrafluoroacetyl (TFA), or benzyloxycarbonyl (Cbz). In certain embodiments of a compound of Formula (AA), R1 is a resin, an amino acid, a polypeptide, or a polynucleotide. In certain embodiments of a compound of Formula (AA), R2 is OH, O-methyl, O-ethyl, or Ot-butyl. In certain embodiments of a compound of Formula (AA), R2 is a resin, an amino acid, a polypeptide, or a polynucleotide. In certain embodiments of a compound of Formula (AA), R2 is a polynucleotide. In certain embodiments of a compound of Formula (AA), R2 is a ribonucleic acid (RNA). In certain embodiments of a compound of Formula (AA), R2 is a tRNA. In certain embodiments of a compound of Formula (AA), the tRNA specifically recognizes a selector codon.In certain embodiments of a compound of Formula (AA), the selector codon is selected from the group consisting of an amber codon, an ochre codon, an opal codon, a unique codon, a rare codon, an unnatural codon, a five-base codon, and a four-base codon. In certain embodiments of a compound of Formula (AA), R2 is an inhibitory tRNA.

[0606]

[0390] In certain embodiments of compounds of Formula (AA),

[0607] [ka] (i) A is substituted lower alkylene, C4-arylene, substituted arylene, heteroarylene, substituted heteroarylene, alkarylene, substituted alkarylene, aralkylene, or substituted aralkylene; B is optional and, when present, is lower alkylene, substituted lower alkylene, lower alkenylene, substituted lower alkenylene, -O-, -O-(alkylene or substituted alkylene)-, -S-, -S(O)-, -S(O)2-, -NS(O)2-, -OS(O)2-, -C(O)-, -C(O)-(alkylene or substituted alkylene)-, -C (S)-, -N(R'')-, -C(O)N(R'')-, -CON(R'')-(alkylene or substituted alkylene)-, -CSN(R'')-, -N(R'')CO-(alkylene or substituted alkylene)-, -N(R'')C(O)O-, -N(R'')C(S)-, -S(O)N(R''), -S(O)2N(R''), -N(R'')C(O)N(R'')-, -N(R'')C(S)N(R'')-, -N(R'')S(O)N(R'')-, -N(R'')S(O)2N(R'')-, -N(R'')-N=, -C(R'')=NN( (ii) A is optionally a bivalent linker selected from the group consisting of: -C(R")-, -C(R")-N-N-, -C(R")-N-N-, -C(R")-N(R")-N(R")-; (ii) A is optionally a bivalent linker selected from the group consisting of: -C(R")-, -C(R")-N-N-, -C(R")-N(R")-N(R")-; (iii) A is optionally a bivalent linker selected from the group consisting of: -C(R")-, -C(R")-N-N-, -C(R")-N(R")-N(R")-; (iv) A is optionally a bivalent linker selected from the group consisting of: -C(R")-, -C(R")-N-N-, -C(R")-N(R")-N(R")-; (v) A is optionally a bivalent linker selected from the group consisting of: -C(R")-, -C(R")-N-N-, -C(R")-N(R")-N(R")-; (vi ...i) A is optionally a bivalent linker selected from the group consisting of: -C(R")-, -C(R")-N-N-, -C(R")-N(R")-N(R")-; (v) A is optionally a bivalent linker selected from the group consisting of: -C(R")-, -C(R")-N-N-, -C(R")-N-N- substituted alkylene)-, -S-, -S(O)-, -S(O)2-, -NS(O)2-, -OS(O)2-, -C(O)-, -C(O)-(alkylene or substituted alkylene)-, -C(S)-, -N(R'')-, -C(O)N(R'')-, -CON(R'')-(alkylene or substituted alkylene)-, -CSN(R'')-, -N(R'')CO-(alkylene or substituted alkylene)-, -N(R'')C(O)O-, -N(R'')C(S)-, -S(O)N(R''), -S(O)N(R''), -N(R'')C(O)N(R'')-,a bivalent linker selected from the group consisting of —N(R″)C(S)N(R″)—, —N(R″)S(O)N(R″)—, —N(R″)S(O)N(R″)—, —N(R″)-N=, —C(R″)=NN(R″)-, —C(R″)=NN=, —C(R″)-N=N—, and —C(R″)-N(R″)-N(R″)-; (iii) A is lower alkylene; B is optional and, when present, is lower alkylene, substituted lower alkylene, lower alkenylene, substituted lower alkenylene, —O—, —O-(alkenylene), alkylene or substituted alkylene)-, -S-, -S(O)-, -S(O)2-, -NS(O)2-, -OS(O)2-, -C(O)-, -C(O)-(alkylene or substituted alkylene)-, -C(S)-, -N(R'')-, -C(O)N(R'')-, -CSN(R'')-, -CON(R'')-(alkylene or substituted alkylene)-, -N(R'')C(O)O-, -N(R'')C(S)-, -S(O)N(R''), -S(O)2N(R''), -N(R'')C(O)N(R'')-, -N(R'')C(S)N(R'')-, -N(R (iv) A is a bivalent linker selected from the group consisting of -S(O)N(R'')-, -N(R'')S(O)N(R'')-, -N(R'')-N=, -C(R'')=NN(R'')-, -C(R'')=NN=, -C(R'')-N=N-, and -C(R'')-N(R'')-N(R'')-; (iv) A is phenylene and B is lower alkylene, substituted lower alkylene, lower alkenylene, substituted lower alkenylene, -O-, -O-(alkylene or substituted alkylene)-, -S-, -S(O)-, -S(O)-, -NS(O)- , -OS(O)2-, -C(O)-, -C(O)-(alkylene or substituted alkylene)-, -C(S)-, -N(R'')-, -C(O)N(R'')-, -CON(R'')-(alkylene or substituted alkylene)-, -CSN(R'')-, -N(R'')CO-(alkylene or substituted alkylene)-, -N(R'')C(O)O-, -N(R'')C(S)-, -S(O)N(R''), -S(O)2N(R''), -N(R'')C(O)N(R'')-, -N(R'')C(S)N(R'')-, -N(R'')S(O)N(R'')-,J is a bivalent linker selected from the group consisting of: -N(R'')S(O)N(R'')-, -N(R'')-N=, -C(R'')'NN(R'')-, -C(R'')=NN=, -C(R'')-N=N-, and -C(R'')-N(R'')-N(R'')-;

[0608] [ka] wherein each R″ in J is independently H, alkyl, or substituted alkyl; R1 is optional and, if present, is H, an amino protecting group, a resin, an amino acid, a polypeptide, or a polynucleotide; R2 is optional and, if present, is OH, an ester protecting group, a resin, an amino acid, a polypeptide, or a polynucleotide; each R3 and R4 is independently H, halogen, lower alkyl, or substituted lower alkyl; and R is H, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl.

[0609]

[0391] In certain embodiments, the unnatural amino acid has the formula BB:

[0610] [ka] or a salt thereof, wherein D is -Ar-W- or -W-Y-C(O)-Y-W-; and Ar is

[0611] [ka] wherein each of W1, W2, and W3 is independently a single bond or lower alkylene, each X1 is independently -NH-, -O-, or -S-, each Y1 is independently a single bond, -NH-, or -O-, each Y2 is independently a single bond, -NH-, -O-, or N- or C-linked pyrrolidinylene, one of Z1, Z2, and Z3 is -N-, and the other of Z1, Z2, and Z3 is independently -CH-. In certain embodiments, the unnatural amino acid has the formula BBa:

[0612] [ka] wherein D is as defined in the context of formula BB. In certain embodiments, the unnatural amino acid is according to formula BBb:

[0613] [ka] or a salt thereof, wherein W4 is C1 to C 10 In a further embodiment, W4 is C1-C5 alkylene. In one embodiment, W4 is C1-C3 alkylene. In one embodiment, W4 is C1 alkylene. In certain embodiments, the unnatural amino acid is

[0614] [ka]

[0615] [ka] or salts thereof. Such unnatural amino acids may be in the form of a salt or may be incorporated into an unnatural amino acid polypeptide, polymer, polysaccharide, or polynucleotide, and may optionally be post-translationally modified.

[0616] In certain embodiments, the modified amino acid has the formula CC:

[0617] [ka] or a salt thereof, wherein Ar is

[0618] [ka] wherein V is a single bond, lower alkylene, or -W1-W2-, one of W1 and W2 is absent or lower alkylene, and the other is -NH-, -O-, or -S-, each X1 is independently -NH-, -O-, or -S-, one of Z1, Z2, and Z3 is -CH- or -N-, and the others of Z1, Z2, and Z3 are each independently -CH-, and R is lower alkyl. In certain embodiments, Ar is

[0619] [ka] and V is -NH-, where one of Z, Z, and Z is -N-. In certain embodiments, V is a single bond, -NH-, or -CHNH-.

[0620] In certain embodiments, Ar is

[0621] [ka] wherein Z1, Z2, Z3, and X1 are as defined in the context of formula CC. In certain embodiments according to this paragraph, V is -W1-W2-, where one of W1 and W2 is absent or -CH2-, and the other is -NH-, -O-, or -S-. In certain embodiments according to this paragraph, V is a single bond, -NH-, or -CH2NH-. In certain embodiments according to this paragraph, Z1 is N. In certain embodiments according to this paragraph, Z2 is N. In certain embodiments according to this paragraph, Z3 is N. In certain embodiments according to this paragraph, Z1 is CH, Z3 is CH, and X1 is S.

[0622] In certain embodiments, Ar is

[0623] [ka] wherein Z1, Z2, and Z3 are as defined in the context of formula CC. In certain embodiments according to this paragraph, V is -W1-W2-, where one of W1 and W2 is absent or -CH2-, and the other is -NH-, -O-, or -S-. In certain embodiments according to this paragraph, V is a single bond, -NH-, or -CH2NH-. In certain embodiments according to this paragraph, Z1 is N. In certain embodiments according to this paragraph, Z2 is N. In certain embodiments according to this paragraph, Z3 is N.

[0624] In certain embodiments, Ar is

[0625] [ka] wherein Z1, Z3, and X1 are as defined in the context of formula CC. In certain embodiments according to this paragraph, V is -W1-W2-, where one of W1 and W2 is absent or -CH2-, and the other is -NH-, -O-, or -S-. In certain embodiments according to this paragraph, V is a single bond, -NH-, or -CH2NH-. In certain embodiments according to this paragraph, Z1 is N. In certain embodiments according to this paragraph, Z3 is N. In certain embodiments according to this paragraph, Z1 is CH, Z3 is CH, and X1 is S.

[0626] In certain embodiments, the modified amino acid has the formula CCa:

[0627] [ka] where Ar, V, and R are defined in the context of formula CC.

[0628] In one embodiment, a compound of any of formulae CC and CCa is provided, wherein V is a single bond. In another embodiment, a compound of any of formulae CC and CCa is provided, wherein V is -NH-. In another embodiment, a compound of any of formulae CC and CCa is provided, wherein V is -CHNH-.

[0629]

[0398] In certain embodiments, the modified amino acid has the formula DD:

[0630] [ka] or a salt thereof, wherein V and R are as defined in formula CC. In certain embodiments according to this paragraph, V is -W1-W2-, where one of W1 and W2 is absent or -CH2-, and the other is -NH-, -O-, or -S-. In certain embodiments, V is a single bond, -NH-, or -CH2NH-. In certain embodiments, V is a single bond or -CH2NH-, and R is methyl.

[0631]

[0399] In certain embodiments, the modified amino acid has the formula EE:

[0632] [ka] or a salt thereof, wherein V and R are as defined in formula CC. In certain embodiments according to this paragraph, V is -W1-W2-, where one of W1 and W2 is absent or -CH2-, and the other is -NH-, -O-, or -S-. In certain embodiments, V is a single bond, -NH-, or -CH2NH-. In certain embodiments, V is a single bond, -NH-, or -CH2NH-, and R is methyl.

[0633]

[0400] In certain embodiments, the modified amino acid has the formula FF:

[0634] [ka] or a salt thereof, wherein V and R are as defined in formula CC. In certain embodiments according to this paragraph, V is -W1-W2-, where one of W1 and W2 is absent or -CH2-, and the other is -NH-, -O-, or -S-. In certain embodiments, V is a single bond, -NH-, or -CH2NH-. In certain embodiments, V is a single bond, -NH-, or -CH2NH-, and R is methyl.

[0635]

[0401] In certain embodiments, the modified amino acid has the formula GG:

[0636] [ka] or a salt thereof, wherein V and R are as defined in formula CC. In certain embodiments according to this paragraph, V is -W1-W2-, where one of W1 and W2 is absent or -CH2-, and the other is -NH-, -O-, or -S-. In certain embodiments, V is a single bond, -NH-, or -CH2NH-. In certain embodiments, V is a single bond, -NH-, or -CH2NH-, and R is methyl.

[0637]

[0402] In certain embodiments, the modified amino acid has the formula HH:

[0638] [ka] or a salt thereof, wherein V and R are as defined in formula CC. In certain embodiments according to this paragraph, V is -W1-W2-, where one of W1 and W2 is absent or -CH2-, and the other is -NH-, -O-, or -S-. In certain embodiments, V is a single bond, -NH-, or -CH2NH-. In certain embodiments, V is a single bond, -NH-, or -CH2NH-, and R is methyl.

[0639]

[0403] In certain embodiments, the modified amino acid has the formula JJ:

[0640] [ka] or a salt thereof, wherein V and R are as defined in formula CC. In certain embodiments according to this paragraph, V is -W1-W2-, where one of W1 and W2 is absent or -CH2-, and the other is -NH-, -O-, or -S-. In certain embodiments, V is a single bond, -NH-, or -CH2NH-. In certain embodiments, V is a single bond, -NH-, or -CH2NH-, and R is methyl.

[0641]

[0404] In certain embodiments, the modified amino acid has the formula KK:

[0642] [ka] or a salt thereof, wherein V and R are as defined in formula CC. In certain embodiments according to this paragraph, V is -W1-W2-, where one of W1 and W2 is absent or -CH2-, and the other is -NH-, -O-, or -S-. In certain embodiments, V is a single bond, -NH-, or -CH2NH-. In certain embodiments, V is a single bond, -NH-, or -CH2NH-, and R is methyl.

[0643]

[0405] In certain embodiments, the modified amino acid has the formula LL:

[0644] [ka] or a salt thereof, wherein V and R are as defined in formula CC. In certain embodiments according to this paragraph, V is -W1-W2-, where one of W1 and W2 is absent or -CH2-, and the other is -NH-, -O-, or -S-. In certain embodiments, V is a single bond, -NH-, or -CH2NH-. In certain embodiments, V is a single bond, -NH-, or -CH2NH-, and R is methyl.

[0645] In certain embodiments, the modified amino acid is selected from the group consisting of Formulas 51-62:

[0646] [ka] or a salt thereof.

[0647] In certain embodiments, the unnatural amino acid is selected from the group consisting of compounds 30, 53, 56, 59, 60, 61, and 62 described above. In certain embodiments, the unnatural amino acid is compound 30. In certain embodiments, the unnatural amino acid is compound 56. In some embodiments, the unnatural amino acid is compound 61. In some embodiments, the unnatural amino acid is compound 62.

[0648] 8. Forms of compounds of formula (I) and subformulas In some embodiments, the present specification provides: (a) antibody conjugates, e.g., of Formula I or II, as described herein, and pharmaceutically acceptable salts and compositions thereof; (b) antibody conjugates, e.g., of Formula I or II, as described herein, and pharmaceutically acceptable salts and compositions thereof, for use in the treatment and / or prevention of cancer; (c) a process for the preparation of an antibody conjugate described herein, e.g., of Formula I or II, as described in more detail elsewhere herein; (d) a pharmaceutical formulation comprising an antibody conjugate described herein, e.g., of Formula I or II, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent; (e) a pharmaceutical formulation comprising an antibody conjugate, or a pharmaceutically acceptable salt thereof, described herein, e.g., of Formula I or II, together with one or more other active anti-cancer agents, optionally in a pharmaceutically acceptable carrier or diluent; (f) Use of the antibody conjugate or composition thereof for the treatment of cancer, and / or an inflammatory disease or condition, and / or a proliferative disease or condition. is provided.

[0649] optically active compound It is understood that the antibody conjugates and / or payloads of the antibody conjugates provided herein have several chiral centers and may exist and be isolated in optically active and racemic forms. Some compounds may exhibit polymorphism. It is understood that any racemic, optically active, diastereomeric, polymorphic, or stereoisomeric form of the compounds provided herein, or mixtures thereof, having the useful properties described herein, are within the scope of the present invention. Methods for preparing optically active forms (e.g., resolution of racemic forms by recrystallization techniques, synthesis from optically active starting materials, chiral synthesis, or chromatographic separation using chiral stationary phases) are well known in the art.

[0650]

[0410] Similarly, most amino acids are chiral (designated as L or D, with the L enantiomer being the naturally occurring configuration) and can exist as separate enantiomers.

[0651]

[0411] Examples of methods for obtaining optically active materials are known in the art and include at least the following. i) Physical separation of crystals - a technique for manually separating macroscopic crystals of individual enantiomers. This technique can be used when crystals of separate enantiomers exist, i.e., when the substance is an aggregate and the crystals are visually distinct; ii) simultaneous crystallization - a technique in which the individual enantiomers are crystallized separately from a solution of the racemate, a technique that is only possible if the racemate is a conglomerate in the solid state; iii) Enzymatic resolution - a technique for partial or complete separation of a racemate by reacting the enantiomers at different rates with an enzyme; iv) enzymatic asymmetric synthesis - a synthetic technique that uses an enzymatic reaction in at least one step of the synthesis to obtain an enantiomerically pure or enriched synthetic precursor of the desired enantiomer; v) Chemical asymmetric synthesis - a synthetic technique in which a desired enantiomer is synthesized from an achiral precursor under conditions that result in asymmetry (i.e., chirality) in the product, which may be achieved using a chiral catalyst or chiral auxiliary; vi) Diastereomeric separation - a technique in which a racemic compound is reacted with an enantiomerically pure reagent (chiral auxiliary) that converts the individual enantiomers into diastereomers. The resulting diastereomers are then separated by chromatography or crystallization due to their now more distinct structural differences, and the chiral auxiliary is later removed to give the desired enantiomer. vii) First and second order asymmetric transformations - techniques in which either the diastereomers from the racemate equilibrate to a point where the diastereomer from the desired enantiomer predominates in solution, or preferential crystallization of the diastereomer from the desired enantiomer upsets the equilibrium and ultimately converts all of the material to a crystalline diastereomer from the desired enantiomer, which is then released from the diastereomer. viii) Kinetic Resolution - This technique refers to achieving partial or complete resolution of a racemate (or further resolution of a partially resolved compound) by the unequal reaction rates of enantiomers with chiral, non-racemic reagents or catalysts under kinetic conditions; ix) Enantiospecific synthesis from non-racemic precursors - a synthetic technique for the preparation of the desired enantiomer from non-chiral starting materials, in which the stereochemical integrity is not or only minimally compromised during the synthesis; x) Chiral liquid chromatography - a technique in which the enantiomers of a racemate are separated in a liquid mobile phase by their different interactions with a stationary phase. The stationary phase may be made from a chiral material, or the mobile phase may contain additional chiral material to induce the different interactions. xi) Chiral gas chromatography - a technique in which the racemate is volatilized and the enantiomers are separated by their different interactions in a gaseous mobile phase with a column containing a fixed non-racemic chiral adsorbent phase; xii) Chiral solvent extraction - a technique for separating enantiomers by preferentially dissolving one enantiomer in a particular chiral solvent; xiii) Transport across chiral membranes - a technique in which a racemate is placed in contact with a thin film barrier. The barrier typically separates two miscible fluids containing the racemate, and a driving force such as a concentration or pressure difference causes preferential transport across the membrane barrier. Separation occurs as a result of the non-racemic chiral nature of the membrane, which allows only one enantiomer of the racemate to pass through.

[0652] In some embodiments, provided herein are compositions comprising antibody conjugates of Formula (I), (II), (Xa-e), and / or (XIa-d) that are substantially free of the specified enantiomer of the compound. In certain embodiments, in the methods and compositions, the antibody conjugate and / or payload is substantially free of enantiomers. In some embodiments, compositions comprising a compound comprise at least 85%, 90%, 95%, 98%, and 99% to 100% by weight of the compound, with the remainder comprising other species or enantiomers.

[0653] isotopically enriched compounds

[0413] Also provided herein are isotopically enriched compounds, for example, but not limited to, isotopically enriched antibody conjugates of formula (I), (II), (Xa-e), and / or (XIa-d).

[0654]

[0414] Isotopically enriching pharmaceuticals (e.g., deuteriumizing) to improve pharmacokinetics ("PK"), pharmacodynamics ("PD"), and toxicity profiles has previously been demonstrated for several classes of drugs. For example, Lijinsky et.al., Food Cosmet.Toxicol.,20:393(1982);Lijinsky et.al.,J.Nat.Cancer Inst.,69:1127(1982);Mangold et.al.,Mutation Res.308:33(1994);Gordon et.al.,Drug See Metab. Dispos., 15:589 (1987); Zello et. al., Metabolism, 43:487 (1994); Gately et. al., J. Nucl. Med., 27:388 (1986); Wade D, Chem. Biol.

[0655]

[0415] Isotopic enrich...

Claims

1. 1. An antibody conjugate comprising an antibody or antigen-binding fragment thereof covalently linked to a drug payload (PA) and further covalently linked to an immunomodulatory payload (IM), the drug payload (PA) is a residue of a cytotoxic compound selected from the group consisting of alkylating agents, DNA crosslinking agents, antitumor antibiotics, antimetabolites, antimitotic agents, histone deacetylase (HDAC) inhibitors, telomerase inhibitors, and immunogenic cell death agents; Immunomodulatory payloads (IM) include kinase inhibitors, growth factor inhibitors, calcineurin inhibitors, CRAC inhibitors, PARP1 antagonists, PPARγ agonists, Kvl. 3 antagonists, PP2A agonists, MYD88 inhibitors, BCL-2 inhibitors, adenosine A2A receptor (A2ar) agonists, Toll-like receptor 7 / 8 (TLR7 / 8) agonists, Toll-like receptor 4 (TLR4) agonists, Toll-like receptor 9 (TLR9) agonists, calcium-activated potassium channel (Kca3.1) agonists, TGF-R1 inhibitors, TGF-R2 inhibitors, GLi 1 inhibitors, tankyrase (TNKS) antagonists, Traf2 and Nck interacting kinase (TNIK) antagonists, lenalidomide, thalidomide, and pomalidomide, vitamin D receptor (VDR) agonists, and agonists of the STING (stimulator of interferon genes) pathway.

2. The antibody conjugate of claim 1 , wherein the antimitotic agent is a microtubule disrupting agent.

3. 3. The antibody conjugate of claim 2, wherein the immunomodulatory payload is selected from the group consisting of a Toll-like receptor 7 / 8 (TLR7 / 8) agonist, a Toll-like receptor 4 (TLR4) agonist, and a Toll-like receptor 9 (TLR9) agonist.

4. 2. The antibody conjugate of claim 1, wherein the immunomodulatory payload is an agonist of the STING (stimulator of interferon genes) pathway and is selected from MK-1454, ADU-S100, and SB11285.

5. The antibody conjugate of any one of claims 1 to 4, wherein the drug payload is linked to the antibody or antigen-binding fragment via a linker.

6. The antibody conjugate of any one of claims 1 to 5, wherein the immunomodulatory payload is linked to the antibody or antigen-binding fragment via a linker.

7. Formula (I): 【Chemistry 1】 This is due to where Ab is an antibody, or an antigen-binding fragment thereof; Each L is independently an optional linker; each PA is independently a drug payload moiety; Each IM is independently an immune modulating payload residue; The subscript n is an integer selected from 1 to 8; the subscript m is an integer selected from 1 to 8; The antibody conjugate of any one of claims 1 to 6, wherein each bracketed group is covalently linked to an Ab.

8. Formula (II): 【Chemistry 2】 or a mixture of pharma-ceutically acceptable salts, solvates, stereoisomers, tautomers, or positional isomers thereof, wherein each W1 in each occurrence is independently a single bond, absent, or a divalent spacer; Each X, in each occurrence, is independently absent or 【Chemistry 3】 and subscript b is an integer from 1 to 10; each RA is absent or, if present, is independently selected at each occurrence from C1-3 alkyl; each RT is absent or, if present, is independently at each occurrence a release-inducing group; each HP is absent or, if present, is independently at each occurrence a hydrophilic group; each W6, in each occurrence, is independently a peptide residue or absent; each SG, at each occurrence, is independently absent or a divalent spacer group; each R', at each occurrence, is independently a divalent residue of a conjugated group; The subscript n is an integer selected from 1 to 30; the subscript m is an integer selected from 1 to 30; Ab is an antibody or antigen-binding fragment thereof; PA is a cytotoxic compound payload residue; The antibody conjugate of claim 7, wherein IM is an immunomodulatory payload residue.

9. SG, in each occurrence, independently: 【Chemistry 4】 and the subscript d is an integer selected from 1 to 10, 【Chemistry 5】 The antibody conjugate of claim 8 , wherein indicates the point of attachment to the remainder of the formula.

10. SG, in each occurrence, independently 【Chemistry 6】 And each 【Chemistry 7】 10. The antibody conjugate of claim 8, wherein indicates the point of attachment to the remainder of the formula.

11. W1, if present, 【Chemistry 8】 and the subscript e is an integer selected from 1 to 10, 【Chemistry 9】 The antibody conjugate according to any one of claims 8 to 10, wherein denotes the point of attachment to the remainder of the formula.

12. W1, if present, 【Chemistry 10】 And each 【Chemistry 11】 The antibody conjugate according to any one of claims 8 to 10, wherein denotes the point of attachment to the remainder of the formula.

13. The antibody conjugate of any one of claims 8 to 12, wherein W6, if present, in each occurrence is independently a dipeptide or tripeptide residue.

14. W6, if present, is independently in each occurrence: 【Chemistry 12】 And each 【Chemistry 13】 The antibody conjugate according to any one of claims 8 to 12, wherein denotes the point of attachment to the remainder of the formula. Quote.

15. RT, at each occurrence, independently 【Chemistry 14】 and 【Chemistry 15】 The antibody conjugate according to any one of claims 8 to 14, wherein denotes the point of attachment to the remainder of the formula.

16. HP, when present, independently at each occurrence: 【Chemistry 16】 where subscript b is an integer from 1 to 10; 【Chemistry 17】 The antibody conjugate according to any one of claims 8 to 15, wherein denotes the point of attachment to the remainder of the formula.

17. R', in each occurrence, is independently 【Chemistry 18】 and R201 is C1-6 alkyl, 【Chemistry 19】 denotes the attachment point to the rest of the equation, 【Chemistry 20】 indicates the point of attachment to the antibody or antigen-binding fragment thereof, 【Chemistry 21】 represents the point of attachment to the antibody or antigen-binding fragment thereof via the sulfur atom of a cysteine ​​residue.

18. The antibody drug conjugate of any one of claims 8 to 17, wherein the antibody or antigen-binding fragment thereof is selected from the group consisting of anti-BCMA, anti-Muc16, trastuzumab, sofitizumab, anti-GFP, and anti-FolRa, or antigen-binding fragments thereof.

19. The antibody or antigen-binding fragment thereof may comprise two or more non-naturally occurring antigens suitable for conjugation. The antibody conjugate of any one of claims 8 to 18, comprising an amino acid.

20. 20. The antibody conjugate of claim 19, wherein at least one of the two or more unnatural amino acid residues is a pAMF residue.

21. 20. The antibody conjugate of claim 19, wherein the antibody or antigen-binding fragment thereof comprises a Y180pAMF mutation, a F404pAMF mutation, or both.

22. The antibody conjugate of any one of claims 1 to 21, wherein the antibody or antigen-binding fragment thereof is modified by substitution or addition of one or more glutamine (Q) residues.

23. 23. The antibody conjugate of claim 22, wherein the one or more glutamine residues are in a Q tag selected from the group consisting of LLQGA, YAHQAHY, YRYRQ, PNPQLPF, PKPQQFM, GQQQLG, WALQRPH, WELQRPY, YPMQGWF, LSLSQG, GGGLLQGG, GLLQG, GSPLAQSHGG, GLLQGG, GLLQGG, GLLQ, LLQLLQGA, LLQGA, LLQYQGA, LLQGSG, LLQYQG, LLQLLQG, SLLQG, LLQLQ, LLQLLQ, LLQGR, LLQGPA, LLQGPP or GGLLQGPP.

24. 24. The antibody conjugate of any one of claims 1 to 23, wherein the ratio of cytotoxic compound:immunomodulatory compound is about 1-3:1 or greater than 3:

1.

25. The antibody conjugate of any one of claims 1 to 24, wherein the ratio of PA:IM is about 1:1, 2:1, 3:1, or greater than 3:

1.

26. The payload (PA) is selected from the group consisting of altretamine, ansamitocin P3, bendamustine hydrochloride, bleomycin, bortezomib, busulfan, cabazitaxel, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clofarabine, colchicine, combrestatin-A4, cytarabine, cyclophosphamide, dacarbazine, dactinomycin, daunorubicin hydrochloride, docetaxel, cephalosporin ... Taxel, dolastatin 10, dolastatin 15, doxorubicin hydrochloride, eribulin mesylate, epirubicin, epothilone A-F, etoposide, floxuridine, fludarabine, 5-fluorouracil, gemcitabine, hemiasterin (e.g., HTI-286, E7974), idarubicin, ifosfamide, irinotecan, ixabepilone, ixazomib, leucovorin, lomustine, rozoxantrone, mastitis, Itansinoids (e.g., DM1, DM4), mechlorethamine, melphalan, mercaptopurine, methotrexate, mitomycin, mitotane, mitoxantrone, nelarabine, nedaplatin, omacetaxine mepesuccinate, oxaliplatin, paclitaxel, pemetrexed disodium, pentostatin, pixantrone, pralatrexate, procarbazine hydrochloride, pyrrolobenzodiazepines (PBDs) 26. The antibody conjugate of any one of claims 1 to 25, wherein the cytotoxic compound is a residue selected from the group consisting of: , e.g., SG3199), radium dichloride 223, streptozocin, suberanilohydroxamic acid (SAHA), thioguanine, thiotepa, temozolomide, teniposide, topotecan hydrochloride, valrubicin, vincristine sulfate, vinblastine sulfate, vinedesine, and vinorelbine tartrate.

27. The antibody conjugate of claim 26, wherein the cytotoxic compound is an immunogenic cell death agent.

28. The immunogenic cell death agent is mitoxantrone, oxaliplatin, cyclophosphamide 28. The antibody conjugate of claim 27, wherein the antibody is selected from the group consisting of: doxorubicin, daunorubicin, epirubicin, idarubicin, and bortezomib.

29. 27. The antibody conjugate of claim 26, wherein the cytotoxic compound is a maytansinoid, hemiasterin, anthracycline, or a pyrrolobenzodiazepine.

30. The maytansinoid is 【Chemical 22】 30. The antibody conjugate of claim 29,

31. The hemiasterlin is 【Chemistry 23】 30. The antibody conjugate of claim 29,

32. The pyrrolobenzodiazepine is 【Chemistry 24】 30. The antibody conjugate of claim 29,

33. The P.A. 【Chemistry 25】 The antibody conjugate of any one of claims 1 to 25, wherein the residue is

34. The immunomodulatory payload (IM) 【Chemistry 26】 4-amino-2-butoxy-7,8-dihydro-8-[[3-(1-pyrrolidinylmethyl)phenyl]methyl]-6(5H)-pteridinone (vesatolimod, GS9620, CAS number 1228585-88-3), 1-(2-methylpropyl)-1H-imidazol[4,5-c]quinolin-4-amine (imiquimod, CAS number 99011-02-6), 1-(4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol (resquimod, R848 , CAS No. 144875-48-9), 4-amino-2-[(ethylamino)methyl]-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol (gardiquimod, CAS No. 1020412-43-4), N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide (3 M-001), 2-propylthiazolo[4,5-c]quinolin-4-amine (3M-002), 4-amino-2-(ethoxymethyl)-α,α-dimethyl-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinoline-1-ethanol hydrate (3M-003), N-(1-(4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c] 34. The antibody conjugate of any one of claims 1 to 33, which is a residue of an immunomodulatory compound selected from the group consisting of N-(4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl)methanesulfonamide (CAS Nos. 532959-63-0, 3M-852A, PF-4878691), 2-methyl-1-(2,2,4-trimethylpent-4-en-1-yl)-1H-imidazo[4,5-c]quinolin-4-amine (S-34240), loxoribine, CL264, ssRNA40, and SM-276001.

35. The immunomodulatory payload has formula (III): 【Chemistry 27】 or a residue of a pharma- ceutically acceptable salt, solvate, or N-oxide thereof; During the ceremony, R1a, R1b, R2a, and R2b, at each occurrence, are independently selected from hydrogen and C1-6 alkyl; Ring A is a cycloalkyl, heterocycloalkyl, monocyclic aryl, monocyclic heteroaryl, fused bicyclic aryl, or fused bicyclic heteroaryl, where the heterocycloalkyl and each heteroaryl contains 1, 2, 3, or 4 heteroatoms independently selected from N, S, and O; Ring B is a 4-membered N-linked heterocycloalkyl substituted with 1-2 R3, said heterocycloalkyl containing 1 or 2 heteroatoms independently selected from N, S, and O, and R3, in each occurrence, is independently -N(R3a)2, -OR3b, -C(R3c)2NH2, C1-6 alkyl, heterocycloalkyl, heteroaryl, or partially saturated heteroaryl; or two R3 bonded to the same carbon together with the carbon atom to which they are bonded form a spiroheterocycloalkyl, where the R3 heterocycloalkyl, spiroheterocycloalkyl, heteroaryl, and partially saturated heteroaryl contain 1, 2, 3, or 4 heteroatoms independently selected from N, S, and O, and are optionally substituted with 1-2 C1-3 alkyl; or Ring B is a 5-6 membered N-linked heterocycloalkyl further substituted with 1-3 R3 or a 5-6 membered N-linked heteroaryl substituted with 1-3 R3, said heterocycloalkyl and heteroaryl containing 1 or 2 heteroatoms independently selected from N, S, and O, and R3, in each occurrence, is independently -N(R3a)2, -OR3b, -C(R3c)2NH2, heterocycloalkyl, heteroaryl, or partially saturated heteroaryl; or two R3 bonded to the same carbon together with the carbon atom to which they are bonded form a spiroheterocycloalkyl, where the R3 heterocycloalkyl, spiroheterocycloalkyl, heteroaryl, and partially saturated heteroaryl contain 1, 2, 3, or 4 heteroatoms independently selected from N, S, and O, and are optionally substituted with 1-2 C1-3 alkyl; or Ring B is a 7-10 membered N-linked heterocycloalkyl substituted with 1-3 R3 or a 5-10 membered N-linked heteroaryl substituted with 1-3 R3, wherein said heterocycloalkyl and heteroaryl contain 1, 2, 3, or 4 heteroatoms independently selected from N, S, and O, and R3, at each occurrence, is independently -N(R3a)2, -OR3b, -C(R3c)2NH2, C1-6alkyl, heterocycloalkyl, heteroaryl, or partially saturated heteroaryl; two R3 bonded to the same carbon, together with the carbon atom to which they are bonded, form a spiroheterocycloalkyl, where the R3 heterocycloalkyl, spiroheterocycloalkyl, heteroaryl, and partially saturated heteroaryl contain 1, 2, 3, or 4 heteroatoms independently selected from N, S, and O, and are optionally further substituted with 1-2 C1-3 alkyl; R3a, at each occurrence, is independently selected from hydrogen, C1-6 alkyl, -C(=O)-CH2NH2, and cycloalkyl; R3b in each occurrence is independently hydrogen; 【Chemistry 28】 (wherein q1 is 1, 2 or 3) and -CH2-aryl-CH2NH2; R3c at each occurrence is independently selected from hydrogen and C1-6 alkyl, or two R3c together with the carbon atom to which they are attached form a cycloalkyl; R4 is C1-6 alkyl; R5 is a C3-6 cycloalkyl or a C1-6 alkyl, each of which is optionally substituted with 1, 2, or 3 R5a groups independently selected from halo, hydroxy, alkoxy, amino, C1-6 alkylamino, C1-6 dialkylamino, C3-6 cycloalkyl, aryl, and heteroaryl, where heteroaryl contains 1, 2, 3, or 4 heteroatoms independently selected from N, S, and O, and any of the C3-6 cycloalkyl, aryl, and heteroaryl of R5a are 1, 2, or 3 optionally substituted groups independently selected from halo, hydroxy, alkyl, and haloalkyl; The immunomodulatory payload (IM) is linked to its linker L via an amino group of R3 or an amino group of ring B; An antibody conjugate according to any one of claims 1 to 33.

36. I.M. 【Chemistry 29-1】 【Chemistry 29-2】 【Chemistry 29-3】 【Chemistry 29-4】 wherein each 【Chemistry 30】 The antibody conjugate of claim 35, wherein indicates the point of attachment to the remainder of the formula.

37. 【Chemical 31】 but, 【Hua 32-1】 【Hua 32-2】 【Chemistry 32-3】 【Chemistry 32-4】 wherein each 【Chemical 33】 The antibody conjugate of any one of claims 1 to 36, wherein indicates the point of attachment to the remainder of the formula.

38. The immunomodulatory payload has formula (IV): 【Chemical 34】 or a residue of a pharma- ceutically acceptable salt, solvate, or N-oxide thereof, wherein One of Xa and Xb is -N=, and the other is -N(Ra)-; Ra is C1-C6-alkyl, Xc and Xd are independently C1-C6-alkylene; Rb is hydrogen; An antibody conjugate according to any one of claims 7 to 17.

39. The immunomodulatory payload has formula (IVa) or (IVb): 【Chemistry 35】 or a residue of a pharma- ceutically acceptable salt, solvate, or N-oxide thereof.

40. I.M. 【Chemical 36】 wherein: 【Chemical 37】 The antibody conjugate of claim 38, wherein indicates the point of attachment to the remainder of the formula.

41. 【Catalogue 38】 but, 【Chemistry 39-1】 【Chemistry 39-2】 【Chemistry 39-3】 【Chemistry 39-4】 wherein each 【Chemistry 40】 The antibody conjugate of any one of claims 1 to 40, wherein indicates the point of attachment to the remainder of the formula.

42.

41. but, 【Chemistry 42-1】 【Chemistry 42-2】 【Chemistry 42-3】 【Chemistry 42-4】 or a mixture of pharma- ceutically acceptable salts, solvates, stereoisomers, tautomers, or positional isomers thereof, wherein: 【Chemistry 43】 The antibody conjugate of any one of claims 1 to 41, wherein indicates the point of attachment to the remainder of the formula.

43. The P.A. 【Chemistry 44】 is selected from the group consisting of Here, each 【Chemistry 45】 The antibody conjugate of any one of claims 1 to 42, wherein indicates the point of attachment to the remainder of the formula. 【Request 44】 【Chemical 46】 but, 【Chemistry 47】 or a mixture of pharma- ceutically acceptable salts, solvates, stereoisomers, tautomers, or positional isomers thereof, wherein each 【Chemistry 48】 The antibody conjugate of any one of claims 1 to 43, wherein indicates the point of attachment to the remainder of the formula.

45. 【Catalogue 49-1】 【Chemistry 49-2】 【Chemistry 49-3】 【Chemistry 49-4】 or a pharma- ceutically acceptable salt, solvate, stereoisomer, tautomer, or positional isomer mixture thereof.

46. A pharmaceutical composition comprising the antibody conjugate of any one of claims 1 to 45 and a pharma- ceutically acceptable carrier.

47. 47. Use of an effective amount of an antibody conjugate according to any one of claims 1 to 45 or a pharmaceutical composition according to claim 46 in the preparation of a medicament for the treatment of a disease or condition in a subject in need thereof.

48. 47. Use of an effective amount of an antibody conjugate according to any one of claims 1 to 45 or a pharmaceutical composition according to claim 46 in the preparation of a medicament for the diagnosis of a disease or condition in a subject in need thereof.

49. 49. The use of claim 47 or 48, wherein the disease or condition is cancer or an inflammatory disease or condition.

50. 49. The use of claim 47 or 48, wherein the antibody conjugate or composition is administered in combination or alternation with a second agent.

51. A process for preparing an antibody-conjugate according to any one of claims 1 to 45, comprising the steps of: (i) preparing a conjugate of a first payload with a light chain (LC) of an antibody or an antigen-binding fragment thereof; (ii) expressing the heavy chain (HC) of said antibody or an antigen-binding fragment thereof in the presence of the conjugated LC of step (i); and (iii) conjugating the heavy chain of step (ii) to a second payload. The process includes:

52. 52. The process of claim 51, wherein the first payload is an IM and the second payload is a PA.

Citation Information

Patent Citations

  • Anthracycline derivative conjugates, methods for preparing the same, and their uses as antitumor compounds.

    JP2011528360A

  • Compounds for targeted immunotherapy

    JP2015524399A

  • Method for producing an immune ligand / payload complex

    JP2016511279A

  • Pyrrolobenzodiazepine-antibody conjugates

    JP2018502902A

  • antibody drug conjugate

    JP2018507844A